<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="s">
		<monograph id="1" status="active">
			<mono_name>salicylic acid topical</mono_name>
			<section type="none" id="sidelem4x19">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>salmeterol (Rx)</mono_name>
			<info>
				<pronunciation>(sal-met′er-ole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x281">
						<country code="CAN">Serevent </country>
					</tradename>
					<tradename id="tnidelem4x280">Serevent Diskus</tradename>
				</tradenames>
				<class type="func"> β-Adrenergic agonist, bronchodilator</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x40">
				<sec_title>Action:</sec_title>
				<para>Causes bronchodilation by action on β<emphasis style="inf">2</emphasis> (pulmonary) receptors by increasing levels of cAMP, which relaxes smooth muscle with little effect on heart rate; maintains improvement in FEV from 3 to 12 hr; prevents nocturnal asthma symptoms</para>
			</section>
			<section type="uses" id="sidelem4x48">
				<sec_title>Uses:</sec_title>
				<para>Prevention of exercise-induced bronchospasm, COPD, asthma</para>
			</section>
			<section type="contra" id="sidelem4x53">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sympathomimetics, tachydysrhythmias, severe cardiac disease, monotherapy treatment of asthma</para>
				<section type="none" id="sidelem4x58">
					<section type="none" id="sidelem4x59">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, cardiac disorders, hyperthyroidism, diabetes mellitus, hypertension, closed-angle glaucoma, seizures, acute asthma, as a substitute to corticosteroids, QT prolongation</para>
						<para>
							<bbw>Asthma-related death, children &lt;4 yr</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x74">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x82">
					<label>•</label>
					<sec_title>Adult/child ≥4 yr<route> INH</route></sec_title>
					<para>
						<list id="lidelem4x82">
							<item>
								<label>•</label>
								<para> 50 mcg (1 inhalation as dry powder) q12hr;  50 mcg (1 inhalation) <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr before exercise</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x95">
					<section type="none" id="sidelem4x96">
						<sec_title>Available forms:</sec_title>
						<para> Inhalation powder 50 mcg/blister</para>
					</section>
					<section type="none" id="sidelem4x101">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x105">
								<item>
									<label>•</label>
									<para>Gum, sips of water for dry mouth</para>
								</item>
								<item>
									<label>•</label>
									<para>Use <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr before exercise for exercise-induced bronchospasm prevention</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use spacer with this product</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in foil pouch; do not expose to temperature &gt;86° F (30° C); discard 6 wk after removal from foil pouch</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x132">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x135">
					<section type="none" id="sidelem4x136">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tremors, anxiety,</emphasis> insomnia, headache, dizziness, fever</para>
					</section>
					<section type="none" id="sidelem4x144">
						<sec_title>CV:</sec_title>
						<para> Palpitations, tachycardia, hypo/hypertension, angina, <emphasis style="bold">dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x151">
						<sec_title>EENT:</sec_title>
						<para> Dry nose, irritation of nose and throat</para>
					</section>
					<section type="none" id="sidelem4x156">
						<sec_title>GI:</sec_title>
						<para> Heartburn, nausea, vomiting, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x161">
						<sec_title>MS:</sec_title>
						<para> Muscle cramps</para>
					</section>
					<section type="none" id="sidelem4x166">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x174">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x177">
					<section type="none" id="sidelem4x178">
						<sec_title>INH:</sec_title>
						<para> Onset 30-50 min; peak 4 hr; duration 12 hr; metabolized in liver; excreted in urine, breast milk; crosses placenta, blood-brain barrier; protein binding 94%-98%; terminal half-life 3-5 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x183">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CV effect—CYP3A4 inhibitors (itraconazole, ketoconazole, nelfinavir, nefazodone, saquinavir)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of aerosol bronchodilators</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of salmeterol—tricyclics, MAOIs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> salmeterol action—other β-blockers</para>
			</section>
			<section type="considerations" id="sidelem4x202">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x205">
					<section type="none" id="sidelem4x206">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x214">
							<label>•</label>
							<sec_title>Respiratory function</sec_title>
							<para>
								<list id="lidelem4x214">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory function:</emphasis> vital capacity, forced expiratory volume, ABGs, lung sounds, heart rate and rhythm</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x219">
								<item>
									<para>
										<emphasis alert="nurse">Paradoxical bronchospasm: dyspnea, wheezing, chest tightness</emphasis>
<bbw>Children should not use this product as monotherapy for asthma, use only with persistent asthma in those whose symptoms are not wellcontrolled with a long-term asthma product</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x233">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x237">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of dyspnea, wheezing</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x243">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x248">
								<item>
									<label>•</label>
									<para>Not to use for exercise-induced bronchospasm; never to exhale into diskus; to hold level, keep mouthpiece dry</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x253">
								<item>
									<label>•</label>
									<para>Not to use OTC medications because extra stimulation may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x258">
								<item>
									<label>•</label>
									<para>Review package insert with patient</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x263">
								<item>
									<label>•</label>
									<para>To avoid getting powder in eyes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x268">
								<item>
									<label>•</label>
									<para>To avoid smoking, smoke-filled rooms, persons with respiratory infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x273">
								<item>
									<label>•</label>
									<para>Not for treatment of acute exacerbation, a fast-acting β-blocker should be used instead</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x279">
								<item>
									<para>
										<emphasis alert="nurse">To immediately report dyspnea after use if ≥1 canister is used in 2 mo time</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x284">
								<item>
									<label>•</label>
									<para>To notify prescriber if &gt;4 inhalations are needed, or if product is no longer working</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x289">
								<item>
									<label>•</label>
									<para>Not to get canister or mouthpiece wet, not to use spacer, not to exhale into mouthpiece</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x294">
								<item>
									<label>•</label>
									<para>To take other products as prescribed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active" ha="yes">
			<mono_name> sargramostim (GM-CSF) (Rx)</mono_name>
			<info>
				<pronunciation>(sar-gram′oh-stim)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x3141">Leukine</tradename>
					<tradename id="tnidelem4x3140">GM-CSF</tradename>
				</tradenames>
				<class type="func"> Biologic modifier</class>
				<class type="chem"> Granulocyte macrophage colony-stimulating factor (GM-CSF)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x324">
				<para>
					<confusion>
						<tradename id="tnidelem4x3240">Leukine</tradename>
						<drug type="generic" refid="idelem4x3240">leucovorin/Leukeran</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x328">
				<sec_title>Action:</sec_title>
				<para>Stimulates proliferation and differentiation of hematopoietic progenitor cells (granulocytes, macrophages)</para>
			</section>
			<section type="uses" id="sidelem4x333">
				<sec_title>Uses:</sec_title>
				<para>Acceleration of myeloid recovery in patients with non–Hodgkin’s lymphoma, acute lymphoblastic leukemia, acute myelogenous leukemia, autologous bone marrow transplantation in Hodgkin’s disease; bone marrow transplantation failure or engraftment delay, mobilization and transplant of peripheral blood progenitor cells (PBPCs)</para>
				<section type="none" id="sidelem4x339">
					<section type="none" id="sidelem4x340">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Aplastic anemia, Crohn’s disease, HIV, ganciclovir- or zidovudine-induced neutropenia, malignant melanoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x345">
				<sec_title>Contraindications:</sec_title>
				<para>Neonates; hypersensitivity to GM-CSF, benzyl alcohol, yeast products; excessive leukemic myeloid blast in bone marrow, peripheral blood</para>
				<section type="none" id="sidelem4x350">
					<section type="none" id="sidelem4x351">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children; lung/cardiac/renal/hepatic disease; pleural, pericardial effusions, peripheral edema, leukocytosis, mannitol hypersensitivity, hepatic/renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x356">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x359">
					<section type="none" id="sidelem4x360">
						<sec_title>Myeloid recovery in Hodgkin’s disease, non-Hodgkin’s lymphoma, acute lymphocytic leukemia</sec_title>
						<para>
							<emphasis style="bold">Adult: IV</emphasis> 250 mcg/m<emphasis style="sup">2</emphasis>/day over a 2-hr period beginning 2-4 hrs after infusion of bone marrow and not &lt;24 hrs after last dose of chemotherapy or radiotherapy</para>
						<para>
							<emphasis style="bold">Child (unlabeled): SUBCUT/IV</emphasis> 250 mcg/m<emphasis style="sup">2</emphasis>/day beginning 2-4 hrs after infusion of bone marrow and not &lt;24 hrs after last dose of chemotherapy</para>
					</section>
					<section type="none" id="sidelem4x377">
						<sec_title>Acceleration of myeloid recovery</sec_title>
						<section type="none" id="sidelem4x385">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x385">
									<item>
										<label>•</label>
										<para> 250 mcg/m<emphasis style="sup">2</emphasis>/day × 14 days; give over 2 hr; may repeat in 7 days; may repeat 500 mcg/m<emphasis style="sup">2</emphasis>/day × 14 days after another 7 days if no improvement</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x395">
						<sec_title>Mobilization of PBPCs</sec_title>
						<section type="none" id="sidelem4x403">
							<label>•</label>
							<sec_title>Adult<route> IV/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x403">
									<item>
										<label>•</label>
										<para> 250 mcg/m<emphasis style="sup">2</emphasis>/day during collection of PBPCs</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x410">
						<sec_title>After PBPC transplantation</sec_title>
						<section type="none" id="sidelem4x418">
							<label>•</label>
							<sec_title>Adult<route> IV/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x418">
									<item>
										<label>•</label>
										<para> 250 mcg/m<emphasis style="sup">2</emphasis>/day until ANC &gt;1500 cells/mm<emphasis style="sup">3</emphasis> × 3 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x428">
						<sec_title>Aplastic anemia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x436">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x436">
									<item>
										<label>•</label>
										<para> 250-500 mcg/day or 5 mcg/kg/day × 14-90 days, used with erythropoietin or immunosuppressive therapy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x440">
						<sec_title>HIV (unlabeled)</sec_title>
						<section type="none" id="sidelem4x448">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x448">
									<item>
										<label>•</label>
										<para> 250 mcg/m<emphasis style="sup">2</emphasis>/day 3×/wk for ≤20 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x455">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj lyophilized 250 mcg; sol for inj 500 mcg/ml</para>
					</section>
					<section type="none" id="sidelem4x460">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x464">
								<item>
									<label>•</label>
									<para>Store in refrigerator; do not freeze</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x470">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x474">
									<item>
										<label>•</label>
										<para>No further dilution of reconstituted sol is needed; take care not to inject intradermally</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x480">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x485">
									<item>
										<label>•</label>
										<para>After reconstituting with 1 ml sterile water for inj without preservative; do not reenter vial; discard unused portion; direct reconstitution sol at side of vial; rotate contents; do not shake</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x493">
								<label>•</label>
								<sec_title>
									<route>(bone marrow transplant or failure of graft);</route>
								</sec_title>
								<para>
									<list id="lidelem4x493">
										<item>
											<label>•</label>
											<para>Dilute in 0.9% NaCl inj to prepare IV infusion; if final concentration is &lt;10 mcg/ml, add human albumin to make final concentration of 0.1% to NaCl before adding sargramostim to prevent adsorption; for a final concentration of 0.1% albumin, add 1 mg human albumin/1 ml 0.9% NaCl inj run over 2 hr  over 4 hr  over 24 hr as cont infusion  give within 6 hr after reconstitution</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amikacin, aminophylline, aztreonam, bleomycin, butorphanol, calcium gluconate, CARBOplatin, carmustine, ceFAZolin, cefepime, cefotaxime, cefoTEtan, ceftizoxime, cefTRIAXone, cefuroxime, cimetidine, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, dexamethasone, diphenhydrAMINE, DOPamine, DOXOrubicin, doxycycline, droperidol, etoposide, famotidine, fentaNYL, floxuridine, fluconazole, fluorouracil, furosemide, gentamicin, granisetron, heparin, IDArubicin, ifosfamide, immune globulin, magnesium sulfate, mannitol, mechlorethamine, meperidine, mesna, methotrexate, metoclopramide, metroNIDAZOLE, minocycline, mitoXANtrone, netilmicin, pentostatin, piperacillin/tazobactam, potassium chloride, prochlorperazine, promethazine, ranitidine, teniposide, ticarcillin, ticarcillin-clavulanate, trimethoprim-sulfamethoxazole, vinBLAStine, vinCRIStine, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x508">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x511">
					<section type="none" id="sidelem4x512">
						<sec_title>CNS:</sec_title>
						<para> Fever, malaise, CNS disorder, weakness, chills, dizziness, syncope, headache</para>
					</section>
					<section type="none" id="sidelem4x517">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Transient supraventricular tachycardia,</emphasis> peripheral edema, <emphasis style="bold">pericardial effusion,</emphasis> hypotension, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x528">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, anorexia, <emphasis style="bold">GI hemorrhage,</emphasis> stomatitis, <emphasis style="bold">liver damage,</emphasis> hyperbilirubinemia</para>
					</section>
					<section type="none" id="sidelem4x539">
						<sec_title>GU:</sec_title>
						<para> Urinary tract disorder, abnormal kidney function</para>
					</section>
					<section type="none" id="sidelem4x544">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Blood dyscrasias, hemorrhage</emphasis></para>
					</section>
					<section type="none" id="sidelem4x551">
						<sec_title>INTEG:</sec_title>
						<para> Alopecia, rash, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x556">
						<sec_title>MS:</sec_title>
						<para> Bone pain, myalgia</para>
					</section>
					<section type="none" id="sidelem4x561">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x566">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life elimination: IV 60 min, SUBCUT 2-3 hr; detected within 5 min after administration, peak 2 hr</para>
			</section>
			<section type="interactions" id="sidelem4x571">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> myeloproliferation—lithium, corticosteroids</para>
				<section type="none" id="sidelem4x578">
					<section type="none" id="sidelem4x579">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bilirubin, BUN, creatinine, eosinophils, LFTs, leukocytes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x586">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x589">
					<section type="none" id="sidelem4x590">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x596">
								<item>
									<para>
										<emphasis alert="nurse">Blood studies: CBC, differential count before treatment, 2 × weekly; leukocytosis may occur (WBC &gt;50,000 cells/mm<emphasis style="sup">3</emphasis>, ANC &gt;20,000 cells/mm<emphasis style="sup">3</emphasis>), platelets; if ANC &gt;20,000/mm<emphasis style="sup">3</emphasis> or 10,000/mm<emphasis style="sup">3</emphasis> after nadir has occurred or platelets &gt;500,000/mm<emphasis style="sup">3</emphasis>, reduce dose by <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> or discontinue; if blast cells occur, discontinue</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x622">
								<item>
									<label>•</label>
									<para>Renal, hepatic studies before treatment: BUN, creatinine, urinalysis; AST, ALT, alk phos; 2 × weekly monitoring is needed in renal/hepatic disease</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x630">
							<label>•</label>
							<sec_title>
								<route>Hypersensitivity,</route>
							</sec_title>
							<para>
								<list id="lidelem4x630">
									<item>
										<label>•</label>
										<para> rashes, local inj- site reactions; usually transient</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x634">
								<item>
									<label>•</label>
									<para>Body weight, hydration status; increased fluid retention in cardiac disease; pulmonary function</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x639">
								<item>
									<label>•</label>
									<para>Constitutional symptoms: asthenia, chills, fever, headache, malaise</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x644">
								<item>
									<label>•</label>
									<para>Myalgia, arthralgia in legs, feet; use analgesics, antipyretics</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x653">
							<label>•</label>
							<sec_title>Gasping syndrome in neonates<route> due to benzyl alcohol hypersensitivity, do not use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x656">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x660">
								<item>
									<label>•</label>
									<para>Therapeutic response: WBC and differential recovery</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x666">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x670">
								<item>
									<label>•</label>
									<para>To report dyspnea to health care provider</para>
								</item>
								<item>
									<label>•</label>
									<para>Review all aspects of product use</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active" ha="yes">
			<mono_name> saxagliptin (Rx)</mono_name>
			<info>
				<pronunciation>(sax-a-glip′tin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x6880">Onglyza</tradename>
				</tradenames>
				<class type="func"> Antidiabetic, oral</class>
				<class type="chem"> Dipeptidyl-peptidase-4 inhibitor (DPP-4 inhibitor)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x698">
				<para>
					<confusion>
						<tradename id="tnidelem4x6980">saxagliptin</tradename>
						<drug type="generic" refid="idelem4x6980">sitaGLIPtin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x702">
				<sec_title>Action:</sec_title>
				<para>Slows the inactivation of incretin hormones; improves glucose homeostasis, improves glucose-dependent insulin synthesis, lowers glucagon secretions, and slows gastric emptying time</para>
			</section>
			<section type="uses" id="sidelem4x707">
				<sec_title>Uses:</sec_title>
				<para>In adults, type 2 diabetes mellitus as monotherapy or in combination with other antidiabetic agents</para>
			</section>
			<section type="contra" id="sidelem4x712">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, angioedema</para>
				<section type="none" id="sidelem4x717">
					<section type="none" id="sidelem4x718">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), geriatric patients, GI obstruction, surgery, thyroid/renal/hepatic disease, trauma, diabetic ketoacidosis (DKA), type 1 diabetes, heart failure</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x723">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x731">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x731">
							<item>
								<label>•</label>
								<para> 2.5-5 mg; may use with other antidiabetic agents other than insulin; if used with insulin, a lower dose may be needed; max 2.5 mg with strong 3A415 inhibitors</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x735">
					<section type="none" id="sidelem4x736">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x744">
							<label>•</label>
							<sec_title>Adult<route> PO CCr ≤50 ml/min, 2.5 mg daily</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x747">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 5 mg</para>
					</section>
					<section type="none" id="sidelem4x752">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x755">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x759">
									<item>
										<label>•</label>
										<para>May be taken with/without food</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not break or cut tabs</para>
									</item>
									<item>
										<label>•</label>
										<para>Conversion from other antidiabetic agents; change may be made with gradual dosage change</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight containers at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x780">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x783">
					<section type="none" id="sidelem4x784">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x791">
						<sec_title>RESP:</sec_title>
						<para> Upper respiratory infection</para>
					</section>
					<section type="none" id="sidelem4x796">
						<sec_title>ENDO:</sec_title>
						<para> Hypoglycemia (renal impairment)</para>
					</section>
					<section type="none" id="sidelem4x801">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> abdominal pain, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x811">
						<sec_title>INTEG:</sec_title>
						<para> Urticaria, <emphasis style="bold">angioedema, anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x818">
						<sec_title>MISC:</sec_title>
						<para> Lymphopenia, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x823">
						<sec_title>CV:</sec_title>
						<para> Edema</para>
					</section>
					<section type="none" id="sidelem4x828">
						<sec_title>EENT:</sec_title>
						<para> Sinusitis</para>
					</section>
					<section type="none" id="sidelem4x833">
						<sec_title>GU:</sec_title>
						<para> UTI</para>
					</section>
					<section type="none" id="sidelem4x838">
						<sec_title>META:</sec_title>
						<para> Hypoglycemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x843">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed, excreted by the kidneys (unchanged 24%), terminal half-life 2.5 hr, 3.1 hr metabolite, peak 2 hr, duration 24 hr</para>
			</section>
			<section type="interactions" id="sidelem4x848">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—androgens, insulins, β-blockers, cimetidine, corticosteroids, salicylates, MAOIs, fibric acid derivatives, FLUoxetine, insulin, sulfonylureas, ACE inhibitors; strong CYP3A4/5 inhibitors</para>
				<para>
					<emphasis alert="lifethreat">Drug/Herb</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antidiabetic effect—garlic, horse chestnut</para>
				<para>
					<emphasis alert="lifethreat">Drug/Lab Test</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> lymphocytes, glucose</para>
			</section>
			<section type="considerations" id="sidelem4x869">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x872">
					<section type="none" id="sidelem4x873">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x881">
							<label>•</label>
							<sec_title>
								<route>Hypoglycemic reactions</route>
							</sec_title>
							<para>
								<list id="lidelem4x881">
									<item>
										<label>•</label>
										<para> (sweating, weakness, dizziness, anxiety, tremors, hunger); monitor blood glucose, HbA1c <emphasis style="bold">renal studies:</emphasis> BUN, creatinine during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x892">
							<label>•</label>
							<sec_title>Heart failure<route> history of risk factors for heart failure, use cautiously in these patients</route></sec_title>
						</section>
						<section type="none" id="sidelem4x898">
							<label>•</label>
							<sec_title>Pancreatitis<route> abdominal pain, nausea, vomiting; discontinue</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x901">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x905">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in polyuria, polydipsia, polyphagia; clear sensorium; absence of dizziness; stable gait, blood glucose at normal level</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x911">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x915">
								<item>
									<label>•</label>
									<para>To perform regular self-monitoring of blood glucose using blood-glucose meter</para>
								</item>
								<item>
									<label>•</label>
									<para>About the symptoms of hypo/hyperglycemia; what to do about each</para>
								</item>
								<item>
									<label>•</label>
									<para>That product must be continued on daily basis; about consequences of discontinuing product abruptly</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications, alcohol, digoxin, exenatide, insulins, nateglinide, repaglinide, and other products that lower blood glucose unless approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That diabetes is lifelong; that this product is not a cure, only controls symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>That all food included in diet plan must be eaten to prevent hypo/hyperglycemia</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID</para>
								</item>
								<item>
									<label>•</label>
									<para>To take product without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber when surgery, trauma, stress occurs because dose may need to be adjusted</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active" ru="yes">
			<mono_name> scopolamine (Rx)</mono_name>
			<info>
				<pronunciation>(skoe-pol′a-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x9682">Maldemar</tradename>
					<tradename id="tnidelem4x9681">Scopace</tradename>
					<tradename id="tnidelem4x9680">Transderm Scop</tradename>
				</tradenames>
				<class type="func"> Cholinergic blocker</class>
				<class type="chem"> Belladonna alkaloid</class>
			</info>
			<section type="uses" id="sidelem4x978">
				<sec_title>Uses:</sec_title>
				<para>Preoperatively to produce amnesia, sedation and to decrease secretions; motion sickness, parkinsonian symptoms</para>
			</section>
			<section type="contra" id="sidelem4x983">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, closed-angle glaucoma, myasthenia gravis, GI/GU obstruction, hypersensitivity to belladonna, barbiturates</para>
			</section>
			<section type="doses" id="sidelem4x988">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x991">
					<section type="none" id="sidelem4x992">
						<sec_title>Motion sickness</sec_title>
						<section type="none" id="sidelem4x1000">
							<label>•</label>
							<sec_title>Adult<route> TD</route></sec_title>
							<para>
								<list id="lidelem4x1000">
									<item>
										<label>•</label>
										<para> 1 patch 4 hr before travel and q3days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1004">
						<sec_title>Parkinsonian symptoms</sec_title>
						<section type="none" id="sidelem4x1012">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1012">
									<item>
										<label>•</label>
										<para> 0.4-0.8 mg q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1016">
						<sec_title>Preoperatively</sec_title>
						<section type="none" id="sidelem4x1024">
							<label>•</label>
							<sec_title>Adult<route> IM/IV/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x1024">
									<item>
										<label>•</label>
										<para> 0.32-0.65 mg;  apply 1 patch <emphasis style="smallcaps">pm</emphasis> before surgery or 1 hr before c-section</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1034">
						<sec_title>Nausea and vomiting</sec_title>
						<section type="none" id="sidelem4x1042">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x1042">
									<item>
										<label>•</label>
										<para> 0.6-1 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1049">
							<label>•</label>
							<sec_title>Child<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x1049">
									<item>
										<label>•</label>
										<para> 0.006 mg/kg; max 0.3 mg/dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>selegiline (Rx)</mono_name>
			<info>
				<pronunciation>(se-le′ji-leen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x10582">Eldepryl</tradename>
					<tradename id="tnidelem4x10581">Emsam</tradename>
					<tradename id="tnidelem4x10580">Zelapar</tradename>
				</tradenames>
				<class type="func"> Antiparkinson agent</class>
				<class type="chem"> MAOI, type B</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1068">
				<para>
					<confusion>
						<tradename id="tnidelem4x10680">Eldepryl</tradename>
						<drug type="generic" refid="idelem4x10680">enalapril</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1072">
				<sec_title>Action:</sec_title>
				<para>Increased dopaminergic activity by inhibition of MAO type B activity; not fully understood</para>
			</section>
			<section type="uses" id="sidelem4x1077">
				<sec_title>Uses:</sec_title>
				<para>Adjunct management of Parkinson’s disease for patients being treated with levodopa/carbidopa who had poor response to therapy; depression (transdermal)</para>
				<section type="none" id="sidelem4x1082">
					<section type="none" id="sidelem4x1083">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Alzheimer’s disease, depression</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1088">
				<sec_title>Contraindications:</sec_title>
				<para>Children/adolescents (suicide/hypertensive crisis), hypersensitivity, breastfeeding</para>
				<section type="none" id="sidelem4x1093">
					<section type="none" id="sidelem4x1094">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1099">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1107">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1107">
							<item>
								<label>•</label>
								<para> 10 mg/day given with levodopa/carbidopa in divided doses, 5 mg at breakfast and lunch; after 2-3 days, begin to reduce dose of levodopa/carbidopa 10%-30%;  1.25 mg (1 tab) × 6 wk or more initially, then 2.5 mg (2 tabs) dissolved on tongue daily before breakfast; max 2.5 mg/day;  6 mg/24 hr initially, increase by 3 mg/24 hr at ≥2 wk, up to 12 mg/24 hr if needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1118">
					<section type="none" id="sidelem4x1119">
						<sec_title>Alzheimer’s disease (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1127">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1127">
									<item>
										<label>•</label>
										<para> 5 mg bid <emphasis style="smallcaps">am</emphasis>, <emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1136">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5 mg; caps 5 mg; oral disintegrating tabs 1.25 mg; transdermal 6 mg/24 hr (20 mg/20 cm<emphasis style="sup">2</emphasis>), 9 mg/24 hr (30 mg/30 cm<emphasis style="sup">2</emphasis>), 12 mg/24 hr (40 mg/40 cm<emphasis style="sup">2</emphasis>)</para>
					</section>
					<section type="none" id="sidelem4x1150">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1153">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1159">
									<item>
										<para>
											<emphasis alert="nurse">Do not use in children due to risk for hypertensive crisis</emphasis>
										</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1164">
									<item>
										<label>•</label>
										<para>Product until NPO before surgery</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1169">
									<item>
										<label>•</label>
										<para>Adjust dosage to response</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1174">
									<item>
										<label>•</label>
										<para>With meals; limit protein taken with product</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1179">
									<item>
										<label>•</label>
										<para>Dosing bid in <emphasis style="smallcaps">am</emphasis> and afternoon; avoid <emphasis style="smallcaps">pm</emphasis> or bedtime dosing</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1190">
									<item>
										<label>•</label>
										<para>At doses of &lt;10 mg/day because of risks associated with nonselective inhibition of MAO</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x1198">
								<label>•</label>
								<sec_title>Oral disintegrating tab</sec_title>
								<para>
									<list id="lidelem4x1198">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral disintegrating tab:</emphasis> peel back foil; remove tab; do not push through foil; place tab on tongue; allow to dissolve; swallow with saliva</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x1202">
							<sec_title>Transdermal route</sec_title>
							<para>
								<list id="lidelem4x1206">
									<item>
										<label>•</label>
										<para>Apply to dry, intact skin on upper torso, upper thigh, or outer surface of upper arm q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1212">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1215">
					<section type="none" id="sidelem4x1216">
						<sec_title>CNS:</sec_title>
						<para> Increased tremors, chorea, restlessness, blepharospasm, increased bradykinesia, grimacing, tardive dyskinesia, dystonic symptoms, involuntary movements, increased apraxia, hallucinations, <emphasis style="italic">dizziness,</emphasis> mood changes, nightmares, delusions, lethargy, apathy, overstimulation, sleep disturbances, headache, migraine, numbness, muscle cramps, confusion, anxiety, tiredness, vertigo, personality change, back/leg pain, <emphasis style="bold">suicide in child/adolescent, suicidal ideation in adults</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1226">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, hypo/hypertension, dysrhythmia, palpitations, angina pectoris, <emphasis style="bold">tachycardia,</emphasis> edema, <emphasis style="bold">sinus bradycardia,</emphasis> syncope, <emphasis style="bold">hypertensive crisis (children)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1239">
						<sec_title>EENT:</sec_title>
						<para> Diplopia, dry mouth, blurred vision, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x1244">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, constipation, weight loss, anorexia, diarrhea, heartburn, rectal bleeding, poor appetite, dysphagia, xerostomia</para>
					</section>
					<section type="none" id="sidelem4x1249">
						<sec_title>GU:</sec_title>
						<para> Slow urination, nocturia, prostatic hypertrophy, urinary hesitation, retention, frequency, sexual dysfunction</para>
					</section>
					<section type="none" id="sidelem4x1254">
						<sec_title>INTEG:</sec_title>
						<para> Increased sweating, alopecia, hematoma, rash, photosensitivity, facial hair; site reactions (transdermal)</para>
					</section>
					<section type="none" id="sidelem4x1259">
						<sec_title>RESP:</sec_title>
						<para> Asthma, SOB</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1264">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption (tab) 40-90 min, (oral disintegrating tab) 10-15 min; peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2 hr; rapidly metabolized (active metabolites: <emphasis style="italic">N</emphasis>-desmethyldeprenyl, amphetamine, methamphetamine); metabolites excreted in urine; half-life 10 hr, orally disintegrating tab 1.3 hr; protein binding up to 85%</para>
			</section>
			<section type="interactions" id="sidelem4x1278">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Fatal interaction: opioids (especially meperidine); do not administer together</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Serotonin syndrome (confusion, seizures, fever, hypertension, agitation); death—FLUoxetine, PARoxetine, sertraline, fluvoxaMINE (discontinue 5 wk before selegiline treatment); do not use together</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Fatal interaction: do not use with tricyclics</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> side effects of levodopa/carbidopa</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> unusual behavior, psychosis —dextromethorphan</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—antihypertensives</para>
				<section type="none" id="sidelem4x1308">
					<section type="none" id="sidelem4x1309">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> VMA</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine ketones, urine glucose</para>
						<para>
							<emphasis style="bold">False negative:</emphasis> urine glucose (glucose oxidase)</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> uric acid, urine protein</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1328">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1331">
					<section type="none" id="sidelem4x1332">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1340">
							<label>•</label>
							<sec_title>Parkinson’s symptoms</sec_title>
							<para>
								<list id="lidelem4x1340">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Parkinson’s symptoms:</emphasis> decreased rigidity, unsteady gait, weakness, tremors</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1344">
								<item>
									<label>•</label>
									<para>Cardiac status: tachycardia/bradycardia; B/P, respiration throughout treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1352">
							<label>•</label>
							<sec_title>
								<route>suicidal ideation may occur</route>
							</sec_title>
							<para>
								<list id="lidelem4x1352">
									<item>
										<label>•</label>
										<para>Mental status: affect, mood, behavioral changes, depression; perform suicide assessment on all patients, </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1357">
								<item>
									<para>
										<emphasis alert="nurse">Opioids; if patient has received, do not administer selegiline; fatal reactions have occurred</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1362">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1367">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1371">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in akathisia, improved mood</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1377">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1382">
								<item>
									<label>•</label>
									<para>To change positions slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1390">
							<label>•</label>
							<sec_title>Hypertensive crisis<route> nausea, vomiting, sweating, agitation, change in mental status, headache, chest pain; to notify prescriber immediately</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1396">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> to report twitching, sweating, shivering, diarrhea to prescriber immediately</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1399">
								<item>
									<label>•</label>
									<para>To use product exactly as prescribed; if discontinued abruptly, parkinsonian crisis may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1407">
							<label>•</label>
							<sec_title>Pregnancy<route> to report if pregnancy is planned or suspected, pregnancy (C); to avoid breastfeeding</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1410">
								<item>
									<label>•</label>
									<para>To use during the day to prevent insomnia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1415">
								<item>
									<label>•</label>
									<para>To avoid heating pads, hot tubs when using transdermal products</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1420">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until response is known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1425">
								<item>
									<label>•</label>
									<para>To avoid foods high in tyramine: cheese, pickled products, wine, beer, large amounts of caffeine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1431">
								<item>
									<para>
										<emphasis alert="nurse">Not to exceed recommended dose of 10 mg (PO) because this might precipitate hypertensive crisis; to report severe headache, other unusual symptoms</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>selenium topical</mono_name>
			<section type="none" id="sidelem4x1444">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>sertraline (Rx)</mono_name>
			<info>
				<pronunciation>(ser′tra-leen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x14530">Zoloft</tradename>
				</tradenames>
				<class type="func"> Antidepressant</class>
				<class type="chem"> SSRI</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1463">
				<para>
					<confusion>
						<tradename id="tnidelem4x14630">Zoloft</tradename>
						<drug type="generic" refid="idelem4x14630">Zocor</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1467">
				<sec_title>Action:</sec_title>
				<para>Inhibits serotonin reuptake in CNS; increases action of serotonin; does not affect dopamine, norepinephrine</para>
			</section>
			<section type="uses" id="sidelem4x1472">
				<sec_title>Uses:</sec_title>
				<para>Major depressive disorder, obsessive-compulsive disorder (OCD), posttraumatic stress disorder (PTSD), panic disorder, social anxiety disorder, premenstrual dysphoric disorder (PMDD)</para>
				<section type="none" id="sidelem4x1477">
					<section type="none" id="sidelem4x1478">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Premature ejaculation, pruritus with cholestatic liver disease, hot flashes during menopause, breast cancer patients taking tamoxifen; men with prostate cancer secondary to androgen-deprivation therapy, separation anxiety disorder</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1483">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or SSRIs</para>
				<section type="none" id="sidelem4x1488">
					<section type="none" id="sidelem4x1489">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, renal/hepatic disease, epilepsy, recent MI, latex sensitivity (dropper of oral concentration)</para>
						<para>
							<bbw>Children, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1504">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1507">
					<section type="none" id="sidelem4x1508">
						<sec_title>Major depression/OCD</sec_title>
						<section type="none" id="sidelem4x1516">
							<label>•</label>
							<sec_title>Adult/geriatric patient/adolescent (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1516">
									<item>
										<label>•</label>
										<para> 25-50 mg/day; may increase to max of 200 mg/day; do not change dose at intervals of &lt;1 wk; administer daily in <emphasis style="smallcaps">am</emphasis> or <emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1529">
							<label>•</label>
							<sec_title>Child 6-12 yr (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1529">
									<item>
										<label>•</label>
										<para> 25 mg/day, increase by 25-50 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1533">
						<sec_title>Premenstrual dysphoric disorder</sec_title>
						<section type="none" id="sidelem4x1541">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1541">
									<item>
										<label>•</label>
										<para> 50-150 mg nightly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1545">
						<sec_title>Premature ejaculation (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1553">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1553">
									<item>
										<label>•</label>
										<para> 50 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1557">
						<sec_title>Pruritus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1565">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1565">
									<item>
										<label>•</label>
										<para> 50-100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1569">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x1577">
							<label>•</label>
							<sec_title>Adult<route> PO use lower dose or less frequent dosing intervals</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1580">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 50, 100 mg; oral sol 20 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x1585">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1590">
								<item>
									<label>•</label>
									<para>Store at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1595">
								<item>
									<label>•</label>
									<para>Increased fluids, bulk in diet for constipation, urinary retention</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1600">
								<item>
									<label>•</label>
									<para>With food, milk for GI symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1605">
								<item>
									<label>•</label>
									<para>Crushed if patient is unable to swallow medication whole</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1610">
								<item>
									<label>•</label>
									<para>Sugarless gum, hard candy, frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1618">
							<label>•</label>
							<sec_title>Oral concentration</sec_title>
							<para>
								<list id="lidelem4x1618">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral concentration:</emphasis> dilute before use with 4 oz (<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> cup) of water, orange juice, ginger ale, or lemon/lime soda; do not mix with other liquids</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1628">
								<item>
									<label>•</label>
									<para>Avoid use with other CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1633">
								<item>
									<label>•</label>
									<para>Dropper contains latex</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1638">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1641">
					<section type="none" id="sidelem4x1642">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Insomnia, agitation, somnolence, dizziness, headache, tremors, fatigue,</emphasis> paresthesia, twitching, confusion, ataxia, gait abnormality (geriatric patients), <emphasis style="bold">seizures, neuroleptic malignant-syndrome–like reaction, serotonin syndrome, suicidal ideation,</emphasis> anxiety, drowsiness</para>
					</section>
					<section type="none" id="sidelem4x1653">
						<sec_title>CV:</sec_title>
						<para> Palpitations, chest pain</para>
					</section>
					<section type="none" id="sidelem4x1658">
						<sec_title>EENT:</sec_title>
						<para> Vision abnormalities, yawning, tinnitus, intraocular pressure</para>
					</section>
					<section type="none" id="sidelem4x1663">
						<sec_title>ENDO:</sec_title>
						<para> SIADH (geriatric patients); diabetes mellitus</para>
					</section>
					<section type="none" id="sidelem4x1668">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, nausea, constipation, anorexia, dry mouth,</emphasis> dyspepsia, <emphasis style="italic">vomiting, flatulence,</emphasis> weight gain/loss, <emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1681">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Male sexual dysfunction,</emphasis> micturition disorder</para>
					</section>
					<section type="none" id="sidelem4x1689">
						<sec_title>INTEG:</sec_title>
						<para> Increased sweating, rash, hot flashes</para>
					</section>
					<section type="none" id="sidelem4x1694">
						<sec_title>MISC:</sec_title>
						<para> Hyponatremia, <emphasis style="bold">neonatal abstinence syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1701">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x1704">
					<section type="none" id="sidelem4x1705">
						<sec_title>PO:</sec_title>
						<para> Peak 4.5-8.4 hr; steady-state 1 wk; plasma protein binding 98%; elimination half-life 26 hr; extensively metabolized; metabolite excreted in urine, bile; weak inhibitor of CYP3A4, moderate inhibitor of CYP2D6</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1710">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x1714">
						<item>
							<label>•</label>
							<para>Altered lithium levels: lithium</para>
						</item>
						<item>
							<label>•</label>
							<para>Disulfiram reaction: disulfiram and oral concentration due to alcohol content</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis alert="nurse">Fatal reactions: MAOIs, pimozide</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sertraline levels—cimetidine, warfarin, other highly protein-bound products</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of antidepressants (tricyclics), diazepam, TOLBUTamide, warfarin, benzodiazepines, SUMAtriptan, phenytoin, cloZAPine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—anticoagulants, NSAIDs, thrombolytic, platelet inhibitors, salicylates</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, neuroleptic malignant syndrome—SSRIs, SNRIs, serotonin-receptor agonists, tricyclics, sibutramine, traZODone, busPIRone, linezolid, traMADol</emphasis>
				</para>
				<section type="none" id="sidelem4x1745">
					<section type="none" id="sidelem4x1746">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="lifethreat">Increase: of SSRI, serotonin syndrome—St. John’s wort, SAM-e, tryptophan; do not use together</emphasis>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS effect—kava kava, valerian</para>
					</section>
					<section type="none" id="sidelem4x1756">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine screen for benzodiazepines</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1767">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1770">
					<section type="none" id="sidelem4x1771">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Mental status: mood, sensorium, affect, suicidal tendencies (child/young adult), increase in psychiatric symptoms, depression, panic attacks, OCD, PTSD, social anxiety disorder</bbw>
						</para>
						<para>
							<list id="lidelem4x1787">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin syndrome (hyperthermia, hypertension, rigidity, delirium, coma, myoclonus) or neuroleptic malignant-like syndrome (muscle cramps, fever, unstable B/P, agitation, tremors, mental changes)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1793">
								<item>
									<para>
										<emphasis alert="nurse">Bleeding (platelet serotonin depletion): GI bleeding, ecchymoses, epistaxis, hematomas, petechiae, hemorrhage</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1798">
								<item>
									<label>•</label>
									<para>LFTs, thyroid function tests, growth rate, weight at baseline and periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1803">
								<item>
									<label>•</label>
									<para>B/P (lying/standing), pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; VS q4hr in patients with CV disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1808">
								<item>
									<label>•</label>
									<para>Weight weekly; appetite may decrease with product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1813">
								<item>
									<label>•</label>
									<para>Urinary retention, constipation, especially in geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1818">
								<item>
									<label>•</label>
									<para>Alcohol consumption; hold dose until morning</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1823">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1827">
								<item>
									<label>•</label>
									<para>Therapeutic response: significant improvement in depression, OCD</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1833">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1838">
								<item>
									<label>•</label>
									<para>That therapeutic effect may take ≥1 wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1843">
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities requiring alertness because drowsiness, dizziness, blurred vision may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1848">
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use; may cause nausea, headache, malaise</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1853">
								<item>
									<label>•</label>
									<para>To avoid alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1858">
								<item>
									<label>•</label>
									<para>May be taken without regard to food</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1866">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> agitation, nausea, vomiting, diarrhea, twitching, sweating, shivering; report to prescriber immediately</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1872">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnant or if planning to become pregnant, pregnancy (C) or breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>sildenafil (Rx)</mono_name>
			<info>
				<pronunciation>(sil-den′a-fill)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x18891">Revatio</tradename>
					<tradename id="tnidelem4x18890">Viagra</tradename>
				</tradenames>
				<class type="func"> Erectile agent, antihypertensive, peripheral vasodilator</class>
				<class type="chem"> Phosphodiesterase type-5 inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1899">
				<para>
					<confusion>
						<tradename id="tnidelem4x18990">Viagra</tradename>
						<drug type="generic" refid="idelem4x18990">Allegra</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1903">
				<sec_title>Action:</sec_title>
				<para>Enhances the effect of nitric oxide (NO) by inhibiting phosphodiesterase type 5 (PDE5), which is necessary for degrading cGMP in the corpus cavernosum</para>
			</section>
			<section type="uses" id="sidelem4x1908">
				<sec_title>Uses:</sec_title>
				<para>Treatment of erectile dysfunction, improvement in exercise ability, pulmonary hypertension</para>
				<section type="none" id="sidelem4x1913">
					<section type="none" id="sidelem4x1914">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Sexual dysfunction (women); lower urinary tract symptoms and erectile dysfunction (with alfuzosin); altitude sickness, Raynaud’s disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1919">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or nitrates</para>
				<section type="none" id="sidelem4x1924">
					<section type="none" id="sidelem4x1925">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), anatomical penile deformities, sickle cell anemia, leukemia, multiple myeloma, retinitis pigmentosa, bleeding disorders, active peptic ulceration, CV/renal/hepatic disease, multiproduct antihypertensive regimens, geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1930">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1933">
					<section type="none" id="sidelem4x1934">
						<sec_title>Erectile dysfunction (Viagra only)</sec_title>
						<section type="none" id="sidelem4x1942">
							<label>•</label>
							<sec_title>Adult male &lt;65 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1942">
									<item>
										<label>•</label>
										<para> 50 mg 1 hr before sexual activity; may be increased to 100 mg or decreased to 25 mg; max frequency 1×/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1949">
							<label>•</label>
							<sec_title>Adult ≥65 yr (male)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1949">
									<item>
										<label>•</label>
										<para> 25 mg as needed about 1 hr before sexual activity</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1954">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x1962">
							<label>•</label>
							<sec_title>Adult<route> PO (Child-Pugh A, B) 25 mg, take 1 hr before sexual activity; max 1×/day; CCr &lt;30 ml/min, 25 mg starting dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1965">
						<sec_title>Pulmonary hypertension (Revatio only)</sec_title>
						<section type="none" id="sidelem4x1973">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1973">
									<item>
										<label>•</label>
										<para> 20 mg tid; take 4-6 hr apart;  10 mg tid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1981">
							<sec_title>
								<route>Pulmonary hypertension induced by altitude sickness (unlabeled)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x1987">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1987">
									<item>
										<label>•</label>
										<para> 40 mg 6-8 hr after arriving at 14,272 ft, then 40 mg tid × 6 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1991">
						<sec_title>Anorgasmy in antidepressant therapy/sexual dysfunction in women (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1999">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1999">
									<item>
										<label>•</label>
										<para> 50 mg 60-90 min before sexual activity</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2003">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 20, 25, 50, 100 mg; sol for inj 10 mg/12.5 ml</para>
					</section>
					<section type="none" id="sidelem4x2008">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2016">
							<label>•</label>
							<sec_title>Erectile dysfunction</sec_title>
							<para>
								<list id="lidelem4x2016">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Erectile dysfunction:</emphasis> give approximately 1 hr before sexual activity; do not use more than 1×/day; give on empty stomach for better absorption</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2023">
							<label>•</label>
							<sec_title>Pulmonary hypertension</sec_title>
							<para>
								<list id="lidelem4x2023">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pulmonary hypertension:</emphasis> give 3×/day, 4-6 hr apart</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2027">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2030">
					<section type="none" id="sidelem4x2031">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, flushing, dizziness,</emphasis> transient global amnesia, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2041">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">MI, sudden death, CV collapse, TIAs, ventricular dysrhythmias, CV hemorrhage</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2048">
						<sec_title>MISC.:</sec_title>
						<para> <emphasis style="italic">Dyspepsia, nasal congestion, UTI, abnormal vision, diarrhea, rash,</emphasis><emphasis style="bold">nonarteritic ischemic optic neuropathy,</emphasis> hearing loss, priapism, <emphasis style="bold">sickle cell crisis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2060">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed; bioavailability 40%; metabolized by P45 CYP3A4, 2C9 in the liver (active metabolites); terminal half-life 4 hr; peak 15-30 min; reduced absorption with high-fat meal; excreted in feces, urine</para>
			</section>
			<section type="interactions" id="sidelem4x2065">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not use with nitrates; fatal fall in B/P</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sildenafil levels—cimetidine, erythromycin, ketoconazole, itraconazole, antiretroviral protease inhibitors, tacrolimus</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> sildenafil levels—CYP-450 inducers, rifampin, barbiturates, bosentan, carBAMazepine, dexamethasone, phenytoin, nevirapine, rifabutin, troglitazone; antacids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> B/P—α-blockers, alcohol, amlodipine, angiotensin II receptor blockers</para>
				<section type="none" id="sidelem4x2085">
					<section type="none" id="sidelem4x2086">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> product effect—grapefruit</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption—high-fat meal</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2097">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2100">
					<section type="none" id="sidelem4x2101">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2109">
							<label>•</label>
							<sec_title>Phosphodiesterase type 5 inhibitors with lopinavir/ritonavir (Kaletra)<route> assess for hypotension, visual changes, prolonged erection, syncope; give only 25 mg q48hr and monitor for adverse reactions</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2112">
								<item>
									<label>•</label>
									<para>Erectile dysfunction before use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2118">
								<item>
									<para>
										<emphasis alert="nurse">Any severe loss of vision while taking this or any similar products; products should not be used</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2124">
								<item>
									<para>
										<emphasis alert="nurse">Use of organic nitrates that should not be used with this product</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2132">
							<label>•</label>
							<sec_title>MI, sudden death, CV collapse<route> those with an MI within 6 mo, resting hypotension &lt;90/50, resting hypertension &gt;170/100, fluid depletion should use this product cautiously; may occur right after sexual activity to days afterward</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2138">
							<label>•</label>
							<sec_title>Sickle cell crisis (vasoocclusive crisis)<route> when used for pulmonary hypertension, may require hospitalization</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2141">
								<item>
									<label>•</label>
									<para>Cardiac status, hemodynamic parameters, exercise tolerance in pulmonary hypertension: B/P, pulse</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2146">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2150">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing pulmonary hypertension/improved exercise tolerance; ability to perform sexually (male)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2156">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2161">
								<item>
									<label>•</label>
									<para>That product does not protect against sexually transmitted diseases, including HIV</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2166">
								<item>
									<label>•</label>
									<para>That product absorption is reduced with a high-fat meal</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2171">
								<item>
									<label>•</label>
									<para>That product should not be used with nitrates in any form</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2176">
								<item>
									<label>•</label>
									<para>That tabs may be split</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2183">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber immediately and to stop taking product if vision/hearing loss occurs or erection lasts &gt;4 hr</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2191">
							<label>•</label>
							<sec_title>
								<route>That erections lasting &gt;4 hr may occur; report to prescriber immediately</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2197">
							<label>•</label>
							<sec_title>
								<route>Do not use more than 100 mg in 24 hr</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>silodosin (Rx)</mono_name>
			<info>
				<pronunciation>(si-lo′do-seen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x22050">Rapaflo</tradename>
				</tradenames>
				<class type="func"> Selective α-adrenergic blocker, BPH agent</class>
				<class type="chem"> Sulfamoylphenethylamine derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x2218">
				<sec_title>Action:</sec_title>
				<para>Binds preferentially to α<emphasis style="inf">1A</emphasis>-adrenoceptor subtype located mainly in the prostate</para>
			</section>
			<section type="uses" id="sidelem4x2226">
				<sec_title>Uses:</sec_title>
				<para>Symptoms of benign prostatic hyperplasia (BPH)</para>
			</section>
			<section type="contra" id="sidelem4x2231">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, renal failure, hepatic disease</para>
				<section type="none" id="sidelem4x2236">
					<section type="none" id="sidelem4x2237">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, females, geriatric patients, renal/hepatic disease, hypotension, ocular surgery, orthostatic hypotension, prostate cancer, syncope</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2242">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2250">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2250">
							<item>
								<label>•</label>
								<para> 8 mg/day with meal; max 8 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2254">
					<section type="none" id="sidelem4x2255">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x2263">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-49 ml/min, 4 mg/day; CCr &lt;30 ml/min, not recommended</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2266">
						<sec_title>Available forms:</sec_title>
						<para> Cap 4, 8 mg</para>
					</section>
					<section type="none" id="sidelem4x2271">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2275">
								<item>
									<label>•</label>
									<para>Give with meal at same time each day</para>
								</item>
								<item>
									<label>•</label>
									<para>Cap may be opened and sprinkled in applesauce</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature; protect from light and moisture</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2291">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2294">
					<section type="none" id="sidelem4x2295">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache,</emphasis> asthenia, insomnia, syncope</para>
					</section>
					<section type="none" id="sidelem4x2303">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension</para>
					</section>
					<section type="none" id="sidelem4x2308">
						<sec_title>EENT:</sec_title>
						<para> Nasal congestion, rhinorrhea, sinusitis</para>
					</section>
					<section type="none" id="sidelem4x2313">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, abdominal pain, jaundice</para>
					</section>
					<section type="none" id="sidelem4x2318">
						<sec_title>GU:</sec_title>
						<para> Abnormal ejaculation, priapism, urinary incontinence</para>
					</section>
					<section type="none" id="sidelem4x2323">
						<sec_title>HEMA:</sec_title>
						<para> Purpura</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2328">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Decreased absorption with high-fat/high-calorie meal, half-life of metabolite 24 hr, metabolized in liver, excreted via urine, extensively protein bound (97%)</para>
			</section>
			<section type="interactions" id="sidelem4x2333">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> silodosin effect—CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir, antiretroviral protease inhibitors, aprepitant, chloramphenicol, conivaptan, dalfopristin, danazol, delavirdine, efavirenz, fosaprepitant, fluconazole, fluvoxaMINE, imatinib, isoniazid, mifepristone, nefazodone, tamoxifen, telithromycin, troleandomycin, voriconazole, zileuton, zafirlukast)</para>
				<section type="none" id="sidelem4x2340">
					<section type="none" id="sidelem4x2341">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> silodosin effect—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x2348">
						<sec_title>Drug Lab/Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2355">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2358">
					<section type="none" id="sidelem4x2359">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2367">
							<label>•</label>
							<sec_title>Prostatic hyperplasia</sec_title>
							<para>
								<list id="lidelem4x2367">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Prostatic hyperplasia:</emphasis> change in urinary patterns at baseline and throughout treatment, testing for prostate cancer, before administration is recommended</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2371">
								<item>
									<label>•</label>
									<para>BUN, uric acid, urodynamic studies (urinary flow rates, residual volume)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2376">
								<item>
									<label>•</label>
									<para>I&amp;O ratios, weight daily; edema, report weight gain or edema</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2381">
								<item>
									<label>•</label>
									<para>B/P, monitor for orthostatic hypotension</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2386">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2390">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of BPH</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2396">
						<sec_title>Teach patient/family</sec_title>
						<para>
							<list id="lidelem4x2401">
								<item>
									<label>•</label>
									<para>Not to drive, operate machinery until effect known</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2409">
							<label>•</label>
							<sec_title>
								<route>Not to use with grapefruit juice</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2412">
								<item>
									<label>•</label>
									<para>To take with same meal each day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>silver nitrate 1% ophthalmic</mono_name>
			<section type="none" id="sidelem4x2420">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="12" status="active">
			<mono_name>silver nitrate 1% sulfacetamide sodium ophthalmic</mono_name>
			<section type="none" id="sidelem4x2427">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>silver sulfADIAZINE topical</mono_name>
			<section type="none" id="sidelem4x2434">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="14" status="active">
			<mono_name>simeprevir</mono_name>
			<info>
				<pronunciation>(sim-e′pre-vir)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x24430">Olysio</tradename>
				</tradenames>
				<class type="func"> Antiviral, antihepatitis agent</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2449">
				<sec_title>Action:</sec_title>
				<para>Prevents formation of mature viral proteins by inhibiting hepatitis C viral (HCV) replication by blocking proteolytic activity of the hepatitis C virus NS3/4A protease</para>
			</section>
			<section type="uses" id="sidelem4x2454">
				<sec_title>Uses:</sec_title>
				<para>Chronic C infection, hepatitis, (HCV, genotype 1) in adults with compensated liver disease</para>
			</section>
			<section type="contra" id="sidelem4x2459">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, male-mediated teratogenicity, pregnancy (X) in combination</para>
				<section type="none" id="sidelem4x2464">
					<section type="none" id="sidelem4x2465">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), (alone), breastfeeding, Asian patients, liver transplant, UV exposure, hepatic disease, serious rash, children</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2470">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2478">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2478">
							<item>
								<label>•</label>
								<para> 150 mg daily with food with peginterferon alfa and ribavirin ×12 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2482">
					<section type="none" id="sidelem4x2483">
						<sec_title>Available forms:</sec_title>
						<para> Cap 150 mg</para>
					</section>
					<section type="none" id="sidelem4x2488">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2493">
								<item>
									<label>•</label>
									<para>By mouth with food; swallow whole</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2498">
								<item>
									<label>•</label>
									<para>Do not use as monotherapy; if peginterferon alfa or ribavirin are discontinued, discontinue simeprevir and do not restart</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2503">
								<item>
									<label>•</label>
									<para>Obtain NS3 Q8OK polymorphism test before starting treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2511">
							<label>•</label>
							<sec_title>Treatment naïve/prior relapse</sec_title>
							<para>
								<list id="lidelem4x2511">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Treatment naïve/prior relapse:</emphasis> after initial 3-drug treatment, give another 12 wk with peginterferon alfa and ribavirin × another 12 wk; if HCV RNA concentrations ≥25 interstitial units/ml, discontinue all 3 drugs</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2518">
							<label>•</label>
							<sec_title>Prior nonresponders (partial/null)</sec_title>
							<para>
								<list id="lidelem4x2518">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Prior nonresponders (partial/null):</emphasis> after initial 3-drug treatments, give an additional 36 wk of peginterferon alfa and ribavirin; monitor HCV RNA at wk 4, 12, 24; if ≥25 interstitial units/ml, discontinue products</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2522">
								<item>
									<label>•</label>
									<para>Keep in original container</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2527">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2530">
					<section type="none" id="sidelem4x2531">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, conjunctivitis</para>
					</section>
					<section type="none" id="sidelem4x2536">
						<sec_title>GI:</sec_title>
						<para> Hyperbilirubinemia, nausea</para>
					</section>
					<section type="none" id="sidelem4x2541">
						<sec_title>INTEG:</sec_title>
						<para> Exfoliative dermatitis, pruritus, photosensitivity, vasculitis</para>
					</section>
					<section type="none" id="sidelem4x2546">
						<sec_title>MISC:</sec_title>
						<para> Rash, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2551">
				<sec_title>Pharmacokinetics</sec_title>
				<para>99.9% protein binding, excreted 91% feces half-life 40 hrs, metabolized primarily by CYP3A4, also a mild inhibitor of intestinal CYP3A4 and CYP1A2</para>
			</section>
			<section type="interactions" id="sidelem4x2556">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of CYP3A4 inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> simeprevir effects—bromocriptine, chloramphenicol, cimetidine, dalfopristin/quinupristin, danazol, FLUoxetine, isoniazid, lanreotide, octreotide, zafirlukast, erythromycin, protease inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of amiodarone, atorvastatin, disopyramide, digoxin, flecainide, mexiletine, propafenone, quinidine, calcium channel blockers, rosuvastatin, PDE<emphasis style="inf">5</emphasis> inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> simeprevir effect—CYP3A4 inducers (carbamazepine, dexamethasone, phenobarbital, rifampin, efavirenz, etravirine)</para>
				<section type="none" id="sidelem4x2579">
					<section type="none" id="sidelem4x2580">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> simeprevir level—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x2587">
						<sec_title>Drug/Food</sec_title>
						<para>Food increases bioavailability</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2592">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2595">
					<section type="none" id="sidelem4x2596">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2601">
								<item>
									<label>•</label>
									<para>Allergic reaction: rash, pruritus, exfoliative dermatitis</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2609">
							<label>•</label>
							<sec_title>Asian patients<route> levels may be 3.4-fold higher</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2615">
							<label>•</label>
							<sec_title>Pregnancy<route> if planned or suspected; if pregnant call the Pregnancy Registry 800-258-4263, pregnancy (X) in combination</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2618">
								<item>
									<label>•</label>
									<para>Liver function tests; serum HCV RNA concentrations at wk 4, 12, and 24 and at end of treatment; pregnancy tests</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2623">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2627">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of chronic hepatitis C</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2633">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2638">
								<item>
									<label>•</label>
									<para>That optimal duration of treatment is unknown; that product is not a cure; that transmission may still occur, to use precautions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2643">
								<item>
									<label>•</label>
									<para>To avoid use with other medications unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2648">
								<item>
									<label>•</label>
									<para>To use protective clothing, sunscreen; photosensitivity may occur and can be severe</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2653">
								<item>
									<label>•</label>
									<para>Not to stop abruptly unless directed; worsening of hepatitis may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2661">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected; to avoid breastfeeding; use 2 reliable forms of contraception; do not try to conceive for at least 6 mo after discontinuation of this drug combination</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2664">
								<item>
									<label>•</label>
									<para>Teach patient to use cautiously in sulfonamide allergy; do not take the drug as single agent; must use as combination therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2669">
								<item>
									<label>•</label>
									<para>That periodic laboratory testing, follow-up will be required</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2674">
								<item>
									<label>•</label>
									<para>To report nausea, vomiting, rash, trouble breathing to prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active">
			<mono_name>simethicone (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(si-meth′i-kone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x26878">
						<country code="CAN">Barriere </country>
					</tradename>
					<tradename id="tnidelem4x26877">
						<country code="CAN">Gas Relief </country>
					</tradename>
					<tradename id="tnidelem4x26876">Gas-Relief</tradename>
					<tradename id="tnidelem4x26875">Gas-X</tradename>
					<tradename id="tnidelem4x26874">Mylanta Gas Relief</tradename>
					<tradename id="tnidelem4x26873">Mylanta Gas</tradename>
					<tradename id="tnidelem4x26872">Mylicon</tradename>
					<tradename id="tnidelem4x26871">
						<country code="CAN">Ovol </country>
					</tradename>
					<tradename id="tnidelem4x26870">Phazyme</tradename>
				</tradenames>
				<class type="func"> Antiflatulent</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2702">
				<para>
					<confusion>
						<tradename id="tnidelem4x27020">Mylicon</tradename>
						<drug type="generic" refid="idelem4x27020">Mylanta Gas Simethicone/Cimetidine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2706">
				<sec_title>Action:</sec_title>
				<para>Disperses/prevents mucous gas pockets in GI system, lowers surface tension of gas bubbles</para>
			</section>
			<section type="uses" id="sidelem4x2711">
				<sec_title>Uses:</sec_title>
				<para>Flatulence</para>
				<section type="none" id="sidelem4x2716">
					<section type="none" id="sidelem4x2717">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Dyspepsia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2722">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, GI obstruction/perforation</para>
				<section type="none" id="sidelem4x2727">
					<section type="none" id="sidelem4x2728">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), abdominal pain, fistula, hiatal hernia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2733">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2741">
					<label>•</label>
					<sec_title>Adult and child &gt;12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2741">
							<item>
								<label>•</label>
								<para> 40-125 mg after meals and at bedtime prn, max 500 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2748">
					<label>•</label>
					<sec_title>Child 2-12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2748">
							<item>
								<label>•</label>
								<para> 40-50 mg after meals and at bedtime prn, max 240 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2755">
					<label>•</label>
					<sec_title>Child &lt;2 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2755">
							<item>
								<label>•</label>
								<para> 20 mg qid prn</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2759">
					<section type="none" id="sidelem4x2760">
						<sec_title>Available forms:</sec_title>
						<para> Chew tabs 40, 150, 166 mg; tabs 60, 80, 95, 125 mg; drops 20 mg/0.3 ml; caps 95, 180 mg; soft gel caps 125, 180 mg; oral dissolving film 62.5 mg</para>
					</section>
					<section type="none" id="sidelem4x2765">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2769">
								<item>
									<label>•</label>
									<para>After meals, at bedtime; shake susp well before giving; chew tabs should be chewed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2775">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2778">
					<section type="none" id="sidelem4x2779">
						<sec_title>GI:</sec_title>
						<para> Belching, rectal flatus, diarrhea</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2785">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2788">
					<section type="none" id="sidelem4x2789">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2793">
								<item>
									<label>•</label>
									<para>Reason for excess gas production, decreased bowel sounds, recent surgery, other GI conditions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2799">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2803">
								<item>
									<label>•</label>
									<para>Therapeutic response: reduction of abdominal gas, discomfort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2809">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2813">
								<item>
									<label>•</label>
									<para>That tabs must be chewed</para>
								</item>
								<item>
									<label>•</label>
									<para>To shake susp well before pouring</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active">
			<mono_name>simvastatin (Rx)</mono_name>
			<info>
				<pronunciation>(sim-va-sta′tin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x28290">Zocor</tradename>
				</tradenames>
				<class type="chem"> HMG-CoA reductase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2839">
				<para>
					<confusion>
						<tradename id="tnidelem4x28390">Zocor</tradename>
						<drug type="generic" refid="idelem4x28390">Cozaar/Zoloft</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2843">
				<sec_title>Action:</sec_title>
				<para>Inhibits HMG-CoA reductase enzyme, which reduces cholesterol synthesis</para>
			</section>
			<section type="uses" id="sidelem4x2848">
				<sec_title>Uses:</sec_title>
				<para>As an adjunct for primary hypercholesterolemia (types IIa, IIb), isolated hypertriglyceridemia (Frederickson type IV), and type III hyperlipoproteinemia, CAD, heterozygous familial hypercholesterolemia; MI/stroke prophylaxis</para>
			</section>
			<section type="contra" id="sidelem4x2853">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity, active hepatic disease</para>
				<section type="none" id="sidelem4x2858">
					<section type="none" id="sidelem4x2859">
						<sec_title>Precautions:</sec_title>
						<para> Past hepatic disease, alcoholism, severe acute infections, trauma, severe metabolic disorders, electrolyte imbalances, Chinese patients</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2864">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2872">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2872">
							<item>
								<label>•</label>
								<para> 20-40 mg/day in <emphasis style="smallcaps">pm</emphasis> initially; usual range 5-40 mg/day in <emphasis style="smallcaps">pm</emphasis>, max 40 mg/day for most patients, max 80 mg/day for patients taking 80 mg/day chronically without myopathy; dosage adjustments may be made in ≥4-wk intervals; those taking verapamil and amiodarone max 20 mg/day; max &lt;80 mg for Chinese patients taking lipid-modifying niacin doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2885">
					<label>•</label>
					<sec_title>Child/adolescent ≥10 yr including girls ≥1 yr postmenarche<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2885">
							<item>
								<label>•</label>
								<para> 10 mg in <emphasis style="smallcaps">pm</emphasis>, range 10-40 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2892">
					<section type="none" id="sidelem4x2893">
						<sec_title>With diltiazem/verapamil/dronedarone</sec_title>
						<section type="none" id="sidelem4x2901">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2901">
									<item>
										<label>•</label>
										<para> 5-10 mg in <emphasis style="smallcaps">pm</emphasis>, max 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2908">
						<sec_title>With amiodarone, amoLODIPine, ranolazine</sec_title>
						<section type="none" id="sidelem4x2916">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2916">
									<item>
										<label>•</label>
										<para> 5-20 mg daily in evening, max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2920">
						<sec_title>Heterozygous familial hypercholesterolemia</sec_title>
						<section type="none" id="sidelem4x2928">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2928">
									<item>
										<label>•</label>
										<para> 40 mg daily in evening, make dosage adjustments q4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2932">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 20, 40, 80 mg</para>
					</section>
					<section type="none" id="sidelem4x2937">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2941">
								<item>
									<label>•</label>
									<para>Total daily dose in evening</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in cool environment in tight container protected from light</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2952">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2955">
					<section type="none" id="sidelem4x2956">
						<sec_title>CNS:</sec_title>
						<para> Headache, cognitive impairment</para>
					</section>
					<section type="none" id="sidelem4x2961">
						<sec_title>GI:</sec_title>
						<para> Nausea, constipation, diarrhea, dyspepsia, flatus, abdominal pain, <emphasis style="bold">liver dysfunction, pancreatitis,</emphasis> hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x2969">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x2974">
						<sec_title>MS:</sec_title>
						<para> Muscle cramps, myalgia, <emphasis style="bold">myositis, rhabdomyolysis,</emphasis> myopathy</para>
					</section>
					<section type="none" id="sidelem4x2982">
						<sec_title>RESP:</sec_title>
						<para> Upper respiratory tract infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2987">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver (active metabolites); &gt;98% protein bound; excreted primarily in bile, feces (60%), kidneys (15%); peak 1-2 hr; half-life 3 hr</para>
			</section>
			<section type="interactions" id="sidelem4x2993">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not use with cycloSPORINE, gemfibrozil</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: effects of warfarin</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: rhabdomyolysis, myalgia; do not use concurrently—CYP3A4 inhibitors, niacin, erythromycin, clofibrate, clarithromycin, ketoconazole, itraconazole, protease inhibitors, macrolide antibiotics, danazol, delavirdine, nefazodone, verapamil, diltiazem, amiodarone, azole antifungals, telithromycin, voriconazole</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> simvastatin effect—ATP1B1 inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> serum level of digoxin</para>
				<section type="none" id="sidelem4x3019">
					<section type="none" id="sidelem4x3020">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect—red yeast, rice</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x3031">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> simvastatin level grapefruit juice (large amounts)</para>
					</section>
					<section type="none" id="sidelem4x3038">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CK, LFTs, HbA1c</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3045">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3048">
					<section type="none" id="sidelem4x3049">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3054">
								<item>
									<label>•</label>
									<para>Diet history: fat consumption; baseline and lipid profile: LDL, HDL, TG, cholesterol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3059">
								<item>
									<label>•</label>
									<para>Hepatic studies at baseline, after 4-6 wk, periodically thereafter; AST, ALT, may increase</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3065">
								<item>
									<para>
										<emphasis alert="nurse">Rhabdomyolysis: muscle tenderness, increased CPK levels (10× above upper normal limit); therapy should be discontinued, more likely in those receiving &gt;80 mg/day, first year of treatment, those ≥65 yr, females</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3070">
								<item>
									<label>•</label>
									<para>Renal studies in patients with compromised renal systems: BUN, I&amp;O ratio, creatinine</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3075">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3079">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in LDL, total cholesterol, triglycerides; increase in HDL; slowing CAD</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3085">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3090">
								<item>
									<label>•</label>
									<para>That blood work will be necessary during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3095">
								<item>
									<label>•</label>
									<para>To report severe GI symptoms, headache</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3100">
								<item>
									<label>•</label>
									<para>That previously prescribed regimen will continue: low-cholesterol diet, exercise program, smoking cessation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3108">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is suspected or planned; pregnancy (X); not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3111">
								<item>
									<label>•</label>
									<para>To take in evening</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3116">
								<item>
									<label>•</label>
									<para>To report muscle pain, weakness, abdominal pain, dark urine, yellowing of skin, eyes, memory loss</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active" ha="yes">
			<mono_name> sirolimus (Rx)</mono_name>
			<info>
				<pronunciation>(seer-oh-lie′mus)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x31280">Rapamune</tradename>
				</tradenames>
				<class type="func"> Immunosuppressant</class>
				<class type="chem"> Macrolide</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3138">
				<sec_title>Action:</sec_title>
				<para>Produces immunosuppression by inhibiting T-lymphocyte activation and proliferation</para>
			</section>
			<section type="uses" id="sidelem4x3143">
				<sec_title>Uses:</sec_title>
				<para>Organ transplants to prevent rejection; recommended use is with cycloSPORINE and corticosteroids</para>
			</section>
			<section type="contra" id="sidelem4x3148">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity to this product, components of product</para>
				<section type="none" id="sidelem4x3153">
					<section type="none" id="sidelem4x3154">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children &lt;13 yr, severe cardiac/renal/hepatic disease; diabetes mellitus, hyperkalemia, hyperuricemia, hypertension, interstitial lung disease, hyperlipidemia, soya lecithin hypersensitivity</para>
						<para>
							<bbw>Lymphomas, infection, other malignancies, liver transplant, requires a specialized setting, requires an experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3169">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3177">
					<label>•</label>
					<sec_title>Adult/adolescent ≥40 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3177">
							<item>
								<label>•</label>
								<para> 2 mg/day with 6 mg loading dose</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3184">
					<label>•</label>
					<sec_title>Child &gt;13 yr weighing &lt;40 kg (88 lb)<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3184">
							<item>
								<label>•</label>
								<para> 1 mg/m<emphasis style="sup">2</emphasis>/day, 3 mg/m<emphasis style="sup">2</emphasis> loading dose</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3194">
					<section type="none" id="sidelem4x3195">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x3203">
							<label>•</label>
							<sec_title>Adult/child ≥13 yr/&lt;40 kg<route> PO reduce by 33% for maintenance dose (mild to moderate hepatic impairment); reduce by 50% for maintenance dose (severe hepatic impairment)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3206">
						<sec_title>Available forms:</sec_title>
						<para> Oral sol 1 mg/ml; tabs 0.5 mg, 1 mg, 2 mg</para>
					</section>
					<section type="none" id="sidelem4x3212">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3220">
							<label>•</label>
							<sec_title>
								<route>Prophylaxis for Pneumocystis jiroveci pneumonia for 1 yr after transplantation; prophylaxis for CMV is recommended for 90 days after transplantation in those at increased risk for CMV</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3226">
								<item>
									<label>•</label>
									<para>All medications PO if possible; avoid IM inj; bleeding may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3231">
								<item>
									<label>•</label>
									<para>For 3 days before transplant surgery; patients should be placed in protective isolation; give at same time of day; give 4 hr after cycloSPORINE oral sol or caps; do not give with grapefruit juice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3236">
								<item>
									<label>•</label>
									<para>Use amber oral dose syringe and withdraw amount of oral sol needed from bottle; empty correct dose into plastic/glass container holding 60 ml of water/orange juice; stir vigorously and have patient drink at once; refill container with additional 120 ml water/orange juice; stir vigorously and have patient drink at once; if using a pouch, squeeze entire contents into container; follow above directions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3241">
								<item>
									<label>•</label>
									<para>Store protected from light, refrigerate; stable for 30 days after opening (sol)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3246">
								<item>
									<label>•</label>
									<para>Do not crush, chew; store tabs at room temperature
<bbw>Only those experienced in immunosuppressant therapy and transplant should use this drug, must use in a specialized care setting with adequate medical equipment</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3261">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3264">
					<section type="none" id="sidelem4x3265">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tremors, headache, insomnia, paresthesia,</emphasis> chills, fever</para>
					</section>
					<section type="none" id="sidelem4x3273">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="italic">atrial fibrillation, CHF, hypotension, palpitation, tachycardia,</emphasis> peripheral edema, <emphasis style="bold">thrombosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3283">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, photophobia</para>
					</section>
					<section type="none" id="sidelem4x3288">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, constipation, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3295">
						<sec_title>GU:</sec_title>
						<para> UTIs, <emphasis style="bold">albuminuria, hematuria, proteinuria, renal failure, nephrotic syndrome,</emphasis> increased creatinine</para>
					</section>
					<section type="none" id="sidelem4x3303">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, leukopenia, thrombocytopenia, purpura, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3310">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, acne,</emphasis> photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x3318">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia, increased creatinine, edema, hypercholesterolemia, <emphasis style="italic">hyperlipemia,</emphasis> hypophosphatemia, weight gain, hypo/hyperkalemia, hyperuricemia, hypomagnesemia, hypertriglyceridemia</para>
					</section>
					<section type="none" id="sidelem4x3326">
						<sec_title>MS:</sec_title>
						<para> Arthralgia</para>
					</section>
					<section type="none" id="sidelem4x3331">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pleural effusion, atelectasis,</emphasis><emphasis style="italic">dyspnea,</emphasis> pneumonitis, pulmonary embolism/fibrosis</para>
					</section>
					<section type="none" id="sidelem4x3341">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Lymphoma, exfoliative dermatitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3348">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed; peak 1 hr single dose, 2 hr multiple dosing; protein binding 92%; extensively metabolized by CYP3A4 enzyme system, half-life 57-63 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3353">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: angioedema—ACE inhibitors, angiotensin-II–receptor antagonists, cephalosporins, iodine-containing radiopaque contrast media, neuromuscular blockers, NSAIDs, penicillins, salicylates, thrombolytics</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> blood levels—antifungals, calcium channel blockers, cimetidine, danazol, erythromycin, cycloSPORINE, metoclopramide, bromocriptine, HIV-protease inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> blood levels—carBAMazepine, PHENobarbital, phenytoin, rifamycin, rifapentine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of vaccines</para>
				<section type="none" id="sidelem4x3373">
					<section type="none" id="sidelem4x3374">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x3378">
								<item>
									<label>•</label>
									<para>St. John’s wort: may decrease the effect of sirolimus</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3384">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x3388">
								<item>
									<label>•</label>
									<para>Alters bioavailability; use consistently with/without food; do not use with grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3394">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, alk phos, lipids, triglycerides, total cholesterol, BUN, creatinine, LDH, phosphate</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, sodium</para>
						<para>
							<emphasis style="bold">Increase or decrease:</emphasis> magnesium, glucose, calcium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3409">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3412">
					<section type="none" id="sidelem4x3413">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3418">
								<item>
									<label>•</label>
									<para>Blood levels in patients who may have altered metabolism, trough level ≥15 ng/ml are associated with increased adverse reactions; monitor trough concentrations in all patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3423">
								<item>
									<label>•</label>
									<para>Creatinine/BUN, CBC, serum potassium</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3431">
							<label>•</label>
							<sec_title>Lipid profile</sec_title>
							<para>
								<list id="lidelem4x3431">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Lipid profile:</emphasis> cholesterol, triglycerides; lipid-lowering agent may be needed
<bbw>Infection and development of lymphoma; only those experienced in immunosuppressant therapy and organ transplantation should use this product; use only in renal transplant</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3447">
							<label>•</label>
							<sec_title>High risk<route> those with Baniff grade 3 acute rejection or vascular rejection before cycloSPORINE withdrawal, dialysis dependent, creatinine &gt;4.5 mg/dl, African descent, re-transplants, multiorgan transplant, high panel of reactive antibodies</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3453">
							<label>•</label>
							<sec_title>Pulmonary fibrosis, pulmonary effusion, pneumonitis<route> dyspnea, cough, hypoxia; some fatal cases have occurred</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3459">
							<label>•</label>
							<sec_title>Wound dehiscence and anastomotic disruption<route> wound, vascular, airway, ureteral, biliary, inhibition of growth factors; do not combine with corticosteroids, not recommended in lung or liver transplant</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3465">
							<label>•</label>
							<sec_title>Anaphylaxis, angioedema, exfoliative dermatitis<route> more common when given with ACE inhibitors; do not use if a hypersensitivity reaction occurs</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x3469">
								<item>
									<para>
										<emphasis alert="nurse">Bone marrow suppression: Hgb, WBC, platelets during treatment each mo; if leukocytes &lt;3000/mm<emphasis style="sup">3</emphasis> or platelets &lt;100,000/mm<emphasis style="sup">3</emphasis>, product should be discontinued or reduced; decreased hemoglobin level</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3481">
								<item>
									<para>
										<emphasis alert="nurse">Hepatotoxicity: alk phos, AST, ALT, amylase, bilirubin, dark urine, jaundice, itching, light-colored stools; product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3486">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3490">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of graft rejection; immunosuppression with autoimmune disorders</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3496">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3502">
								<item>
									<para>
										<emphasis alert="nurse">To report fever, rash, severe diarrhea, chills, sore throat, fatigue; serious infections may occur; clay-colored stools, cramping (hepatotoxicity); fever, chills, sore throat (infection)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3507">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with known infections to reduce risk for infection</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3515">
							<label>•</label>
							<sec_title>
								<route>To use contraception before, during, for 12 wk after product discontinued; to avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3518">
								<item>
									<label>•</label>
									<para>To use sunscreen, protective clothing to prevent burns, skin cancer</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3523">
								<item>
									<label>•</label>
									<para>Not to use with grapefruit juice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3528">
								<item>
									<label>•</label>
									<para>To avoid vaccines</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3533">
								<item>
									<label>•</label>
									<para>That lifelong use will be required to prevent rejection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3538">
								<item>
									<label>•</label>
									<para>That continuing follow-up exams and blood work will be required</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3543">
								<item>
									<label>•</label>
									<para>Not to get on skin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3548">
								<item>
									<label>•</label>
									<para>How to use product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3553">
								<item>
									<label>•</label>
									<para>To take with or without regard to food, at same time, consistently</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3558">
								<item>
									<label>•</label>
									<para>Take 4 hr after cycloSPORINE</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active" ha="yes">
			<mono_name> sitaGLIPtin (Rx)</mono_name>
			<info>
				<pronunciation>(sit-a-glip′tin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x35700">Januvia</tradename>
				</tradenames>
				<class type="func"> Antidiabetic, oral</class>
				<class type="chem"> Dipeptidyl-peptidase-4 inhibitor (DPP-4 inhibitor)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x3580">
				<sec_title>Action:</sec_title>
				<para>Slows the inactivation of incretin hormones; improves glucose homeostasis, improves glucose-dependent insulin secretion, lowers glucagon secretions, and slows gastric emptying time</para>
			</section>
			<section type="uses" id="sidelem4x3585">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus as monotherapy or in combination with other antidiabetic agents</para>
			</section>
			<section type="contra" id="sidelem4x3590">
				<sec_title>Contraindications:</sec_title>
				<para>Angioedema, diabetic ketoacidosis (DKA)</para>
				<section type="none" id="sidelem4x3595">
					<section type="none" id="sidelem4x3596">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), geriatric patients, GI obstruction, surgery, thyroid/renal/hepatic disease, trauma, breastfeeding, pancreatitis, hypercortisolism, hyperglycemia, hyperthyroidism, hypogylcemia, ileus, pituitary insufficiency, surgery, type 1 diabetes mellitus, diabetic ketoacidosis, adrenal insufficiency, burns</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3602">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3610">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3610">
							<item>
								<label>•</label>
								<para> 100 mg/day; may use with antidiabetic agents other than insulin</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3614">
					<section type="none" id="sidelem4x3615">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x3623">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-50 ml/min, 50 mg daily; CCr &lt;30 ml/min, 25 mg daily</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3626">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 50, 100 mg</para>
					</section>
					<section type="none" id="sidelem4x3631">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3635">
								<item>
									<label>•</label>
									<para>May be taken with/without food</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not split, crush, chew; swallow whole</para>
								</item>
								<item>
									<label>•</label>
									<para>Conversion from other antidiabetic agents; change may be made with gradual dosage change</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3656">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3659">
					<section type="none" id="sidelem4x3660">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3667">
						<sec_title>ENDO:</sec_title>
						<para> Hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x3672">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> abdominal pain, diarrhea, <emphasis style="bold">pancreatitis,</emphasis> constipation</para>
					</section>
					<section type="none" id="sidelem4x3683">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Acute renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3690">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Peripheral edema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3697">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3704">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed, excreted by the kidneys (unchanged 79%), terminal half-life 12.4 hr, peak 1-4 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3709">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> sitaGLIPtin level—cimetidine, disopyramide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—androgens, insulins, β-blockers, cimetidine, corticosteroids, salicylates, MAOIs, fibric acid derivatives, FLUoxetine, sulfonylureas</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antidiabetic effect—thiazide diuretics, ACE inhibitors, protease inhibitors, sympathomimetics, ARIPiprazole, cloZAPine, OLANZapine, QUEtiapine, risperiDONE, ziprasidone, phenytoin, fosphenytoin, phenothiazines, estrogens, progestins, oral contraceptives</para>
				<section type="none" id="sidelem4x3728">
					<section type="none" id="sidelem4x3729">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antidiabetic effect—garlic, green tea, horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x3736">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> creatinine, LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3743">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3746">
					<section type="none" id="sidelem4x3747">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3755">
							<label>•</label>
							<sec_title>Hypoglycemic reactions</sec_title>
							<para>
								<list id="lidelem4x3755">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypoglycemic reactions:</emphasis> sweating, weakness, dizziness, anxiety, tremors, hunger; hyperglycemic reactions soon after meals</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3760">
								<item>
									<para>
										<emphasis alert="nurse">Serious skin reactions: swelling of face, mouth, lips, dyspnea, wheezing</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3766">
								<item>
									<para>
										<emphasis alert="nurse">Pancreatitis: severe abdominal pain, nausea, vomiting; discontinue product</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3774">
							<label>•</label>
							<sec_title>Renal studies</sec_title>
							<para>
								<list id="lidelem4x3774">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Renal studies:</emphasis> BUN, creatinine during treatment, especially in geriatric patients or those with renal disease</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3778">
								<item>
									<label>•</label>
									<para>Glycosylated hemoglobin A1c; monitor blood glucose (BG) as needed</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3783">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3787">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in polyuria, polydipsia, polyphagia; clear sensorium; absence of dizziness; stable gait, blood glucose, A1c improvement</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3793">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3798">
								<item>
									<label>•</label>
									<para>To perform regular self-monitoring of blood glucose using blood-glucose meter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3803">
								<item>
									<label>•</label>
									<para>About the symptoms of hypo/hyperglycemia; what to do about each; to carry emergency ID</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3808">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned, suspected</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3813">
								<item>
									<label>•</label>
									<para>That product must be continued on daily basis; about consequences of discontinuing product abruptly; to continue health regimen (diet, exercise)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3818">
								<item>
									<label>•</label>
									<para>To avoid OTC medications, alcohol, digoxin, exenatide, insulins, nateglinide, repaglinide, and other products that lower blood glucose unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3823">
								<item>
									<label>•</label>
									<para>That diabetes is a lifelong illness; that product is not a cure, only controls symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3828">
								<item>
									<label>•</label>
									<para>That all food included in diet plan must be eaten to prevent hypo/hyperglycemia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3837">
							<label>•</label>
							<sec_title>
								<route>To immediately notify prescriber of hypersensitivity reactions (rash, swelling of face, trouble breathing)</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active">
			<mono_name>sodium bicarbonate (Rx, <emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x38462">Baking soda</tradename>
					<tradename id="tnidelem4x38461">Neut</tradename>
					<tradename id="tnidelem4x38460">
						<country code="CAN">Sellymin </country>
					</tradename>
				</tradenames>
				<class type="func"> Alkalinizer</class>
				<class type="chem"> NaHCO</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3860">
				<sec_title>Action:</sec_title>
				<para>Orally neutralizes gastric acid, which forms water, NaCl, CO<emphasis style="inf">2</emphasis>; increases plasma bicarbonate, which buffers H<emphasis style="sup">+</emphasis> ion concentration; reverses acidosis IV</para>
			</section>
			<section type="uses" id="sidelem4x3871">
				<sec_title>Uses:</sec_title>
				<para>Acidosis (metabolic), cardiac arrest, alkalinization (systemic/urinary) antacid, salicylate poisoning</para>
				<section type="none" id="sidelem4x3876">
					<section type="none" id="sidelem4x3877">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Contrast media nephrotoxicity prevention</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3882">
				<sec_title>Contraindications:</sec_title>
				<para>Metabolic/respiratory alkalosis, hypochloremia, hypocalcemia</para>
				<section type="none" id="sidelem4x3887">
					<section type="none" id="sidelem4x3888">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, CHF, cirrhosis, toxemia, renal disease, hypertension, hypokalemia, breastfeeding, hypernatremia, Bartter’s syndrome, Cushing syndrome, hyperaldosteronism</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3893">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3896">
					<section type="none" id="sidelem4x3897">
						<sec_title>Acidosis, metabolic (not associated with cardiac arrest)</sec_title>
						<section type="none" id="sidelem4x3905">
							<label>•</label>
							<sec_title>Adult and child<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x3905">
									<item>
										<label>•</label>
										<para> 2-5 mEq/kg over 4-8 hr depending on CO<emphasis style="inf">2</emphasis>, pH, ABGs</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3912">
						<sec_title>Cardiac arrest</sec_title>
						<section type="none" id="sidelem4x3920">
							<label>•</label>
							<sec_title>Adult and child<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x3920">
									<item>
										<label>•</label>
										<para> 1 mEq/kg of 7.5% or 8.4% sol, then 0.5 mEq/kg q10min, then doses based on ABGs</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3927">
							<label>•</label>
							<sec_title>Infant<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3927">
									<item>
										<label>•</label>
										<para> 1 mEq/kg over several min (use only the 0.5 mEq/ml [4.2%] sol for inj)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3931">
						<sec_title>Alkalinization of urine</sec_title>
						<section type="none" id="sidelem4x3939">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3939">
									<item>
										<label>•</label>
										<para> 325 mg to 2 g qid or 48 mEq (4 g), then 12-24 mEq q4hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3946">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3946">
									<item>
										<label>•</label>
										<para> 84-840 mg/kg/day (1-10 mEq/kg) in divided doses q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3950">
						<sec_title>Antacid</sec_title>
						<section type="none" id="sidelem4x3958">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3958">
									<item>
										<label>•</label>
										<para> 300 mg to 2 g chewed, taken with water daily-qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3962">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 300, 325, 600, 650 mg; inj 4.2%, 5%, 7.5%, 8.4%</para>
					</section>
					<section type="none" id="sidelem4x3967">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3970">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x3974">
									<item>
										<label>•</label>
										<para>Chew antacid tablets and drink 8 oz water</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not take antacid with milk because milk-alkali syndrome may result</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3985">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x3989">
									<item>
										<label>•</label>
										<para>Use for cardiac emergencies, not used often in cardiac arrest</para>
									</item>
									<item>
										<label>•</label>
										<para>Use ampules or prefilled syringes only; give by rapid bolus dose; flush with NS before, after use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4000">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x4004">
									<item>
										<label>•</label>
										<para>Diluted in an equal amount of compatible sol given 2-5 mEq/kg over 4-8 hr, max 50 mEq/hr; slower rate in children</para>
									</item>
									<item>
										<label>•</label>
										<para>Extravasation with IV administration (tissue sloughing, ulceration, necrosis)</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, amifostine, asparaginase, aztreonam, bivalirudin, bumetanide, ceFAZolin, cefepime, cefTAZidime, ceftizoxime, cefTRIAXone, chloramphenicol, cimetidine, cladribine, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, DAPTOmycin, DAUNOrubicin, dexamethasone sodium phosphated exmedetomidine, digoxin, DOCEtaxel, DOXOrubicin, enalaprilat, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fentaNYL, filgrastim, fluconazole, fludarabine, furosemide, gallium nitrate, gemcitabine, gentamicin, granisetron, heparin, hydrocortisone sodium succinate, ifosfamide, indomethacin, insulin, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, melphalan, mesna, meperidine, methylPREDNISolone sodium succinate, metoclopramide, metoprolol, metroNIDAZOLE, milrinone, morphine, nafcillin, nitroglycerin, nitroprusside, PACLitaxel, palonosetron, pantoprazole, PEMEtrexed, penicillin G potassium, phenylephrine, phytonadione, piperacillin/tazobactam, potassium chloride, procainamide, propranolol, propofol, protamine, ranitidine, remifentanil, tacrolimus, teniposide, thiotepa, ticarcillin/clavulanate, tirofiban, tobramycin, tolazoline, vasopressin, vit B complex with C, voriconazole</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4021">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4024">
					<section type="none" id="sidelem4x4025">
						<sec_title>CNS:</sec_title>
						<para> Irritability, headache, confusion, stimulation, tremors, <emphasis style="italic">twitching, hyperreflexia,</emphasis><emphasis style="bold">tetany,</emphasis> weakness, <emphasis style="bold">seizures</emphasis> of alkalosis</para>
					</section>
					<section type="none" id="sidelem4x4038">
						<sec_title>CV:</sec_title>
						<para> Irregular pulse, <emphasis style="bold">cardiac arrest,</emphasis> water retention, edema, weight gain</para>
					</section>
					<section type="none" id="sidelem4x4046">
						<sec_title>GI:</sec_title>
						<para> Flatulence, <emphasis style="italic">belching, distention</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4053">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Metabolic alkalosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4060">
						<sec_title>MS:</sec_title>
						<para> Muscular twitching, tetany, irritability</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4065">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x4068">
					<section type="none" id="sidelem4x4069">
						<sec_title>PO:</sec_title>
						<para> Onset rapid, duration 10 min</para>
					</section>
					<section type="none" id="sidelem4x4074">
						<sec_title>IV:</sec_title>
						<para> Onset 15 min, duration 1-2 hr, excreted in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4079">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects—amphetamines, mecamylamine, quiNINE, quiNIDine, pseudoephedrine, flecainide, anorexiants, sympathomimetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sodium and decrease potassium—corticosteroids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects—lithium, chlorproPAMIDE, barbiturates, salicylates, benzodiazepines, ketoconazole, corticosteroids</para>
				<section type="none" id="sidelem4x4094">
					<section type="none" id="sidelem4x4095">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> sodium, lactate</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4106">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4109">
					<section type="none" id="sidelem4x4110">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4115">
								<item>
									<label>•</label>
									<para>Respiratory and pulse rate, rhythm, depth, lung sounds; notify prescriber of abnormalities</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4123">
							<label>•</label>
							<sec_title>
								<route>Fluid balance</route>
							</sec_title>
							<para>
								<list id="lidelem4x4123">
									<item>
										<label>•</label>
										<para> (I&amp;O, weight daily, edema); notify prescriber of fluid overload; assess for edema, crackles, shortness of breath</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4127">
								<item>
									<label>•</label>
									<para>Electrolytes, blood pH, PO<emphasis style="inf">2</emphasis>, HCO<emphasis style="inf">3</emphasis><emphasis style="sup">−</emphasis>, during treatment; ABGs frequently during emergencies</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4140">
								<item>
									<label>•</label>
									<para>Weight daily with initial therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4148">
							<label>•</label>
							<sec_title>Alkalosis</sec_title>
							<para>
								<list id="lidelem4x4148">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Alkalosis:</emphasis> irritability, confusion, twitching, hyperreflexia stimulation, slow respirations, cyanosis, irregular pulse</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4155">
							<label>•</label>
							<sec_title>Milk-alkali syndrome<route> confusion, headache, nausea, vomiting, anorexia, urinary stones, hypercalcemia</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x4158">
								<item>
									<label>•</label>
									<para>For GI perforation secondary to carbon dioxide in GI tract; may lead to perforation if ulcer is severe enough</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4163">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4167">
								<item>
									<label>•</label>
									<para>Therapeutic response: ABGs, electrolytes, blood pH, HCO<emphasis style="inf">3</emphasis><emphasis style="sup">−</emphasis> WNL</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4178">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4183">
								<item>
									<label>•</label>
									<para>Not to take antacid with milk because milk-alkali syndrome may result; not to use antacid for &gt;2 wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4189">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber if indigestion accompanied by chest pain; trouble breathing; diarrhea; dark, tarry stools; vomit that looks like coffee grounds; swelling of feet/ankles</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4194">
								<item>
									<label>•</label>
									<para>About sodium-restricted diet; to avoid use of baking soda for indigestion</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>sodium polystyrene sulfonate (Rx)</mono_name>
			<info>
				<pronunciation>(po-lee-stye′reen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x42044">Kalexate</tradename>
					<tradename id="tnidelem4x42043">Kayexalate</tradename>
					<tradename id="tnidelem4x42042">
						<country code="CAN">K-Exit</country>
					</tradename>
					<tradename id="tnidelem4x42041">Kionex</tradename>
					<tradename id="tnidelem4x42040">SPS</tradename>
				</tradenames>
				<class type="func"> Potassium-removing resin</class>
				<class type="chem"> Cation exchange resin</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4217">
				<sec_title>Action:</sec_title>
				<para>Removes potassium by exchanging sodium for potassium in body, primarily in large intestine</para>
			</section>
			<section type="uses" id="sidelem4x4222">
				<sec_title>Uses:</sec_title>
				<para>Hyperkalemia in conjunction with other measures</para>
			</section>
			<section type="contra" id="sidelem4x4227">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to saccharin or parabens that may be in some products, GI obstruction, neonate (reduced gut motility)</para>
				<section type="none" id="sidelem4x4232">
					<section type="none" id="sidelem4x4233">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), geriatric patients, renal failure, CHF, severe edema, severe hypertension, sodium restriction, constipation, GI bleeding, hypocalcemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4238">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4246">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4246">
							<item>
								<label>•</label>
								<para> 15 g daily-qid;  enema 30-50 g q1-2hr initially prn, then q6hr prn</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4257">
					<label>•</label>
					<sec_title>Child (unlabeled)<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4257">
							<item>
								<label>•</label>
								<para> 1 g/kg q6hr prn;  1 g/kg q2-6hr prn</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4264">
					<section type="none" id="sidelem4x4265">
						<sec_title>Available forms:</sec_title>
						<para> Powder for susp 453.6 g, 454 g; oral susp 15 g/60 ml</para>
					</section>
					<section type="none" id="sidelem4x4270">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4273">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x4281">
								<label>•</label>
								<sec_title>Powdered resin</sec_title>
								<para>
									<list id="lidelem4x4281">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Powdered resin:</emphasis> each dose of the powdered resin is usually given orally as a suspension in water or in a syrup; usually, the amount of fluid ranges from 20 to 100 ml, depending on the dosage, or 3-4 ml/g of resin; suspensions should be freshly prepared and not stored for &gt;24 hr; the suspension may be also be introduced into the stomach via a tube, or the powdered resin may be mixed with the patient’s food; the powder should not be mixed with foods or liquids that contain a large amount of potassium (bananas or orange juice)</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x4285">
							<sec_title>Rectal route</sec_title>
							<para>
								<list id="lidelem4x4289">
									<item>
										<label>•</label>
										<para>Precede retention enema with a cleansing enema</para>
									</item>
									<item>
										<label>•</label>
										<para>Instruct patient to lie down on left side with lower leg extended and the upper leg flexed for support, or place the patient in the knee–chest position; gently insert a soft, large (28 Fr) rubber tube into the rectum for a distance of about 20 cm; the tip should be well into the sigmoid colon; tape the tube in place; suspend the sodium polystyrene sulfonate powdered resin in 100 ml of an aqueous vehicle (water or sorbitol) that has been warmed to body temperature and introduce through the tube by gravity; the particles should be kept suspended by stirring the suspension during administration; alternatively, 120-180 ml of a commercially available suspension may be administered as a retention enema after the suspension has been warmed to body temperature; following administration, flush the tube with 50-100 ml of fluid and clamp the tube and leave in place; the suspension should be retained in the colon for at least 30-60 min or for several hours, if possible</para>
									</item>
									<item>
										<label>•</label>
										<para>After several hours have passed, administer a cleansing enema using a non–sodium-containing solution at body temperature; up to 2 quarts of fluid may be necessary; drain fluid through a <emphasis style="sans-serif">Y</emphasis>-tube connection; observe the drainage if sorbitol was used</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4308">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4311">
					<section type="none" id="sidelem4x4312">
						<sec_title>GI:</sec_title>
						<para> Constipation, anorexia, nausea, vomiting, diarrhea (sorbitol), fecal impaction, gastric irritation</para>
					</section>
					<section type="none" id="sidelem4x4317">
						<sec_title>META:</sec_title>
						<para> Hypocalcemia, hypokalemia, hypomagnesemia, sodium retention</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4322">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—loop diuretics, cardiac glycosides</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> metabolic alkalosis—magnesium/calcium antacids</para>
				<para>
					<emphasis alert="nurse">Increase: colonic necrosis—sorbitol; do not use concurrently</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—lithium, thyroid hormones</para>
			</section>
			<section type="considerations" id="sidelem4x4342">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4345">
					<section type="none" id="sidelem4x4346">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4354">
							<label>•</label>
							<sec_title>Hyperkalemia<route> confusion, dyspnea, weakness, dysrhythmias; ECG for spiked T waves, depressed ST segments, prolonged QT and widening QRS complex</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x4357">
								<item>
									<label>•</label>
									<para>Bowel function daily; note consistency of stools, times/day</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4365">
							<label>•</label>
							<sec_title>Hypotension</sec_title>
							<para>
								<list id="lidelem4x4365">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypotension:</emphasis> confusion, irritability, muscular pain, weakness</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4372">
							<label>•</label>
							<sec_title>Electrolytes</sec_title>
							<para>
								<list id="lidelem4x4372">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Electrolytes:</emphasis> serum potassium, calcium, magnesium, sodium; acid–base balance</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4376">
								<item>
									<label>•</label>
									<para>I&amp;O ratio, weight daily; crackles, dyspnea, jugular venous distension, edema</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4384">
							<label>•</label>
							<sec_title>
								<route>Digoxin toxicity (nausea, vomiting, blurred vision, anorexia, dysrhythmias) in those receiving digoxin</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4387">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4391">
								<item>
									<label>•</label>
									<para>Therapeutic response: potassium level 3.5-5 mg/dl</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4397">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4401">
								<item>
									<label>•</label>
									<para>About reason for medication and expected results</para>
								</item>
								<item>
									<label>•</label>
									<para>To follow a low-potassium diet, provide sample diet</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid laxatives, antacids, electrolyte-based products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>sofosbuvir</mono_name>
			<info>
				<pronunciation>(soe-fos′bue-vir)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x44220">Sovaldi</tradename>
				</tradenames>
				<class type="func"> Antiviral, antihepatitis agent</class>
				<class type="chem"> Nucleotide analog polymerase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x4432">
				<sec_title>Action:</sec_title>
				<para>Inhibits hepatitis C virus RNA polymerase by incorporating the polymerase into the viral RNA; also acts as a chain terminator</para>
			</section>
			<section type="uses" id="sidelem4x4437">
				<sec_title>Uses:</sec_title>
				<para>Chronic hepatitis C (genotypes 1, 2, 3, 4) with compensated liver disease</para>
			</section>
			<section type="contra" id="sidelem4x4442">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, pregnancy (X) in combination; male-mediated teratogenicity</para>
				<section type="none" id="sidelem4x4447">
					<section type="none" id="sidelem4x4448">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, hepatic/renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4453">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4456">
					<sec_title>Chronic hepatitis C</sec_title>
					<section type="none" id="sidelem4x4459">
						<sec_title>Genotype 1, 4</sec_title>
						<section type="none" id="sidelem4x4467">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4467">
									<item>
										<label>•</label>
										<para> 400 mg daily with peginterferon alfa and ribavirin ×12 wk; may consider use for genotype 1 with only ribavirin ×24 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x4471">
					<sec_title>Chronic hepatitis C</sec_title>
					<section type="none" id="sidelem4x4474">
						<sec_title>Genotype 2</sec_title>
						<section type="none" id="sidelem4x4482">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4482">
									<item>
										<label>•</label>
										<para> 400 mg daily with ribavirin ×12 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x4486">
					<sec_title>Chronic hepatitis C</sec_title>
					<section type="none" id="sidelem4x4489">
						<sec_title>Genotype 3</sec_title>
						<section type="none" id="sidelem4x4497">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4497">
									<item>
										<label>•</label>
										<para> 400 mg daily with ribavirin or daclatasvir ×24 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4501">
						<sec_title>Chronic hepatitis C with hepatocellular carcinoma in those waiting for liver transplant</sec_title>
						<para>
							<emphasis style="bold">Adult: PO</emphasis> 400 mg daily with ribavirin × 48 wks or until transplant</para>
					</section>
					<section type="none" id="sidelem4x4508">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 400 mg</para>
					</section>
					<section type="none" id="sidelem4x4513">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4517">
								<item>
									<label>•</label>
									<para>By mouth without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use as mono therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not crush, break tabs</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4533">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4536">
					<section type="none" id="sidelem4x4537">
						<sec_title>CNS:</sec_title>
						<para> Headache, chills, weakness, fatigue, fever, insomnia</para>
					</section>
					<section type="none" id="sidelem4x4542">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, hyperbilirubinemia</para>
					</section>
					<section type="none" id="sidelem4x4547">
						<sec_title>MISC:</sec_title>
						<para> Rash, pruritus, <emphasis style="bold">neutropenia</emphasis>, anemia, myalgia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4555">
				<sec_title>Pharmacokinetics</sec_title>
				<para>
					<emphasis style="bold">PO:</emphasis> Peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2 hr, excreted by kidneys 80%, 61%-65% protein binding; half-life 0.4-27 hr</para>
			</section>
			<section type="interactions" id="sidelem4x4568">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> sofosbuvir-P-glycoprotein (P-gp) inducers (carBAMazepine, PHENobarbital, phenytoin, rifampin); OXcarbazepine, rifabutin, rifapentine, tipranavir; avoid concurrent use</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bradycardia—amiodarone, avoid using together</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sofosbuvir level—carvedilol, cobicistat</para>
				<section type="none" id="sidelem4x4583">
					<section type="none" id="sidelem4x4584">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="lifethreat">Decrease: sofosbuvir level—St. John’s wort, do not use together</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4590">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4593">
					<section type="none" id="sidelem4x4594">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4599">
								<item>
									<label>•</label>
									<para>Serum HCV-RNA baseline and periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4604">
								<item>
									<label>•</label>
									<para>Severe renal disease/GFR &lt;30 ml/min/1.73 m<emphasis style="sup">2</emphasis>: monitor BUN, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4612">
								<item>
									<label>•</label>
									<para>Geriatric patients more carefully; may develop renal, cardiac symptoms more rapidly</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4620">
							<label>•</label>
							<sec_title>Pregnancy<route> if planned or suspected; if pregnant call the Pregnancy Registry 800-258-4263; obtain pregnancy test before starting treatment, women who have HIV-1 and HCV who are taking antiretrovirals also should enroll with the registry</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4623">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4627">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of chronic hepatitis C</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4633">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4638">
								<item>
									<label>•</label>
									<para>That optimal duration of treatment is unknown; that product is not a cure; that transmission may still occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4643">
								<item>
									<label>•</label>
									<para>To avoid use with other medications unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4649">
								<item>
									<label>•</label>
									<para>Not to stop abruptly unless directed; worsening of hepatitis may occur, not to use alone, keep in original container</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4657">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected; use 2 forms of reliable contraception; avoid breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>solifenacin (Rx)</mono_name>
			<info>
				<pronunciation>(sol-i-fen′a-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x46650">VESIcare</tradename>
				</tradenames>
				<class type="func"> Urinary antispasmodic, anticholinergic</class>
				<class type="chem"> Antimuscarinic</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4675">
				<para>
					<confusion>
						<tradename id="tnidelem4x46750">Vesicare</tradename>
						<drug type="generic" refid="idelem4x46750">Vesanoid</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4679">
				<sec_title>Action:</sec_title>
				<para>Relaxes smooth muscles in urinary tract by inhibiting acetylcholine at postganglionic sites</para>
			</section>
			<section type="uses" id="sidelem4x4684">
				<sec_title>Uses:</sec_title>
				<para>Overactive bladder (urinary frequency, urgency, incontinence)</para>
			</section>
			<section type="contra" id="sidelem4x4689">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, uncontrolled closed-angle glaucoma, urinary retention, gastric retention</para>
				<section type="none" id="sidelem4x4694">
					<section type="none" id="sidelem4x4695">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, renal/hepatic disease, controlled closed-angle glaucoma, bladder outflow obstruction, GI obstruction, decreased GI motility, history of QT prolongation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4700">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4708">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4708">
							<item>
								<label>•</label>
								<para> 5 mg/day, max 10 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4712">
					<section type="none" id="sidelem4x4713">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x4721">
							<label>•</label>
							<sec_title>Adult<route> PO (Child-Pugh B) max 5 mg/day; CCr ≤30 ml/min, 5 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4724">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x4729">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4732">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x4736">
									<item>
										<label>•</label>
										<para>Without regard to meals</para>
									</item>
									<item>
										<label>•</label>
										<para>Swallow product whole with water, liquid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4747">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4750">
					<section type="none" id="sidelem4x4751">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, paresthesia, fatigue, <emphasis style="italic">dizziness,</emphasis> headache, confusion, delirium, depression, drowsiness</para>
					</section>
					<section type="none" id="sidelem4x4759">
						<sec_title>CV:</sec_title>
						<para> Chest pain, hypertension, <emphasis style="bold">QTc prolongation,</emphasis> peripheral edema, palpitations, sinus tachycardia</para>
					</section>
					<section type="none" id="sidelem4x4767">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Vision abnormalities, xerophthalmia,</emphasis> nasal dryness</para>
					</section>
					<section type="none" id="sidelem4x4775">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis> abdominal pain, <emphasis style="italic">constipation, dry mouth,</emphasis> dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x4786">
						<sec_title>GU:</sec_title>
						<para> Dysuria, urinary retention, frequency, UTI</para>
					</section>
					<section type="none" id="sidelem4x4791">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, <emphasis style="bold">angioedema, exfoliative dermatitis,</emphasis> erythema multiforme, <emphasis style="bold">anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4801">
						<sec_title>MISC:</sec_title>
						<para> Hyperthermia</para>
					</section>
					<section type="none" id="sidelem4x4806">
						<sec_title>RESP:</sec_title>
						<para> Bronchitis, cough, pharyngitis, upper respiratory tract infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4811">
				<sec_title>Pharmacokinetics</sec_title>
				<para>90% absorbed; 98% protein bound; extensively metabolized by CYP3A4; excreted in urine 69% (metabolites), feces 22%; terminal half-life 45-68 hr</para>
			</section>
			<section type="interactions" id="sidelem4x4816">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—Class IA, III antidysrhythmias</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—sedatives, hypnotics, benzodiazepines, opioids</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects—CYP3A4 inhibitors (ketoconazole, clarithromycin, diclofenac, doxycycline, erythromycin, isoniazid, nefazodone, propofol, protease inhibitors, verapamil), max dose 5 mg</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects—CYP3A4 inducers (carBAMazepine, nevirapine, PHENobarbital, phenytoin)</para>
				<section type="none" id="sidelem4x4834">
					<section type="none" id="sidelem4x4835">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effects—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x4842">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x4849">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4856">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4859">
					<section type="none" id="sidelem4x4860">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4868">
							<label>•</label>
							<sec_title>Urinary patterns</sec_title>
							<para>
								<list id="lidelem4x4868">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Urinary patterns:</emphasis> distention, nocturia, frequency, urgency, incontinence</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4875">
							<label>•</label>
							<sec_title>Allergic reactions</sec_title>
							<para>
								<list id="lidelem4x4875">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reactions:</emphasis> rash</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4883">
							<label>•</label>
							<sec_title>Angioedema<route> of the face, lips, tongue, larynx</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x4887">
								<item>
									<para>
										<emphasis alert="nurse">Cardiac patients: monitor ECG for QTc prolongation; avoid products that increase QT prolongation</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4892">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4896">
								<item>
									<label>•</label>
									<para>Decreasing dysuria, frequency, nocturia, incontinence</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4902">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4907">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities because dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4912">
								<item>
									<label>•</label>
									<para>That constipation, blurred vision may occur; to notify prescriber if abdominal pain with constipation occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4917">
								<item>
									<label>•</label>
									<para>To take without regard to food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4922">
								<item>
									<label>•</label>
									<para>To swallow tab whole; do not split, crush, chew</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4927">
								<item>
									<label>•</label>
									<para>To call prescriber if severe abdominal pain or constipation lasts for ≥3 days</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4932">
								<item>
									<label>•</label>
									<para>That heat prostration may occur if used in hot environment, sweating is decreased</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4940">
							<label>•</label>
							<sec_title>anticholinergic effects</sec_title>
							<para>
								<list id="lidelem4x4940">
									<item>
										<label>•</label>
										<para>About <emphasis style="bold">anticholinergic effects:</emphasis> blurred vision, constipation, urinary retention, hyperthermia</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="23" status="active">
			<mono_name>somatropin (Rx)</mono_name>
			<info>
				<pronunciation>(soe-ma-troe′pin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x495010">Genotropin</tradename>
					<tradename id="tnidelem4x49509">Humatrope</tradename>
					<tradename id="tnidelem4x49508">Norditropin</tradename>
					<tradename id="tnidelem4x49507">Norditropin Flexpro</tradename>
					<tradename id="tnidelem4x49506">Nutropin</tradename>
					<tradename id="tnidelem4x49505">Nutropin AQ</tradename>
					<tradename id="tnidelem4x49504">Omnitrope</tradename>
					<tradename id="tnidelem4x49503">Saizen</tradename>
					<tradename id="tnidelem4x49502">Serostim</tradename>
					<tradename id="tnidelem4x49501">Tev-Tropin</tradename>
					<tradename id="tnidelem4x49500">Zorbtive</tradename>
				</tradenames>
				<class type="func"> Pituitary hormone</class>
				<class type="chem"> Growth hormone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4960">
				<para>
					<confusion>
						<tradename id="tnidelem4x49600">somatropin</tradename>
						<drug type="generic" refid="idelem4x49600">SUMAtriptan/somatrem</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4964">
				<sec_title>Action:</sec_title>
				<para>Stimulates growth; somatropin is similar to natural growth hormone; both preparations were developed with the use of recombinant DNA</para>
			</section>
			<section type="uses" id="sidelem4x4969">
				<sec_title>Uses:</sec_title>
				<para>Pituitary growth hormone deficiency (hypopituitary dwarfism), children with human growth hormone deficiency/growth failure, AIDS wasting syndrome, cachexia, adults with somatropin deficiency syndrome (SDS), short stature in Noonan syndrome, SHOX deficiency, Turner’s syndrome, Prader-Willi syndrome</para>
			</section>
			<section type="contra" id="sidelem4x4974">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to benzyl alcohol, creosol; closed epiphyses, intracranial lesions, acute respiratory failure, Prader-Willi syndrome with obesity, trauma</para>
				<section type="none" id="sidelem4x4979">
					<section type="none" id="sidelem4x4980">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, newborn, geriatric patients, diabetes mellitus, hypothyroidism, prolonged treatment in adults, scoliosis, sleep apnea, chemotherapy, respiratory disease, glycerin hypersensitivity (with formulations that contain these products)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4985">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4988">
					<section type="none" id="sidelem4x4989">
						<sec_title>Genotropin</sec_title>
						<section type="none" id="sidelem4x4997">
							<label>•</label>
							<sec_title>Child<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x4997">
									<item>
										<label>•</label>
										<para> 0.16-0.24 mg/kg/wk divided into 6 or 7 daily inj; give in abdomen, thigh, buttocks</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5004">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5004">
									<item>
										<label>•</label>
										<para> 0.04-0.08 mg/kg/wk divided into 6-7 daily doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5008">
						<sec_title>Humatrope</sec_title>
						<section type="none" id="sidelem4x5016">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5016">
									<item>
										<label>•</label>
										<para> 0.006 international units/kg/day, max 0.0125 units/kg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5023">
							<label>•</label>
							<sec_title>Child<route> SUBCUT/IM</route></sec_title>
							<para>
								<list id="lidelem4x5023">
									<item>
										<label>•</label>
										<para> 0.18 mg/kg divided into equal doses either on 3 alternate days or 6×/wk, max weekly dose 0.3 mg/kg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5027">
						<sec_title>Nutropin/Nutropin AQ (growth hormone deficiency)</sec_title>
						<section type="none" id="sidelem4x5035">
							<label>•</label>
							<sec_title>Child<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5035">
									<item>
										<label>•</label>
										<para> 0.3 mg/kg/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5039">
						<sec_title>Serostim</sec_title>
						<section type="none" id="sidelem4x5047">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5047">
									<item>
										<label>•</label>
										<para> at bedtime &gt;55 kg, 6 mg; 45-55 kg, 5 mg; 35-45 kg, 4 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5051">
						<sec_title>Norditropin</sec_title>
						<section type="none" id="sidelem4x5059">
							<label>•</label>
							<sec_title>Child<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5059">
									<item>
										<label>•</label>
										<para> 0.024-0.034 mg/kg 6-7×/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5063">
						<sec_title>Replacement of GH in GH deficiency</sec_title>
						<section type="none" id="sidelem4x5071">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5071">
									<item>
										<label>•</label>
										<para> (Saizen) 0.005 mg/kg/day; may increase after 4 wk to max 0.01 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5075">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj (lyophilized) 1.5 mg (4 international units/ml), 4 mg (12 international units/vial), 5 mg (13 international units/vial), 5 mg (15 international units/vial) rDNA origin, 5.8 mg (15 international units/ml), 6 mg (18 international units/ml), 8 mg (24 international units/vial), 10 mg (26 international units/vial); inj 10 mg (30 international units/vial), 5 mg/1.5 ml, 10 mg/1.5 ml, 15 mg/1.5 ml</para>
					</section>
					<section type="none" id="sidelem4x5082">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5086">
								<item>
									<label>•</label>
									<para>Give IM or subcut; do not use IV</para>
								</item>
								<item>
									<label>•</label>
									<para>Discontinue therapy if final height is achieved or epiphyseal fusion occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>Visually inspect parenteral products for particulate matter and discoloration</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5102">
						<sec_title>Reconstitution and storage</sec_title>
						<para/>
					</section>
				</section>
				<section type="none" id="sidelem4x5106">
					<sec_title>Genotropin:</sec_title>
					<para>
						<list id="lidelem4x5111">
							<item>
								<label>•</label>
								<para>Powder, filled in a two-chamber cartridge with the active substance in the front chamber and the diluent in the rear chamber; available in a 5-mg cartridge (green tip) and a 12-mg cartridge (purple tip); the 5- and 12-mg cartridges may be used with the Genotropin Pen or the Genotropin Mixer; also in various doses ranging from 0.2 mg to 2 mg, in single use, auto-mix devices called Genotropin Miniquicks</para>
							</item>
						</list>
					</para>
					<section type="none" id="sidelem4x5119">
						<label>•</label>
						<sec_title>Cartridges</sec_title>
						<para>
							<list id="lidelem4x5119">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Cartridges:</emphasis> store cartridges refrigerated before reconstitution, do not freeze; protect from light; a reconstitution device supplied is used to mix the powder and the diluent; after the powder and diluent are mixed, gently tip the cartridge upside down a few times until powder is dissolved; <emphasis style="italic">do not shake;</emphasis> if solution is cloudy, do not use; following reconstitution, the 5-mg cartridge contains a 5 mg/ml; the 12-mg cartridge contains a 12 mg/ml 5-mg, and 12-mg cartridges contain overfill; the cartridges contain diluent with preservative (m-cresol) and may be stored refrigerated ≤28 days after reconstitution; do not use the 5-mg and 12-mg cartridges in patients with m-cresol hypersensitivity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5129">
						<label>•</label>
						<sec_title>Genotropin Miniquicks</sec_title>
						<para>
							<list id="lidelem4x5129">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Genotropin Miniquicks:</emphasis> after dispensing but before reconstitution, store at ≤77° ≤3 mo; a reconstitution device is supplied and is used to mix the powder and diluent; 10 different strengths are available that each deliver a fixed volume of 0.25 ml; this product contains a diluent with no preservative, refrigerate after reconstitution and use within 24 hr; use the reconstituted solution only once and discard any remaining</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x5133">
					<sec_title>Humatrope:</sec_title>
					<para>
						<list id="lidelem4x5138">
							<item>
								<label>•</label>
								<para>Before reconstitution, store refrigerated</para>
							</item>
						</list>
					</para>
					<section type="none" id="sidelem4x5146">
						<label>•</label>
						<sec_title>Vials</sec_title>
						<para>
							<list id="lidelem4x5146">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Vials:</emphasis> reconstitute each 5-mg vial with 1.5-5 ml of the diluent (contains m-cresol as a preservative) or bacteriostatic water for injection (contains benzoyl alcohol as a preservative); sterile water for injection may be used for patients with a hypersensitivity to m-cresol and benzoyl alcohol; direct the liquid against the glass vial wall; swirl until contents are dissolved; do not shake; if the solution is cloudy, do not use; small, colorless particles may be present after refrigeration, this is not unusual for solutions containing proteins; vials reconstituted with the diluent or bacteriostatic water are stable for 14 days when refrigerated; for vials reconstituted with sterile water, use the vial only once and discard if not used immediately, refrigerate and use within 24 hr; avoid freezing</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5153">
						<label>•</label>
						<sec_title>Cartridges</sec_title>
						<para>
							<list id="lidelem4x5153">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Cartridges:</emphasis> reconstitute cartridges using <emphasis style="italic">only</emphasis> the supplied diluent syringe; the cartridges are designed for use only with the Humatrope injection device; once reconstituted, the cartridges are stable for up to 28 days when stored refrigerated; store the injection device without the needle attached; avoid freezing reconstituted solutions</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x5160">
					<sec_title>Norditropin:</sec_title>
					<para>
						<list id="lidelem4x5164">
							<item>
								<label>•</label>
								<para>Do not use reconstituted solution if it is cloudy or contains particulate matter</para>
							</item>
							<item>
								<label>•</label>
								<para>Before use, store refrigerated</para>
							</item>
							<item>
								<label>•</label>
								<para>Reconstitution of the cartridges is not required; the cartridge is intended for use only with the NordiPen injector; a prefilled, disposable pen, NordiFlex Pen injector, is also available; each cartridge size (5 mg, 10 mg, or 15 mg per 1.5-ml cartridge) has a color-coded corresponding pen, which is graduated to deliver an appropriate dose based on the solution’s concentration; NordiPen and NordiFlex Pen allow administration of a minimum 0.25-mg dose to a maximum 4.5-mg dose, depending on cartridge concentrations; follow directions provided in NordiPen injector instruction booklet</para>
							</item>
							<item>
								<label>•</label>
								<para>After a cartridge has been inserted into the NordiPen injector or once a NordiFlex pen is in use, the pen should be stored refrigerated and used within 4 wk; alternatively, the 5-mg and 10-mg cartridges may be stored in the pen at room temperature, no higher than 77°, for up to 3 wk; NovoFine needles are recommended for administration; wipe the stopper of the pen cartridge with rubbing alcohol</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5188">
					<sec_title>Nutropin:</sec_title>
					<para>
						<list id="lidelem4x5192">
							<item>
								<label>•</label>
								<para>Before reconstitution, store refrigerated</para>
							</item>
							<item>
								<label>•</label>
								<para>Reconstitute each 5-mg vial with 1-5 ml bacteriostatic water for injection (benzyl alcohol preserved) and each 10-mg vial with 1-10 ml of bacteriostatic water for injection (benzyl alcohol preserved); if using for newborns, reconstitute with sterile water for injection; direct the liquid against the glass vial wall; swirl vial with a gentle rotary motion until contents are dissolved completely; do not shake; if the solution is cloudy after reconstitution or refrigeration, do not use; small, colorless particles may be present after refrigeration, this is not unusual for solutions containing proteins</para>
							</item>
							<item>
								<label>•</label>
								<para>Solutions reconstituted with bacteriostatic water for injection are stable for 14 days refrigerated</para>
							</item>
							<item>
								<label>•</label>
								<para>Solutions reconstituted with sterile water for injection should be used immediately and only once; discard any unused portions; avoid freezing reconstituted solutions</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5213">
					<sec_title>Nutropin AQ:</sec_title>
					<para>
						<list id="lidelem4x5218">
							<item>
								<label>•</label>
								<para>Does not require reconstitution; solution should be clear; small, colorless particles may be present after refrigeration, this is not unusual for solutions containing proteins; allow vial or pen cartridge to come to room temperature, and gently swirl; if solution is cloudy, do not use</para>
							</item>
						</list>
					</para>
					<section type="none" id="sidelem4x5226">
						<label>•</label>
						<sec_title>Vials</sec_title>
						<para>
							<list id="lidelem4x5226">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Vials:</emphasis> before inserting needle, wipe the vial septum with rubbing alcohol or antiseptic solution to prevent contamination by microorganisms that may be introduced by repeated needle insertions; administer using sterile disposable syringes and needles; use syringes with small enough volume that the prescribed dose may be drawn from the vial with reasonable accuracy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5233">
						<label>•</label>
						<sec_title>Pen cartridge</sec_title>
						<para>
							<list id="lidelem4x5233">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Pen cartridge:</emphasis> two strengths are available, 10 mg and 20 mg; intended for use only with Nutropin AQ Pen; each pen and cartridge are color coded to ensure accurate placement of the 10-mg or 20-mg cartridge into the appropriate pen; do not use the 20-mg cartridge in the pen intended for the 10-mg cartridge, and vice versa; wipe septum of pen cartridge with rubbing alcohol or antiseptic solution to prevent contamination by microorganisms that may be introduced by repeated needle insertions; administer using sterile, disposable needles; follow the directions provided in the Nutropin AQ Pen Instructions for Use; the Nutropin AQ 10 pen allows administration of a minimum 0.1-mg dose to a maximum 4-mg dose, in 0.1-mg increments; the Nutropin AQ 20 pen allows administration of a minimum 0.2-mg dose to a maximum 8-mg dose, in 0.2-mg increments</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5240">
						<label>•</label>
						<sec_title>Prefilled device</sec_title>
						<para>
							<list id="lidelem4x5240">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Prefilled device:</emphasis> a prefilled multidose, dial-a-dose device is available in 3 strengths; administer using disposable needles; follow the directions provided in the Nutropin AQ NuSpin Instructions for Use; the Nutropin AQ Nuspin 5 allows administration of a minimum dose of 0.05 mg to a maximum dose of 1.75 mg, in increments of 0.05 mg; the Nutropin AQ Nuspin 10 allows administration of a minimum dose of 0.1 mg to a maximum dose of 3.5 mg, in increments of 0.1 mg; the Nutropin AQ Nuspin 20 allows administration of a minimum dose of 0.2 mg to a maximum dose of 7 mg, in increments of 0.2 mg</para>
								</item>
							</list>
						</para>
					</section>
					<para>
						<list id="lidelem4x5244">
							<item>
								<label>•</label>
								<para>After initial use, vials, cartridges, and prefilled devices are stable for 28 days refrigerated; avoid freezing; vials, cartridges, and prefilled devices are light sensitive; protect from light</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5249">
					<sec_title>Omnitrope:</sec_title>
					<para>
						<list id="lidelem4x5254">
							<item>
								<label>•</label>
								<para>Before reconstitution, store vials refrigerated; store in the carton; Omnitrope is sensitive to light</para>
							</item>
						</list>
					</para>
					<section type="none" id="sidelem4x5262">
						<label>•</label>
						<sec_title>Vials</sec_title>
						<para>
							<list id="lidelem4x5262">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Vials:</emphasis> reconstitute the vial with diluent provided using a sterile disposable syringe; swirl the vial gently, but do not shake; if the solution is cloudy after reconstitution, the contents must not be injected; after reconstitution, the 1.5-mg vial may be refrigerated ≤24 hr; the 1.5-mg vial does not contain a preservative and should only be used once; discard any remaining solution; the 5.8-mg vial diluent contains benzoyl alcohol as a preservative; after reconstitution, the contents must be used within 3 wk; after the first injection, store the 5.8-mg vial in the carton, to protect from light, in the refrigerator; avoid freezing</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5269">
						<label>•</label>
						<sec_title>Omnitrope Pen 5 cartridge</sec_title>
						<para>
							<list id="lidelem4x5269">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Omnitrope Pen 5 cartridge:</emphasis> each 5-mg cartridge must be inserted into the Omnitrope Pen 5 delivery system; follow the directions provided in the Omnitrope Instructions for Use; the cartridge contains benzoyl alcohol as a preservative; after the first use, store refrigerated ≤28 days; protect from light, avoid freezing</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5276">
						<label>•</label>
						<sec_title>Omnitrope Pen 10 cartridge</sec_title>
						<para>
							<list id="lidelem4x5276">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Omnitrope Pen 10 cartridge:</emphasis> each 10-mg cartridge must be inserted into the Omnitrope Pen 10 delivery system; follow the directions provided in the Omnitrope Instructions for Use; after the first use, store refrigerated ≤28 days; protect from light, avoid freezing</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x5280">
					<sec_title>Saizen:</sec_title>
					<para>
						<list id="lidelem4x5285">
							<item>
								<label>•</label>
								<para>Before reconstitution, store at room temperature</para>
							</item>
						</list>
					</para>
					<section type="none" id="sidelem4x5293">
						<label>•</label>
						<sec_title>Vials</sec_title>
						<para>
							<list id="lidelem4x5293">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Vials:</emphasis> reconstitute each 5-mg vial with 1-3 ml bacteriostatic water for injection; reconstitute each 8.8-mg vial with 2-3 ml bacteriostatic water for injection (benzoyl alcohol preserved); in patients with hypersensitivity to benzyl alcohol, the vials may be mixed with sterile water for injection; direct the liquid against the glass vial wall; swirl vial with a gentle rotary motion until contents are dissolved completely; do not shake; the solution should be clear; if it is cloudy immediately after reconstitution or refrigeration, do not use; small colorless particles may be present after refrigeration, this is not unusual for solutions containing proteins; after reconstitution, store vials mixed with bacteriostatic water for injection refrigerated and use within 14 days; for vials mixed with sterile water for injection, the solution should be used immediately, and any unused portion should be discarded; avoid freezing</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5300">
						<label>•</label>
						<sec_title>Cartridges</sec_title>
						<para>
							<list id="lidelem4x5300">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Cartridges:</emphasis> available in 4-mg and 8.8-mg click.easy cartridges for use in a compatible injection device; a reconstitution device supplied by the manufacturer is used to mix the Saizen with accompanying diluent containing metacresol; cartridges reconstituted with the diluent containing metascresol are stable under refrigeration for ≤21 days; avoid freezing</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x5304">
					<sec_title>Serostim:</sec_title>
					<para>
						<list id="lidelem4x5309">
							<item>
								<label>•</label>
								<para>Before reconstitution, store vials and diluent at room temperature (15-30° C; 59–86° F)</para>
							</item>
						</list>
					</para>
					<section type="none" id="sidelem4x5317">
						<label>•</label>
						<sec_title>Vials</sec_title>
						<para>
							<list id="lidelem4x5317">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Vials:</emphasis> reconstitute the 5-mg or 6-mg vials with 0.5-1 ml of supplied diluent (sterile water for injection); reconstitute the 4-mg vial with 0.5-1 ml of bacteriostatic water for injection (benzoyl alcohol preserved) and the 8.8-mg vial with 1-2 ml of bacteriostatic water for injection (benzoyl alcohol preserved); direct the liquid against the glass vial wall; swirl vial with a gentle rotary motion until contents are dissolved completely; do not shake; the solution should be clear; if it is cloudy immediately after reconstitution or refrigeration, do not use; small colorless particles may be present after refrigeration, this is not unusual for solutions containing proteins; if reconstituted with sterile water for injection, use within 24 hr; if reconstituted with bacteriostatic water for injection (benzoyl alcohol preserved), the solution is stable for up to 14 days under refrigeration (2-8° C or 36-46° F); avoid freezing</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5326">
						<label>•</label>
						<sec_title>Cartridges</sec_title>
						<para>
							<list id="lidelem4x5326">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Cartridges:</emphasis> available in 8.8-mg click.easy cartridges for use in a compatible injection device; a reconstitution device is supplied by the manufacturer and is used to mix the Serostim with accompanying diluent containing metacresol; after reconstitution, cartridges are stable under refrigeration for ≤21 days; avoid freezing</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x5330">
					<sec_title>Serostim LQ:</sec_title>
					<para>
						<list id="lidelem4x5334">
							<item>
								<label>•</label>
								<para>Before use, store refrigerated</para>
							</item>
							<item>
								<label>•</label>
								<para>Available in 6-mg single-use cartridges that do not require reconstitution; administer using sterile disposable syringes and needles</para>
							</item>
							<item>
								<label>•</label>
								<para>Bring to room temperature before use; discard single-use cartridge after use, even if some drug remains; discard cartridges after the expiration date stated on the product; do not freeze; protect from light</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5350">
					<sec_title>Tev-Tropin:</sec_title>
					<para>
						<list id="lidelem4x5354">
							<item>
								<label>•</label>
								<para>Before reconstitution, store refrigerated</para>
							</item>
							<item>
								<label>•</label>
								<para>Reconstitute each 5-mg vial with 1-5 ml bacteriostatic 0.9% sodium chloride (benzoyl alcohol preserved) for injection; direct the liquid against the glass vial wall; swirl vial with a gentle rotary motion until contents are dissolved completely; do not shake; the solution should be clear; if it is cloudy immediately after reconstitution, do not inject; small, colorless particles may be present after refrigeration, this is not unusual for solutions containing proteins; when administering to newborns, reconstitute with sterile normal saline for injection that is unpreserved</para>
							</item>
							<item>
								<label>•</label>
								<para>Solution reconstituted with bacteriostatic 0.9% sodium chloride is stable for 14 days when stored refrigerated; solution reconstituted with sterile normal saline should be used only once; discard any remaining solution; avoid freezing</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5370">
					<sec_title>Valtropin:</sec_title>
					<para>
						<list id="lidelem4x5374">
							<item>
								<label>•</label>
								<para>Before dispensing, store vials and diluent refrigerated; after dispensing to patients, may be stored at or below 77° F for up to 3 mo</para>
							</item>
							<item>
								<label>•</label>
								<para>Reconstitute each 5-mg vial with the entire contents of the accompanying diluent, which contains metacresol as a preservative; if patients are allergic to metacresol, sterile water for injection may be used; direct the liquid against the glass vial wall; swirl vial with a gentle rotary motion until contents are dissolved completely; do not shake; the solution should be clear, if it is cloudy or contains particulate matter immediately after reconstitution or after refrigeration, do not inject; the final concentration of the reconstituted solution is 3.33 mg/ml</para>
							</item>
							<item>
								<label>•</label>
								<para>After reconstitution with the provided diluent, solutions may be stored refrigerated for up to 14 days; after reconstitution with sterile water for injection, use only one dose of Valtropin per vial and discard the unused portion if not used immediately</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5390">
					<sec_title>Zorbtive:</sec_title>
					<para>
						<list id="lidelem4x5394">
							<item>
								<label>•</label>
								<para>Unreconstituted vials of drug and diluent may be stored at room temperature until expiration date</para>
							</item>
							<item>
								<label>•</label>
								<para>Reconstitute each vial of 4 mg, 5 mg, or 6 mg with 0.5-1 ml sterile water for injection, USP; reconstitute each 8.8 mg with 1-2 ml bacteriostatic water for injection (0.9% benzyl alcohol preserved); in newborns or patients with a benzoyl alcohol hypersensitivity, sterile water for injection may be used; review manufacturer’s labeling for expected concentrations; direct the liquid against the glass vial wall; swirl vial with a gentle rotary motion until contents are dissolved completely; do not shake; the solution should be clear, if it is cloudy after reconstitution or refrigeration, do not use; small colorless particles may be present after refrigeration, this is not unusual for solutions containing proteins</para>
							</item>
							<item>
								<label>•</label>
								<para>After reconstitution with sterile water for injection, use the solution immediately and discard any unused portion; when using bacteriostatic water for injection, reconstituted solutions are stable for up to 14 days refrigerated; avoid freezing vials of drug or diluent or reconstituted vials</para>
							</item>
						</list>
					</para>
					<section type="none" id="sidelem4x5412">
						<section type="none" id="sidelem4x5413">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x5417">
									<item>
										<label>•</label>
										<para>Inject deeply into a large muscle; aspirate before injection; rotate injection sites daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5423">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x5427">
									<item>
										<label>•</label>
										<para>Volumes &gt;1 ml of reconstituted solution are not recommended; do not inject intradermally</para>
									</item>
									<item>
										<label>•</label>
										<para>Allow refrigerated solutions to come to room temperature before injection</para>
									</item>
									<item>
										<label>•</label>
										<para>Subcutaneous injections may be given in the thigh, buttocks, or abdomen; rotate injection sites daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5443">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5446">
					<section type="none" id="sidelem4x5447">
						<sec_title>CNS:</sec_title>
						<para> Headache, growth of intracranial tumor, fever, aggressive behavior</para>
					</section>
					<section type="none" id="sidelem4x5452">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia, ketosis, hypothyroidism, thyroid hormone replacement may be needed</para>
					</section>
					<section type="none" id="sidelem4x5457">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5464">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Hypercalciuria</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5471">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, pain; inflammation at inj site, hematoma</para>
					</section>
					<section type="none" id="sidelem4x5476">
						<sec_title>MS:</sec_title>
						<para> Tissue swelling, joint and muscle pain</para>
					</section>
					<section type="none" id="sidelem4x5481">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Antibodies to growth hormone</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5488">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 15-60 min, duration 7 days, metabolized in liver</para>
			</section>
			<section type="interactions" id="sidelem4x5493">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> epiphyseal closure—androgens, thyroid hormones</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> growth—glucocorticosteroids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> insulin, antidiabetic effect—dosage adjustment may be needed</para>
				<section type="none" id="sidelem4x5508">
					<section type="none" id="sidelem4x5509">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> glucose, urine glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> glucose thyroid hormones</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5520">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5523">
					<section type="none" id="sidelem4x5524">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5529">
								<item>
									<label>•</label>
									<para>Signs/symptoms of diabetes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5534">
								<item>
									<label>•</label>
									<para>Growth hormone antibodies if patient fails to respond to therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5539">
								<item>
									<label>•</label>
									<para>Thyroid function tests: T<emphasis style="inf">3</emphasis>, T<emphasis style="inf">4</emphasis>, T<emphasis style="inf">7</emphasis>, TSH to identify hypothyroidism</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5556">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x5556">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> rash, itching, fever, nausea, wheezing</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5563">
							<label>•</label>
							<sec_title>Hypercalciuria</sec_title>
							<para>
								<list id="lidelem4x5563">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypercalciuria:</emphasis> urinary stones; groin, flank pain; nausea, vomiting, urinary frequency, hematuria, chills</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5567">
								<item>
									<label>•</label>
									<para>Growth rate, bone age of child at intervals during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5575">
							<label>•</label>
							<sec_title>Respiratory infection</sec_title>
							<para>
								<list id="lidelem4x5575">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory infection:</emphasis> in those with Prader-Willi syndrome, may have sleep apnea, upper airway obstruction; discontinue if obstruction occurs</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5579">
								<item>
									<label>•</label>
									<para>Rapid growth: assess for slipped capital femoral epiphysis may also occur in endocrine disorders</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5584">
								<item>
									<label>•</label>
									<para>Monitor ophthalmologic status baseline and periodically; intracranial hypertension may occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5589">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5593">
								<item>
									<label>•</label>
									<para>Therapeutic response: growth in children</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5599">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5604">
								<item>
									<label>•</label>
									<para>That treatment may continue for years; that regular assessments are required</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5609">
								<item>
									<label>•</label>
									<para>To maintain a growth record; to report knee/hip pain or limping</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5614">
								<item>
									<label>•</label>
									<para>That treatment is very expensive</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5622">
							<label>•</label>
							<sec_title>
								<route>Identify creosol or benzyl-alcohol hypersensitivity before use</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="24" status="active">
			<mono_name>sotalol (Rx)</mono_name>
			<info>
				<pronunciation>(sot′ah-lahl)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x56303">Betapace</tradename>
					<tradename id="tnidelem4x56302">Betapace AF</tradename>
					<tradename id="tnidelem4x56301">
						<country code="CAN">Rylosol</country>
					</tradename>
					<tradename id="tnidelem4x56300">Sorine</tradename>
				</tradenames>
				<class type="func"> Antidysrhythmic group III</class>
				<class type="chem"> Nonselective β-blocker</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x5643">
				<sec_title>Action:</sec_title>
				<para>Blockade of β<emphasis style="inf">1</emphasis>- and β<emphasis style="inf">2</emphasis>-receptors leads to antidysrhythmic effect, prolongs action potential in myocardial fibers without affecting conduction, prolongs QT interval, no effect on QRS duration</para>
			</section>
			<section type="uses" id="sidelem4x5656">
				<sec_title>Uses:</sec_title>
				<para>Life-threatening ventricular dysrhythmias; Betapace AF: to maintain sinus rhythm with symptomatic atrial fibrillation/flutter</para>
				<section type="none" id="sidelem4x5661">
					<section type="none" id="sidelem4x5662">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Atrial fibrillation prophylaxis, cardiac surgery, PSVT, Wolff-Parkinson-White (WPW) syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5667">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to β-blockers, cardiogenic shock, heart block (2nd/3rd degree), sinus bradycardia, CHF, bronchial asthma, CCr &lt;40 ml/min</para>
				<para>
					<bbw>Congenital or acquired long QT syndrome, hypokalemia</bbw>
				</para>
				<section type="none" id="sidelem4x5682">
					<section type="none" id="sidelem4x5683">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, major surgery, diabetes mellitus, renal/thyroid disease, COPD, well-compensated heart failure, CAD, nonallergic bronchospasm, electrolyte disturbances, bradycardia, peripheral vascular disease</para>
						<para>
							<bbw>Cardiac dysrhythmias, torsades de pointes, ventricular dysrhythmias, ventricular fibrillation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5698">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5706">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5706">
							<item>
								<label>•</label>
								<para> initial 80 mg bid, may increase to 240-320 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5713">
					<label>•</label>
					<sec_title>Child &gt;2 yr with normal renal function (unlabeled)<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5713">
							<item>
								<label>•</label>
								<para> 30 mg/m<emphasis style="sup">2</emphasis> tid, adjust dose gradually after ≥36 hr to max 60 mg/m<emphasis style="sup">2</emphasis> tid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5723">
					<section type="none" id="sidelem4x5724">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x5732">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-60 ml/min, give q24hr; CCr 10-29 ml/min, give q36-48hr; CCr &lt;10 ml/min, individualize dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5735">
						<sec_title>Life-threatening ventricular dysrhythmias</sec_title>
						<section type="none" id="sidelem4x5743">
							<label>•</label>
							<sec_title>Adult (CCr 40-60 ml/min)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5743">
									<item>
										<label>•</label>
										<para> 75 mg over 5 hr daily, monitor QTc at end of each infusion during initiation and titration; 80 mg PO = 75 mg IV; 120 mg PO = 112.5 mg IV; 160 mg PO = 150 mg IV</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5747">
						<sec_title>Betapace AF</sec_title>
						<section type="none" id="sidelem4x5755">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5755">
									<item>
										<label>•</label>
										<para> initial 80 mg bid, titrate upward to 120 mg bid during initial hospitalization, monitor QTc interval for 2-4 hr after each dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5759">
						<sec_title>Renal dose (Betapace AF)</sec_title>
						<section type="none" id="sidelem4x5767">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &gt;60 ml/min, give q12hr; CCr 40-60 ml/min, give q24hr; CCr &lt;40 ml/min, do not use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5770">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 80, 120, 160, 240 mg; (Betapace AF) 80, 120, 160 mg; inj 150 mg/10 ml (15 mg/ml)</para>
					</section>
					<section type="none" id="sidelem4x5775">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5778">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x5783">
									<item>
										<label>•</label>
										<para>Before, at bedtime; tab may be crushed or swallowed whole; give 1 hr before or 2 hr after meals</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x5788">
									<item>
										<label>•</label>
										<para>Reduced dosage in renal dysfunction</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5796">
								<label>•</label>
								<sec_title>
									<route>Betapace and Betapace AF are not interchangeable</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x5799">
									<item>
										<label>•</label>
										<para>Do not give within 2 hr of antacids</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x5804">
									<item>
										<label>•</label>
										<para>Store in dry area at room temperature; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5809">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x5814">
									<item>
										<label>•</label>
										<para>Dilute to vol of either 120 ml or 300 ml with D<emphasis style="inf">5</emphasis>W, LR</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5825">
								<label>•</label>
								<sec_title>75 mg dose</sec_title>
								<para>
									<list id="lidelem4x5825">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">75 mg dose:</emphasis> withdraw 6 ml sotalol inj (90 mg), add 114 ml dilute to make 120 ml (0.75 mg/ml); or withdraw 6 ml sotalol inj (90 mg), add 294 ml dilute to make 300 ml (0.3 mg/ml)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5832">
								<label>•</label>
								<sec_title>112.5 mg dose</sec_title>
								<para>
									<list id="lidelem4x5832">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">112.5 mg dose:</emphasis> withdraw 9 ml sotalol inj (135 ml), add 111 ml dilute to make 120 ml (1.125 mg/ml); or withdraw 9 ml sotalol (135 mg), add 291 ml dilute to make 300 ml (0.45 mg/ml)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5839">
								<label>•</label>
								<sec_title>150 mg dose</sec_title>
								<para>
									<list id="lidelem4x5839">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">150 mg dose:</emphasis> withdraw 12 ml of sotalol (180 mg), add 108 ml to make 120 ml (1.5 mg/ml); or withdraw 12 ml sotalol (180 mg), add 288 ml to make 300 ml (0.6 mg/ml)</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x5843">
									<item>
										<label>•</label>
										<para>Use infusion pump and infuse 100 or 250 ml over 5 hr at a constant rate</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5848">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5851">
					<section type="none" id="sidelem4x5852">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, mental changes, drowsiness, fatigue, headache, catatonia, depression, anxiety, nightmares, paresthesia, lethargy, insomnia, decreased concentration</para>
					</section>
					<section type="none" id="sidelem4x5858">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Prodysrhythmia, prolonged QT,</emphasis> orthostatic hypotension, bradycardia, <emphasis style="bold">CHF,</emphasis> chest pain, ventricular dysrhythmias, AV block, peripheral vascular insufficiency, palpitations, torsades de pointes; <emphasis style="bold">life-threatening ventricular dysrhythmias (Betapace AF)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5871">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, visual changes, sore throat, double vision; dry, burning eyes</para>
					</section>
					<section type="none" id="sidelem4x5876">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, dry mouth, flatulence, constipation, anorexia, indigestion</para>
					</section>
					<section type="none" id="sidelem4x5881">
						<sec_title>GU:</sec_title>
						<para> Impotence, dysuria, ejaculatory failure, urinary retention</para>
					</section>
					<section type="none" id="sidelem4x5886">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenic purpura</emphasis> (rare), <emphasis style="bold">thrombocytopenia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5896">
						<sec_title>INTEG:</sec_title>
						<para> Rash, alopecia, urticaria, pruritus, fever, diaphoresis</para>
					</section>
					<section type="none" id="sidelem4x5901">
						<sec_title>MISC:</sec_title>
						<para> Facial swelling, decreased exercise tolerance, weight change, Raynaud’s disease</para>
					</section>
					<section type="none" id="sidelem4x5906">
						<sec_title>MS:</sec_title>
						<para> Joint pain, arthralgia, muscle cramps, pain</para>
					</section>
					<section type="none" id="sidelem4x5911">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> dyspnea, wheezing, nasal stuffiness, pharyngitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5919">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x5922">
					<section type="none" id="sidelem4x5923">
						<sec_title>PO:</sec_title>
						<para> Onset 1-2 hr, peak 2-4 hr, duration 8-12 hr, half-life 12 hr, excreted unchanged in urine, crosses placenta, excreted in breast milk, protein binding 0%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5928">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl; CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone)</bbw>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia effect—insulin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of lidocaine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—diuretics, other antihypertensives, nitroglycerin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> β-blocker effects—sympathomimetics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> bronchodilating effects of theophylline, β<emphasis style="inf">2</emphasis>-agonists</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hypoglycemic effects of sulfonylureas</para>
				<section type="none" id="sidelem4x5970">
					<section type="none" id="sidelem4x5971">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False increase:</emphasis> urinary catecholamines</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> glucose, insulin tolerance tests</para>
					</section>
					<section type="none" id="sidelem4x5982">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x5986">
								<item>
									<label>•</label>
									<para>Do not use with hawthorn</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5992">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5995">
					<section type="none" id="sidelem4x5996">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6001">
								<item>
									<label>•</label>
									<para>I&amp;O, weight daily; edema in feet, legs daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6006">
								<item>
									<label>•</label>
									<para>B/P, pulse q4hr; note rate, rhythm, quality</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6011">
								<item>
									<label>•</label>
									<para>Potassium, magnesium levels
<bbw>Requires a specialized care setting: for a minimum of at least 3 days on maintenance dose with continuous ECG monitoring, creatinine clearance; calculate before dosing</bbw>

<bbw>Cardiogenic shock, acute pulmonary edema: do not use, effect can further depress cardiac output</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6035">
								<item>
									<para>
										<emphasis alert="nurse">QT syndrome: apical/radial pulse before administration: notify prescriber of any significant changes; monitor ECG continuously (Betapace AF); use QT interval to determine patient eligibility; baseline QT must be ≤450 msec, if ≥500 msec, frequency or dosage must be decreased or drug discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6040">
								<item>
									<label>•</label>
									<para>Baselines of renal studies before therapy begins</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6048">
							<label>•</label>
							<sec_title>Abrupt discontinuation<route> do not discontinue abruptly, taper over 1-2 wk</route></sec_title>
						</section>
						<section type="none" id="sidelem4x6054">
							<label>•</label>
							<sec_title>
								<route>Dose should be adjusted slowly, with at least 3 days between changes; monitor ECG for QT interval</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6057">
								<item>
									<label>•</label>
									<para>Monitor electrolytes (hypokalemia, hypomagnesia) may increase dysrhythmias</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6062">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6066">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of life-threatening dysrhythmias</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6072">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x6080">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue product abruptly; to taper over 2 wk or may precipitate angina; to take exactly as prescribed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6083">
								<item>
									<label>•</label>
									<para>Not to use antacids or OTC products containing α-adrenergic stimulants (nasal decongestants, OTC cold preparations) unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6088">
								<item>
									<label>•</label>
									<para>To report bradycardia, dizziness, confusion, depression, fever</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6093">
								<item>
									<label>•</label>
									<para>To take pulse at home; advise patient when to notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6098">
								<item>
									<label>•</label>
									<para>To avoid alcohol, smoking, sodium intake</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6103">
								<item>
									<label>•</label>
									<para>To carry emergency ID to identify product being taken, allergies</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6108">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness present</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6116">
							<label>•</label>
							<sec_title>
								<route>To report symptoms of CHF including difficulty breathing, especially on exertion or when lying down; night cough, swelling of extremities</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6119">
								<item>
									<label>•</label>
									<para>To wear support hose to minimize effects of orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6124">
								<item>
									<label>•</label>
									<para>To monitor blood glucose if diabetic</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6132">
							<label>•</label>
							<sec_title>
								<route>That hospitalization will be required for ≥3 days</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="25" status="active">
			<mono_name>spironolactone (Rx)</mono_name>
			<info>
				<pronunciation>(speer′on-oh-lak′tone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x61481">Aldactone</tradename>
					<tradename id="tnidelem4x61480">
						<country code="CAN">Novo-Spiroton </country>
					</tradename>
				</tradenames>
				<class type="func"> Potassium-sparing diuretic</class>
				<class type="chem"> Aldosterone antagonist</class>
			</info>
			<section type="confusion" id="sidelem4x6160">
				<para>
					<confusion>
						<tradename id="tnidelem4x61600">Aldactone</tradename>
						<drug type="generic" refid="idelem4x61600">Aldactazide</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6164">
				<sec_title>Action:</sec_title>
				<para>Competes with aldosterone at receptor sites in distal tubule, thereby resulting in the excretion of sodium chloride and water and the retention of potassium and phosphate</para>
			</section>
			<section type="uses" id="sidelem4x6169">
				<sec_title>Uses:</sec_title>
				<para>Edema of CHF, hypertension, diuretic-induced hypokalemia, primary hyperaldosteronism (diagnosis, short-term treatment, long-term treatment), edema of nephrotic syndrome, cirrhosis of liver with ascites</para>
				<section type="none" id="sidelem4x6174">
					<section type="none" id="sidelem4x6175">
						<sec_title>Unlabeled uses:</sec_title>
						<para> CHF, hirsutism in women, bronchopulmonary dysplasia (BPD), PMS, polycystic ovary syndrome, acne vulgaris, premenstrual syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6180">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, anuria, severe renal disease, hyperkalemia</para>
				<section type="none" id="sidelem4x6185">
					<section type="none" id="sidelem4x6186">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, dehydration, hepatic disease, renal impairment, electrolyte imbalances, metabolic acidosis, gynecomastia, pregnancy (C)</para>
						<para>
							<bbw>Secondary malignancy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6201">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6204">
					<section type="none" id="sidelem4x6205">
						<sec_title>Edema/hypertension</sec_title>
						<section type="none" id="sidelem4x6213">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6213">
									<item>
										<label>•</label>
										<para> 25-200 mg/day in 1-2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6217">
						<sec_title>CHF</sec_title>
						<section type="none" id="sidelem4x6225">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6225">
									<item>
										<label>•</label>
										<para> 12.5-25 mg/day; max 50 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6229">
						<sec_title>Edema</sec_title>
						<section type="none" id="sidelem4x6237">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6237">
									<item>
										<label>•</label>
										<para> 1.5-3.3 mg/kg/day as single dose or in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6241">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x6249">
							<label>•</label>
							<sec_title>Child (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6249">
									<item>
										<label>•</label>
										<para> 1.5-3.3 mg/kg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6253">
						<sec_title>Hypokalemia</sec_title>
						<section type="none" id="sidelem4x6261">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6261">
									<item>
										<label>•</label>
										<para> 25-100 mg/day; if  potassium supplements must not be used</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6268">
						<sec_title>Primary hyperaldosteronism diagnosis</sec_title>
						<section type="none" id="sidelem4x6276">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6276">
									<item>
										<label>•</label>
										<para> 400 mg/day × 4 days or 4 wk depending on test, then 100-400 mg/day maintenance</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6280">
						<sec_title>Edema (nephrotic syndrome, CHF, hepatic disease)</sec_title>
						<section type="none" id="sidelem4x6288">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6288">
									<item>
										<label>•</label>
										<para> 100 mg/day given as single dose or in divided doses, titrate to response</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6296">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6296">
									<item>
										<label>•</label>
										<para> 1.5-3.3 mg/kg/day or 60 mg/m<emphasis style="sup">2</emphasis>/day given daily or in 2-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6303">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x6311">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 10-50 ml/min; give dose q12-24hr; CCr &lt;10 ml/min, avoid use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6314">
						<sec_title>Polycystic ovary syndrome/hirsutism in women (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6322">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6322">
									<item>
										<label>•</label>
										<para> 50-200 mg in 1-2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6326">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 50, 100 mg</para>
					</section>
					<section type="none" id="sidelem4x6331">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6335">
								<item>
									<label>•</label>
									<para>In <emphasis style="smallcaps">am</emphasis> to avoid interference with sleep</para>
								</item>
								<item>
									<label>•</label>
									<para>With food; if nausea occurs, absorption may be decreased slightly</para>
								</item>
								<item>
									<label>•</label>
									<para>Effect may take 2 wk</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6354">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6357">
					<section type="none" id="sidelem4x6358">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> confusion, drowsiness, lethargy, ataxia</para>
					</section>
					<section type="none" id="sidelem4x6366">
						<sec_title>ELECT:</sec_title>
						<para> Hyperchloremic metabolic acidosis, <emphasis style="bold">hyperkalemia,</emphasis> hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x6374">
						<sec_title>ENDO:</sec_title>
						<para> Impotence, gynecomastia, irregular menses, amenorrhea, postmenopausal bleeding, hirsutism, deepening voice, breast pain</para>
					</section>
					<section type="none" id="sidelem4x6379">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> cramps, <emphasis style="bold">bleeding,</emphasis> gastritis, <emphasis style="italic">vomiting,</emphasis> anorexia, nausea, <emphasis style="bold">hepatocellular toxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6395">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6402">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus,</emphasis> urticaria</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6410">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 24-48 hr, peak 48-72 hr, metabolized in liver, excreted in urine, crosses placenta, protein binding &gt;90%, terminal half-life 10-35 hr</para>
			</section>
			<section type="interactions" id="sidelem4x6415">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of antihypertensives, digoxin, lithium</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperchloremic acidosis in cirrhosis—cholestyramine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium-sparing diuretics, potassium products, ACE inhibitors, salt substitutes</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of anticoagulants, monitor INR/PT</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of spironolactone—ASA, NSAIDs</para>
				<section type="none" id="sidelem4x6438">
					<section type="none" id="sidelem4x6439">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium-rich foods, potassium salt substitutes</para>
					</section>
					<section type="none" id="sidelem4x6446">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hypotension—hawthorn, horse chestnut</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> severe photosensitivity—St. John’s wort</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, potassium</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> sodium, magnesium</para>
					</section>
					<section type="none" id="sidelem4x6469">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Interference:</emphasis> 17-OHCS, 17-KS, radioimmunoassay, digoxin assay</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6476">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6479">
					<section type="none" id="sidelem4x6480">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6488">
							<label>•</label>
							<sec_title>Hypokalemia</sec_title>
							<para>
								<list id="lidelem4x6488">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypokalemia:</emphasis> polyuria, polydipsia; dysrhythmias, inluding a U wave on ECG</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6495">
							<label>•</label>
							<sec_title>Hyperkalemia</sec_title>
							<para>
								<list id="lidelem4x6495">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperkalemia:</emphasis> weakness, fatigue, dyspnea, dysrhythmias, confusion, fatigue</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6499">
								<item>
									<label>•</label>
									<para>Electrolytes: sodium, chloride, potassium, BUN, serum creatinine, ABGs, CBC</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6504">
								<item>
									<label>•</label>
									<para>Weight, I&amp;O daily to determine fluid loss; effect of product may be decreased if used daily; ECG periodically with long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6509">
								<item>
									<label>•</label>
									<para>Signs of metabolic acidosis: drowsiness, restlessness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6514">
								<item>
									<label>•</label>
									<para>Confusion, especially in geriatric patients; take safety precautions if needed</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6522">
							<label>•</label>
							<sec_title>Hydration</sec_title>
							<para>
								<list id="lidelem4x6522">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hydration:</emphasis> skin turgor, thirst, dry mucous membranes
<bbw>
												<emphasis alert="lifethreat">Secondary malignancy:</emphasis> assess periodically</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6537">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6541">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in edema of feet, legs, sacral area daily if medication is being used in CHF</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6547">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6551">
								<item>
									<label>•</label>
									<para>To avoid foods with high potassium content: oranges, bananas, salt substitutes, dried apricots, dates; to avoid potassium salt substitutes</para>
								</item>
								<item>
									<label>•</label>
									<para>That drowsiness, ataxia, mental confusion may occur; to observe caution when driving</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of cramps, diarrhea, lethargy, thirst, headache, skin rash, menstrual abnormalities, deepening voice, breast enlargement</para>
								</item>
								<item>
									<label>•</label>
									<para>To take in <emphasis style="smallcaps">am</emphasis>, to prevent sleeplessness</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until reaction is known</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected, pregnancy (C); not to breastfeed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="26" status="active">
			<mono_name>stavudine (d4T) (Rx)</mono_name>
			<info>
				<pronunciation>(sta′vyoo-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x65960">Zerit</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Nucleoside reverse transcriptase inhibitor (NRTI)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x6606">
				<sec_title>Action:</sec_title>
				<para>Prevents replication of HIV by the inhibition of the enzyme reverse transcriptase; causes DNA chain termination</para>
			</section>
			<section type="uses" id="sidelem4x6611">
				<sec_title>Uses:</sec_title>
				<para>Treatment of HIV-1 in combination with other antiretrovirals</para>
			</section>
			<section type="contra" id="sidelem4x6616">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or zidovudine; didanosine, zalcitabine; severe peripheral neuropathy</para>
				<para>
					<bbw>Lactic acidosis</bbw>
				</para>
				<section type="none" id="sidelem4x6631">
					<section type="none" id="sidelem4x6632">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, advanced HIV infection, bone marrow suppression, renal disease, peripheral neuropathy, osteoporosis, obesity</para>
						<para>
							<bbw>Pregnancy (C), hepatic disease, pancreatitis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6647">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6655">
					<label>•</label>
					<sec_title>Adult &gt;60 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6655">
							<item>
								<label>•</label>
								<para> 40 mg q12hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6662">
					<label>•</label>
					<sec_title>Adult &lt;60 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6662">
							<item>
								<label>•</label>
								<para> 30 mg q12hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6669">
					<label>•</label>
					<sec_title>Child &lt;30 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6669">
							<item>
								<label>•</label>
								<para> 1 mg/kg q12hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6676">
					<label>•</label>
					<sec_title>Child ≥30 kg, ≤60 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6676">
							<item>
								<label>•</label>
								<para> 30 mg q12hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6683">
					<label>•</label>
					<sec_title>Child &gt;60 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6683">
							<item>
								<label>•</label>
								<para> 40 mg q12hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6687">
					<section type="none" id="sidelem4x6688">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x6696">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 26-50 ml/min, reduce by 50%, give q12hr; CCr 10-25 ml/min, reduce by 50%, give q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6699">
						<sec_title>Available forms:</sec_title>
						<para> Caps 15, 20, 30, 40 mg; powder for oral sol 1 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x6704">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6708">
								<item>
									<label>•</label>
									<para>With/without meals; absorption does not appear to be lowered when taken with food</para>
								</item>
								<item>
									<label>•</label>
									<para>Use after hemodialysis</para>
								</item>
								<item>
									<label>•</label>
									<para>Every 12 hr around the clock</para>
								</item>
								<item>
									<label>•</label>
									<para>Shake suspension well before using</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6729">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6732">
					<section type="none" id="sidelem4x6733">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Peripheral neuropathy,</emphasis> insomnia, anxiety, depression, dizziness, confusion, <emphasis style="italic">headache,</emphasis> chills/fever, malaise, neuropathy</para>
					</section>
					<section type="none" id="sidelem4x6744">
						<sec_title>CV:</sec_title>
						<para> Chest pain, vasodilation, hypertension</para>
					</section>
					<section type="none" id="sidelem4x6749">
						<sec_title>EENT:</sec_title>
						<para> Conjunctivitis, abnormal vision</para>
					</section>
					<section type="none" id="sidelem4x6754">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Hepatotoxicity,</emphasis><emphasis style="italic">diarrhea, nausea, vomiting,</emphasis> anorexia, dyspepsia, constipation, stomatitis, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6766">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Bone marrow suppression,</emphasis> leukopenia, macrocytosis</para>
					</section>
					<section type="none" id="sidelem4x6774">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> sweating, pruritus, benign neoplasms</para>
					</section>
					<section type="none" id="sidelem4x6782">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Lactic acidosis,</emphasis> asthenia, lipodystrophy</para>
					</section>
					<section type="none" id="sidelem4x6790">
						<sec_title>MS:</sec_title>
						<para> Myalgia, arthralgia</para>
					</section>
					<section type="none" id="sidelem4x6795">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, pneumonia, asthma</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6800">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted in urine, breast milk; peak 1 hr; half-life: elimination 1-1.6 hr</para>
			</section>
			<section type="interactions" id="sidelem4x6805">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—other myelosuppressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> peripheral neuropathy—lithium, dapsone, chloramphenicol didanosine, ethambutol, hydrALAZINE, phenytoin, vinCRIStine, zalcitabine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> stavudine levels—probenecid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> stavudine effect—methadone, zidovudine</para>
			</section>
			<section type="considerations" id="sidelem4x6825">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6828">
					<section type="none" id="sidelem4x6829">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Lactic acidosis and severe hepatomegaly with steatosis:</emphasis> death may result; monitor LFTs</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Pancreatitis:</emphasis> severe upper abdominal pain, radiating to back, nausea, vomiting usually when used in combination with didanosine</bbw>
						</para>
						<para>
							<list id="lidelem4x6856">
								<item>
									<label>•</label>
									<para>Blood studies: WBC, differential, RBC, Hct, Hgb, platelets, serum amylase, lipase, blood glucose, plasma hepatitis C RNA, pregnancy test, serum cholesterol, serum lipids, hepatitis serology, baseline and periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6861">
								<item>
									<label>•</label>
									<para>Renal tests: urinalysis, protein, blood, serum creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6866">
								<item>
									<label>•</label>
									<para>Lipoatrophy/lipodystrophy during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6871">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6876">
								<item>
									<label>•</label>
									<para>Weakness, tremors, confusion, dizziness; product may have to be decreased, discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6881">
								<item>
									<label>•</label>
									<para>Viral load, CD4 counts, plasma HIV RNA at baseline and throughout treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6889">
							<label>•</label>
							<sec_title>Peripheral neuropathy</sec_title>
							<para>
								<list id="lidelem4x6889">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Peripheral neuropathy:</emphasis> tingling, pain in extremities; discontinue product, may not resolve after treatment is discontinued</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6893">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6897">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of HIV</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6903">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x6911">
							<label>•</label>
							<sec_title>About the signs of peripheral neuropathy</sec_title>
							<para>
								<list id="lidelem4x6911">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">About the signs of peripheral neuropathy:</emphasis> burning, weakness, pain, prickling feeling in extremities</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6915">
								<item>
									<label>•</label>
									<para>That product should not be given with antineoplastics</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6920">
								<item>
									<label>•</label>
									<para>That product is not a cure for AIDS but will control symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6925">
								<item>
									<label>•</label>
									<para>To notify prescriber if sore throat, swollen lymph nodes, malaise, fever occur; that other products may be needed to prevent other infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6930">
								<item>
									<label>•</label>
									<para>That, even with use of product, patient may pass AIDS virus to others</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6935">
								<item>
									<label>•</label>
									<para>That follow-up visits are necessary; that serious toxicity may occur; that blood counts must be done q2wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6941">
								<item>
									<para>
										<emphasis alert="nurse">That serious product interactions may occur if other medications are ingested; to see prescriber before taking chloramphenicol, dapsone, CISplatin, didanosine, ethambutol, lithium, antifungals, antineoplastics</emphasis>
<bbw>To notify prescriber if pregnancy is planned or suspected, fatal lactic acidosis may occur, pregnancy (C), avoid breastfeeding</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6955">
								<item>
									<label>•</label>
									<para>That product may cause fainting or dizziness</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="27" status="active" ha="yes">
			<mono_name> succinylcholine (Rx)</mono_name>
			<info>
				<pronunciation>(suk-sin-ill-koe′leen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x69671">Anectine</tradename>
					<tradename id="tnidelem4x69670">Quelicin</tradename>
				</tradenames>
				<class type="func"> Neuromuscular blocker (depolarizing, ultra short)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x6973">
				<sec_title>Action:</sec_title>
				<para>Inhibits transmission of nerve impulses by binding with cholinergic receptor sites, thus antagonizing action of acetylcholine; causes release of histamine</para>
			</section>
			<section type="uses" id="sidelem4x6978">
				<sec_title>Uses:</sec_title>
				<para>Facilitation of endotracheal intubation, skeletal muscle relaxation during orthopedic manipulations</para>
			</section>
			<section type="contra" id="sidelem4x6983">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, malignant hyperthermia, trauma</para>
				<section type="none" id="sidelem4x6988">
					<section type="none" id="sidelem4x6989">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric or debilitated patients, cardiac disease, severe burns, fractures (fasciculations may increase damage) electrolyte imbalances, dehydration, neuromuscular/respiratory/cardiac/renal/hepatic disease, collagen diseases, glaucoma, eye surgery</para>
						<para>
							<bbw>Children &lt;2 yr, hyperkalemia, myopathy, rhabdomyolysis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7005">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7013">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x7013">
							<item>
								<label>•</label>
								<para> 0.3-1.1 mg/kg, max 150 mg, maintenance 0.04-0.07 mg/kg q5-10min as needed;  dilute to concentration of 1-2 mg/ml in D<emphasis style="inf">5</emphasis>W or NS 10-100 mcg/kg/min</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7026">
					<label>•</label>
					<sec_title>Child<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x7026">
							<item>
								<label>•</label>
								<para> initially 1-2 mg/kg;  not recommended</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7033">
					<section type="none" id="sidelem4x7034">
						<sec_title>Available forms:</sec_title>
						<para> Inj 20, 50, 100 mg/ml; powder for inj 100, 500 mg/vial, 1 g/vial</para>
					</section>
					<section type="none" id="sidelem4x7039">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7043">
								<item>
									<label>•</label>
									<para>Give IV or IM; only experienced clinicians familiar with the use of neuromuscular blocking drugs should administer or supervise the use of this product</para>
								</item>
								<item>
									<label>•</label>
									<para>Visually inspect parenteral products for particulate matter and discoloration before use</para>
								</item>
								<item>
									<label>•</label>
									<para>Monitor heart rate and mechanical ventilator status during use</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in refrigerator, powder at room temperature; close tightly</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7064">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x7068">
									<item>
										<label>•</label>
										<para>Recommended for infants and other patients in whom a suitable vein is not accessible</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject into a large muscle, preferably high into the deltoid muscle; aspirate before injection</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7079">
							<sec_title>Rapid IV injection route</sec_title>
							<para>
								<list id="lidelem4x7083">
									<item>
										<label>•</label>
										<para>Owing to tachyphylaxis and prolonged apnea, this method is not recommended for prolonged procedures; rapid IV injection of succinylcholine can result in profound bradycardia or asystole in pediatric patients; as with adults, the risk increases with repeated doses; pretreatment with atropine may be needed</para>
									</item>
									<item>
										<label>•</label>
										<para>No dilution of injection solution is necessary</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject rapidly IV over 10-30 sec</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7099">
							<sec_title>Continuous IV infusion route</sec_title>
							<para>
								<list id="lidelem4x7103">
									<item>
										<label>•</label>
										<para>Not recommended for infants and children owing to risk of malignant hyperthermia</para>
									</item>
									<item>
										<label>•</label>
										<para>This route is preferred for long surgical procedures owing to possible tachyphylaxis and prolonged apnea associated with administration of repeated fractional doses</para>
									</item>
									<item>
										<label>•</label>
										<para>Dilute succinylcholine to a concentration of 1-2 mg/ml with D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">5</emphasis>NS, NS, or 1/6 M sodium lactate injection; 1 g of the powder for injection or 20 ml of a 50-mg/ml solution may be added to 1 L or 500 ml of diluent to give solutions containing 1 or 2 mg/ml, respectively; alternatively, 500 mg of the powder for injection or 10 ml of a 50 mg/ml solution may be added to 500 ml or 250 ml of diluent to give solutions containing 1 or 2 mg/ml, respectively</para>
									</item>
									<item>
										<label>•</label>
										<para>Infuse IV at a rate of 2.5 mg/min (range = 0.5-10 mg/min); adjust rate based on patient’s response and requirements</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Additive compatibilities:</emphasis> Amikacin, cephapirin, isoproterenol, meperidine, methyldopate, morphine, norepinephrine, scopolamine</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Heparin</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Etomidate, heparin, potassium chloride, propofol, vit B/C</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7142">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7145">
					<section type="none" id="sidelem4x7146">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, tachycardia; increased, decreased B/P; <emphasis style="bold">sinus arrest, dysrhythmias,</emphasis> edema</para>
					</section>
					<section type="none" id="sidelem4x7154">
						<sec_title>EENT:</sec_title>
						<para> Increased secretions, intraocular pressure</para>
					</section>
					<section type="none" id="sidelem4x7159">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Myoglobulinemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7166">
						<sec_title>INTEG:</sec_title>
						<para> Rash, flushing, pruritus, urticaria</para>
					</section>
					<section type="none" id="sidelem4x7171">
						<sec_title>MS:</sec_title>
						<para> Weakness, muscle pain, fasciculations, prolonged relaxation, myalgia, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7178">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Prolonged apnea, bronchospasm, cyanosis, respiratory depression,</emphasis> wheezing, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x7186">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7193">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Hydrolyzed in blood, excreted in urine (active/inactive metabolites)</para>
				<section type="none" id="sidelem4x7198">
					<section type="none" id="sidelem4x7199">
						<sec_title>IM:</sec_title>
						<para> Onset 2-3 min, duration 10-30 min</para>
					</section>
					<section type="none" id="sidelem4x7204">
						<sec_title>IV:</sec_title>
						<para> Onset 1 min, peak 2-3 min, duration 6-10 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7209">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> dysrhythmias: theophylline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> neuromuscular blockade—aminoglycosides, β-blockers, cardiac glycosides, clindamycin, lincomycin, procainamide, quiNIDine, local anesthetics, polymyxin antibiotics, lithium, opioids, thiazides, enflurane, isoflurane, magnesium salts, oxytocin</para>
				<section type="none" id="sidelem4x7220">
					<section type="none" id="sidelem4x7221">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x7225">
								<item>
									<label>•</label>
									<para>Blocks succinylcholine: melatonin</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7231">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7234">
					<section type="none" id="sidelem4x7235">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7240">
								<item>
									<label>•</label>
									<para>Electrolyte imbalances (potassium, magnesium); may lead to increased action of product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7245">
								<item>
									<label>•</label>
									<para>VS (B/P, pulse, respirations, airway) until fully recovered; rate, depth, pattern of respirations, strength of hand grip</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7250">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for urinary retention, frequency, hesitancy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7258">
							<label>•</label>
							<sec_title>Recovery</sec_title>
							<para>
								<list id="lidelem4x7258">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Recovery:</emphasis> decreased paralysis of face, diaphragm, leg, arm, rest of body</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7265">
							<label>•</label>
							<sec_title>Allergic reactions<route> rash, fever, respiratory distress, pruritus; product should be discontinued</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7279">
								<item>
									<label>•</label>
									<para>Reassurance if communication is difficult during recovery from neuromuscular blockade; postoperative stiffness is normal, soon subsides</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7284">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7288">
								<item>
									<label>•</label>
									<para>Therapeutic response: paralysis of jaw, eyelid, head, neck, rest of body</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="28" status="active">
			<mono_name>sucralfate (Rx)</mono_name>
			<info>
				<pronunciation>(soo-kral′fate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x73041">Carafate</tradename>
					<tradename id="tnidelem4x73040">
						<country code="CAN">Sulcrate </country>
					</tradename>
				</tradenames>
				<class type="func"> Protectant, antiulcer</class>
				<class type="chem"> Aluminum hydroxide, sulfated sucrose</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7316">
				<para>
					<confusion>
						<tradename id="tnidelem4x73160">Carafate</tradename>
						<drug type="generic" refid="idelem4x73160">Cafergot</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7320">
				<sec_title>Action:</sec_title>
				<para>Forms a complex that adheres to ulcer site, adsorbs pepsin</para>
			</section>
			<section type="uses" id="sidelem4x7325">
				<sec_title>Uses:</sec_title>
				<para>Duodenal ulcer, oral mucositis, stomatitis after radiation of head and neck</para>
				<section type="none" id="sidelem4x7330">
					<section type="none" id="sidelem4x7331">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Gastric/aphthous ulcers, gastroesophageal reflux, NSAID-induced ulcer prophylaxis, proctitis, stomatitis, stress gastritis prophylaxis, <emphasis style="italic">C. difficile</emphasis></para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x7338">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x7343">
					<section type="none" id="sidelem4x7344">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, renal failure; hypoglycemia (diabetics)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7349">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7352">
					<section type="none" id="sidelem4x7353">
						<sec_title>Duodenal ulcers</sec_title>
						<section type="none" id="sidelem4x7361">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7361">
									<item>
										<label>•</label>
										<para> 1 g qid 1 hr before meals, at bedtime</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7368">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7368">
									<item>
										<label>•</label>
										<para> 40-80 mg/kg/day divided</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7372">
						<sec_title>Aphthous ulcer/stomatitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x7380">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7380">
									<item>
										<label>•</label>
										<para> 5-10 ml (500 mg-1 g) swished in mouth for several min; spit or swallow qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7384">
						<sec_title>Gastric ulcer/NSAID-induced ulcer prophylaxis/esophagitis/GERD (unlabeled)</sec_title>
						<section type="none" id="sidelem4x7392">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7392">
									<item>
										<label>•</label>
										<para> 1 g qid, 1 hr before meals and at bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7396">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1 g; oral susp 1 g/10 ml</para>
					</section>
					<section type="none" id="sidelem4x7401">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7404">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x7408">
									<item>
										<label>•</label>
										<para>Do not crush or chew tabs; tabs may be broken or dissolved in water</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not take antacids 30 min before or after sucralfate</para>
									</item>
									<item>
										<label>•</label>
										<para>On an empty stomach 1 hr before meals or other medications and at bedtime</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7429">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7432">
					<section type="none" id="sidelem4x7433">
						<sec_title>CNS:</sec_title>
						<para> Drowsiness, dizziness</para>
					</section>
					<section type="none" id="sidelem4x7438">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia (diabetes mellitus)</para>
					</section>
					<section type="none" id="sidelem4x7443">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Dry mouth, constipation,</emphasis> nausea, gastric pain, vomiting</para>
					</section>
					<section type="none" id="sidelem4x7451">
						<sec_title>INTEG:</sec_title>
						<para> Urticaria, rash, pruritus</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7457">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x7460">
					<section type="none" id="sidelem4x7461">
						<sec_title>PO:</sec_title>
						<para> Duration up to 6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7466">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of tetracyclines, phenytoin, fat-soluble vitamins, digoxin, ketoconazole, theophylline</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of fluoroquinolones</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of sucralfate—antacids, cimetidine, ranitidine</para>
			</section>
			<section type="considerations" id="sidelem4x7481">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7484">
					<section type="none" id="sidelem4x7485">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7493">
							<label>•</label>
							<sec_title>GI symptoms</sec_title>
							<para>
								<list id="lidelem4x7493">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">GI symptoms:</emphasis> abdominal pain, blood in stools</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7500">
							<label>•</label>
							<sec_title>Hypoglycemia</sec_title>
							<para>
								<list id="lidelem4x7500">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypoglycemia:</emphasis> may occur in patients with diabetes mellitus; monitor blood glucose carefully</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7504">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7508">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of pain, GI complaints</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7514">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7518">
								<item>
									<label>•</label>
									<para>To take on empty stomach</para>
								</item>
								<item>
									<label>•</label>
									<para>To take full course of therapy; not to use for &gt;8 wk; to avoid smoking</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid antacids within <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr of product</para>
								</item>
								<item>
									<label>•</label>
									<para>To increase fluids, bulk, exercise to lessen constipation</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="29" status="active">
			<mono_name>sulfamethoxazole-trimethoprim (Rx)</mono_name>
			<info>
				<pronunciation>(trye-meth′oh-prim–sul-fa-meth-ox′a-zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x75507">Bacter-Aid DS</tradename>
					<tradename id="tnidelem4x75506">Bactrim DS</tradename>
					<tradename id="tnidelem4x75505">
						<country code="CAN">Novo-Trimel </country>
					</tradename>
					<tradename id="tnidelem4x75504">
						<country code="CAN">Nu-Cotrimox </country>
					</tradename>
					<tradename id="tnidelem4x75503">Septra</tradename>
					<tradename id="tnidelem4x75502">Septra DS</tradename>
					<tradename id="tnidelem4x75501">Sultrex</tradename>
					<tradename id="tnidelem4x75500">SMZ/TMP</tradename>
				</tradenames>
				<class type="func"> Antiinfective</class>
				<class type="chem"> Sulfonamide—miscellaneous</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x7566">
				<sec_title>Action:</sec_title>
				<para>Sulfamethoxazole (SMZ) interferes with the bacterial biosynthesis of proteins by competitive antagonism of PABA when adequate levels are maintained; trimethoprim (TMP) blocks the synthesis of tetrahydrofolic acid; the combination blocks 2 consecutive steps in the bacterial synthesis of essential nucleic acids and protein</para>
			</section>
			<section type="uses" id="sidelem4x7571">
				<sec_title>Uses:</sec_title>
				<para>UTI, otitis media, acute and chronic prostatitis, shigellosis, chancroid, traveler’s diarrhea, <emphasis style="italic">Enterobacter</emphasis> sp., <emphasis style="italic">Escherichia coli, Haemophilus influenzae (beta-lactamase negative), Haemophilus influenzae (beta-lactamase positive), Klebsiella</emphasis> sp., <emphasis style="italic">Morganella morganii, Pneumocystis carinii, Pneumocystis jiroveci, Proteus mirabilis, Proteus</emphasis> sp., <emphasis style="italic">Proteus vulgaris, Shigella flexneri, Shigella sonnei, Streptococcus pneumonia;</emphasis><emphasis style="bold">may also be effective for</emphasis><emphasis style="italic">Acinetobacter baumannii, Actinomadura madurae, Actinomadura pelletierii, Bordetella pertussis, Burkholderia pseudomallei, Cyclospora cayetanensis, Haemophilus ducreyi, Isospora belli, Klebsiella granulomatis, Legionella micdadei, Legionella pneumophila, Listeria monocytogenes, Moraxella catarrhalis, Neisseria gonorrhoeae, Nocardia asteroides, Nocardia brasiliensis, Nocardia otitidiscaviarum, Pediculus capitis, Plasmodium falciparum, Providencia</emphasis> sp., <emphasis style="italic">Salmonella</emphasis> sp., <emphasis style="italic">Serratia</emphasis> sp., <emphasis style="italic">Shigella</emphasis> sp., <emphasis style="italic">Staphylococcus aureus (MRSA), Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Stenotrophomonas maltophilia, Streptococcus pyogenes</emphasis> (group A beta-hemolytic streptococci), <emphasis style="italic">Streptomyces somaliensis, Toxoplasma gondii, Vibrio cholerae, Viridans streptococci, Yersinia enterocolitica</emphasis></para>
			</section>
			<section type="contra" id="sidelem4x7606">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, infants &lt;2 mo; hypersensitivity to trimethoprim or sulfonamides; pregnancy at term, megaloblastic anemia, CCr &lt;15 ml/min</para>
				<section type="none" id="sidelem4x7611">
					<section type="none" id="sidelem4x7612">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), geriatric patients, infants, renal disease, G6PD deficiency, impaired hepatic/renal function, possible folate deficiency, severe allergy, bronchial asthma, UV exposure, porphyria, hyperkalemia, hypothyroidism</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7619">
				<sec_title>Dosage and routes</sec_title>
				<para>Based on TMP content</para>
				<section type="none" id="sidelem4x7624">
					<section type="none" id="sidelem4x7625">
						<sec_title>UTI</sec_title>
						<section type="none" id="sidelem4x7633">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7633">
									<item>
										<label>•</label>
										<para> 160 mg TMP q12hr × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7640">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7640">
									<item>
										<label>•</label>
										<para> 8 mg/kg TMP/day in 2 divided doses q12hr (treatment): 2 mg/kg/day (prophylaxis)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7644">
						<sec_title>Otitis media</sec_title>
						<section type="none" id="sidelem4x7652">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7652">
									<item>
										<label>•</label>
										<para> 8 mg/kg TMP/day in 2 divided doses q12hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7656">
						<sec_title>Chronic bronchitis</sec_title>
						<section type="none" id="sidelem4x7664">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7664">
									<item>
										<label>•</label>
										<para> 160 mg TMP q12hr × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7668">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">Pneumocystis jiroveci</emphasis>
							</emphasis> pneumonitis</sec_title>
						<section type="none" id="sidelem4x7679">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7679">
									<item>
										<label>•</label>
										<para> 15-20 mg/kg TMP daily in 4 divided doses q6hr × 14-21 days;  15-20 mg/kg/day (based on TMP) in 3-4 divided doses for ≤14 days</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7686">
								<item>
									<label>•</label>
									<para>Dosage reduction necessary in moderate to severe renal impairment (CCr &lt;30 ml/min)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7691">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 80 mg trimethoprim/400 mg sulfamethoxazole, 160 mg trimethoprim/800 mg sulfamethoxazole; susp 200 mg-40 mg/5 ml, 800 mg-160 mg/20 ml; IV 16 mg/80 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x7696">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7699">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x7703">
									<item>
										<label>•</label>
										<para>Medication after C&amp;S; repeat C&amp;S after full course of medication</para>
									</item>
									<item>
										<label>•</label>
										<para>With resuscitative equipment, EPINEPHrine available; severe allergic reactions may occur</para>
									</item>
									<item>
										<label>•</label>
										<para>Without regard to meals</para>
									</item>
									<item>
										<label>•</label>
										<para>With full glass of water to maintain adequate hydration; increase fluids to 2 L/day to decrease crystallization in kidneys</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight, light-resistant container at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7729">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x7733">
									<item>
										<label>•</label>
										<para>After diluting 5 ml of product/125 ml D<emphasis style="inf">5</emphasis>W, run over 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, if using Septra ADD-Vantage vials dilute each 10-ml vial in ADD-Vantage diluent containers containing 250 ml of D5W, infuse over 60-90 min, change site q48-72hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, aldesleukin, allopurinol, amifostine, amphotericin B cholesteryl, atracurium, aztreonam, cefepime, cyclophosphamide, diltiazem, DOXOrubicin liposome, enalaprilat, esmolol, filgrastim, fludarabine, gallium, granisetron, HYDROmorphone, labetalol, LORazepam, magnesium sulfate, melphalan, meperidine, morphine, pancuronium, perphenazine, piperacillin/tazobactam, remifentanil, sargramostim, tacrolimus, teniposide, thiotepa, vecuronium, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7752">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7755">
					<section type="none" id="sidelem4x7756">
						<sec_title>CNS:</sec_title>
						<para> Headache, insomnia, hallucinations, depression, vertigo, fatigue, anxiety, <emphasis style="bold">seizures, product fever,</emphasis> chills, <emphasis style="bold">aseptic meningitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7766">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Allergic myocarditis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7773">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus</para>
					</section>
					<section type="none" id="sidelem4x7778">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, abdominal pain,</emphasis> stomatitis, <emphasis style="bold">hepatitis,</emphasis> glossitis, pancreatitis, diarrhea, <emphasis style="bold">enterocolitis,</emphasis> anorexia, <emphasis style="bold">pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7794">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure, toxic nephrosis;</emphasis> increased BUN, creatinine; crystalluria</para>
					</section>
					<section type="none" id="sidelem4x7802">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, neutropenia, thrombocytopenia, agranulocytosis, hemolytic anemia, hypoprothrombinemia, Henoch-Schönlein purpura, methemoglobinemia, eosinophilia I</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7809">
						<sec_title>INTEG:</sec_title>
						<para> Rash, dermatitis, urticaria, <emphasis style="bold">Stevens-Johnson syndrome,</emphasis> erythema, photosensitivity, pain, inflammation at inj site, <emphasis style="bold">toxic epidermal necrolysis, erythema multiforme</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7819">
						<sec_title>RESP:</sec_title>
						<para> Cough, SOB</para>
					</section>
					<section type="none" id="sidelem4x7824">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, SLE</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7831">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x7834">
					<section type="none" id="sidelem4x7835">
						<sec_title>PO:</sec_title>
						<para> Rapidly absorbed; peak 1-4 hr; half-life 8-13 hr; excreted in urine (metabolites and unchanged), breast milk; crosses placenta; 68% bound to plasma proteins; TMP achieves high levels in prostatic tissue and fluid</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7840">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> thrombocytopenia—thiazide diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> potassium levels—potassium-sparing diuretics, potassium supplements</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemic response—sulfonylurea agents</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulant effects—oral anticoagulants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of dofetilide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> crystalluria—methenamine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bone marrow depressant effects—methotrexate</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hepatic clearance of phenytoin, CYP2C9, CYP3A4 inducers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> response—cycloSPORINE</para>
				<section type="none" id="sidelem4x7880">
					<section type="none" id="sidelem4x7881">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> creatinine, bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7892">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7895">
					<section type="none" id="sidelem4x7896">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7901">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; note color, character, pH of urine if product administered for UTI; output should be 800 ml less than intake; if urine is highly acidic, alkalization may be needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7906">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, creatinine, urinalysis with long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7911">
								<item>
									<label>•</label>
									<para>Type of infection; obtain C&amp;S before starting therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7916">
								<item>
									<label>•</label>
									<para>Blood dyscrasias, skin rash, fever, sore throat, bruising, bleeding, fatigue, joint pain</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7924">
							<label>•</label>
							<sec_title>Allergic reaction<route> rash, dermatitis, urticaria, pruritus, dyspnea, bronchospasm; product should be discontinued at 1st sign of rash; AIDS patients more susceptible</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7927">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7931">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of pain, fever; C&amp;S negative</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7937">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7942">
								<item>
									<label>•</label>
									<para>To take each oral dose with full glass of water to prevent crystalluria; to drink 8-10 glasses of water/day; to take product on an empty stomach 1 hr before meals, 2 hr after meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7947">
								<item>
									<label>•</label>
									<para>To complete full course of treatment to prevent superinfection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7952">
								<item>
									<label>•</label>
									<para>To avoid sunlight; to use sunscreen to prevent burns</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7957">
								<item>
									<label>•</label>
									<para>To avoid OTC medications (aspirin, vit C) unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7965">
							<label>•</label>
							<sec_title>
								<route>To use alternative contraceptive measures; that decreased effectiveness of oral contraceptives may occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7968">
								<item>
									<label>•</label>
									<para>To notify prescriber if skin rash, sore throat, fever, mouth sores, unusual bruising, bleeding occur; to notify prescriber of CNS effects: anxiety, depression, hallucinations, seizures</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="30" status="active">
			<mono_name>sulfaSALAzine (Rx)</mono_name>
			<info>
				<pronunciation>(sul-fa-sal′a-zeen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x79782">Azulfidine</tradename>
					<tradename id="tnidelem4x79781">Azulfidine EN-tabs</tradename>
					<tradename id="tnidelem4x79780">
						<country code="CAN">Salazopyrin </country>
					</tradename>
				</tradenames>
				<class type="func"> GI antiinflammatory, antirheumatic (DMARD)</class>
				<class type="chem"> Sulfonamide</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7990">
				<para>
					<confusion>
						<tradename id="tnidelem4x79900">sulfaSALAzine</tradename>
						<drug type="generic" refid="idelem4x79900">sulfiSOXAZOLE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7994">
				<sec_title>Action:</sec_title>
				<para>Prodrug to deliver sulfapyridine and 5-aminosalicylic acid to colon; antiinflammatory in connective tissue also</para>
			</section>
			<section type="uses" id="sidelem4x7999">
				<sec_title>Uses:</sec_title>
				<para>Ulcerative colitis; RA; juvenile RA (Azulfidine EN-tabs)</para>
				<section type="none" id="sidelem4x8004">
					<section type="none" id="sidelem4x8005">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Crohn’s disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8010">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy at term, children &lt;2 yr; hypersensitivity to sulfonamides or salicylates; intestinal, urinary obstruction; porphyria</para>
				<section type="none" id="sidelem4x8015">
					<section type="none" id="sidelem4x8016">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, impaired renal/hepatic function, severe allergy, bronchial asthma, megaloblastic anemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8021">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8024">
					<section type="none" id="sidelem4x8025">
						<sec_title>Bowel disease</sec_title>
						<section type="none" id="sidelem4x8033">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8033">
									<item>
										<label>•</label>
										<para> 3-4 g/day in divided doses; maintenance 2 g/day in divided doses q6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8040">
							<label>•</label>
							<sec_title>Child ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8040">
									<item>
										<label>•</label>
										<para> 40-60 mg/kg/day in 4-6 divided doses, then 30 mg/kg/day in 4 doses, max 2 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8044">
						<sec_title>Rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x8052">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8052">
									<item>
										<label>•</label>
										<para> 0.5-1 g/day, then increase daily dose by 500 mg/wk to 2 g/day in 2-3 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8057">
						<sec_title>Juvenile rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x8065">
							<label>•</label>
							<sec_title>Child ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8065">
									<item>
										<label>•</label>
										<para> 30-50 mg/kg/24 hr in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8069">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x8077">
							<label>•</label>
							<sec_title>
								<route>Modify dose based on renal impairment, response</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x8081">
							<sec_title>
								<route>Crohn’s disease (unlabeled)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x8087">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8087">
									<item>
										<label>•</label>
										<para> 1 g/15 kg, max 5 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8091">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 500 mg; oral susp 250 mg/5 ml; del rel tabs 500 mg</para>
					</section>
					<section type="none" id="sidelem4x8096">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8100">
								<item>
									<label>•</label>
									<para>Do not break, crush, chew del rel tabs</para>
								</item>
								<item>
									<label>•</label>
									<para>With full glass of water to maintain adequate hydration; increase fluids to 2 L/day to decrease crystallization in kidneys</para>
								</item>
								<item>
									<label>•</label>
									<para>Total daily dose in evenly spaced doses and after meals to help minimize GI intolerance</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8121">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8124">
					<section type="none" id="sidelem4x8125">
						<sec_title>CNS:</sec_title>
						<para> Headache, confusion, insomnia, hallucinations, depression, vertigo, fatigue, anxiety, <emphasis style="bold">seizures,</emphasis> product fever, chills</para>
					</section>
					<section type="none" id="sidelem4x8133">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Allergic myocarditis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8140">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, abdominal pain,</emphasis> stomatitis, <emphasis style="bold">hepatitis,</emphasis> glossitis, pancreatitis, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x8151">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure, toxic nephrosis,</emphasis> increased BUN, creatinine, crystalluria</para>
					</section>
					<section type="none" id="sidelem4x8159">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, neutropenia, thrombocytopenia, agranulocytosis, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8166">
						<sec_title>INTEG:</sec_title>
						<para> Rash, dermatitis, urticaria, <emphasis style="bold">Stevens-Johnson syndrome,</emphasis> erythema, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x8174">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8181">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x8184">
					<section type="none" id="sidelem4x8185">
						<sec_title>PO:</sec_title>
						<para> Partially absorbed; peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-6 hr; duration 6-12 hr; half-life 6 hr; excreted in urine as sulfaSALAzine (15%), sulfapyridine (60%), 5-aminosalicylic acid, metabolites (20%-33%); excreted in breast milk; crosses placenta</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8196">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> leukopenia risk—thiopurines (azaTHIOprine, mercaptopurine)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemic response—oral hypoglycemics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulant effects—oral anticoagulants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of cycloSPORINE, digoxin, folic acid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> renal excretion of methotrexate</para>
				<section type="none" id="sidelem4x8219">
					<section type="none" id="sidelem4x8220">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> iron/folic acid absorption</para>
					</section>
					<section type="none" id="sidelem4x8227">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False positive:</emphasis> urinary glucose test</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8234">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8237">
					<section type="none" id="sidelem4x8238">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8243">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, creatinine, urinalysis (long-term therapy)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8249">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias: skin rash, fever, sore throat, bruising, bleeding, fatigue, joint pain; monitor CBC before therapy and q3mo</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8255">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reaction: rash, dermatitis, urticaria, pruritus, dyspnea, bronchospasm</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8263">
							<label>•</label>
							<sec_title>Ulcerative colitis, proctitis, other inflammatory bowel disease</sec_title>
							<para>
								<list id="lidelem4x8263">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ulcerative colitis, proctitis, other inflammatory bowel disease:</emphasis> character, amount consistency of stools; abdominal pain, cramping, blood, mucus</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8270">
							<label>•</label>
							<sec_title>Rheumatoid arthritis</sec_title>
							<para>
								<list id="lidelem4x8270">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Rheumatoid arthritis:</emphasis> assess mobility, joint swelling, pain, ability to complete activities of daily living</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8274">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8278">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, mucus in stools, pain in joints</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8284">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8289">
								<item>
									<label>•</label>
									<para>To take each oral dose with full glass of water to prevent crystalluria</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8294">
								<item>
									<label>•</label>
									<para>That contact lenses, urine, skin may be yellow-orange</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8299">
								<item>
									<label>•</label>
									<para>To avoid sunlight or use sunscreen to prevent burns</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8307">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of skin rash, sore throat, fever, mouth sores, unusual bruising, bleeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active">
			<mono_name>SUMAtriptan (Rx)</mono_name>
			<info>
				<pronunciation>(soo-ma-trip′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x83153">ALSUMA Auto-injector</tradename>
					<tradename id="tnidelem4x83152">Imitrex</tradename>
					<tradename id="tnidelem4x83151">Sumavel DosePro</tradename>
					<tradename id="tnidelem4x83150">Zecuity</tradename>
				</tradenames>
				<class type="func"> Antimigraine agent</class>
				<class type="chem"> 5-HTB/D receptor agonist, abortive agent, triptan</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x8328">
				<para>
					<confusion>
						<tradename id="tnidelem4x83280">SUMAtriptan</tradename>
						<drug type="generic" refid="idelem4x83280">somatropin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8332">
				<sec_title>Action:</sec_title>
				<para>Binds selectively to the vascular 5-HT<emphasis style="inf">1</emphasis>B/D receptor subtype; exerts antimigraine effect; causes vasoconstriction in cranial arteries</para>
			</section>
			<section type="uses" id="sidelem4x8340">
				<sec_title>Uses:</sec_title>
				<para>Acute treatment of migraine with/without aura and cluster headache</para>
			</section>
			<section type="contra" id="sidelem4x8345">
				<sec_title>Contraindications:</sec_title>
				<para>Angina pectoris, history of MI, documented silent ischemia, Prinzmetal’s angina, ischemic heart disease, IV use, concurrent ergotamine-containing preparations, uncontrolled hypertension, hypersensitivity, basilar or hemiplegic migraine</para>
				<section type="none" id="sidelem4x8350">
					<section type="none" id="sidelem4x8351">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;18 yr, geriatric patients, postmenopausal women, men &gt;40 yr, risk factors for CAD, hypercholesterolemia, obesity, diabetes, impaired renal/hepatic function, overuse</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8356">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8364">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x8364">
							<item>
								<label>•</label>
								<para> ≤6 mg; may repeat in 1 hr; max 12 mg/24 hr;  25 mg with fluids, if no relief in 2 hr, give another dose, max 200 mg/day;  single dose of 5, 10, or 20 mg in 1 nostril, may repeat in 2 hr, max 40 mg/24 hr; 1 puff each nostril q2hr; TD 1 patch (6.5 mg/4 hr) after application push activation button</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8374">
					<section type="none" id="sidelem4x8375">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x8383">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8383">
									<item>
										<label>•</label>
										<para> 25 mg; if no response after 2 hr, give ≤50 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8387">
						<sec_title>Available forms:</sec_title>
						<para> Inj 4, 6 mg/0.5 ml; tabs 25, 50, 100 mg; nasal spray 5 mg/100 mcl-U; dose spray device 20 mg/100 mcl-U; transdermal patch 6.5 mg/4 hr</para>
					</section>
					<section type="none" id="sidelem4x8392">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x8395">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x8399">
									<item>
										<label>•</label>
										<para>Swallow tabs whole; do not break, crush, or chew</para>
									</item>
									<item>
										<label>•</label>
										<para>Take tabs with fluids as soon as symptoms appear; may take a 2nd dose &gt;4 hr; max 200 mg/24 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8410">
							<sec_title>SUBCUT route</sec_title>
							<para>SUBCUT only just below the skin; avoid IM or IV administration; use only for actual migraine attack<list id="lidelem4x8415">
									<item>
										<label>•</label>
										<para>Give 1st dose supervised by medical staff to patients with coronary artery disease or those at risk for CAD</para>
									</item>
								</list></para>
						</section>
						<section type="none" id="sidelem4x8421">
							<sec_title>Nasal route</sec_title>
							<para>
								<list id="lidelem4x8425">
									<item>
										<label>•</label>
										<para>May give as 2 sprays of 5 mg in 1 nostril or 1 spray in each nostril (10 mg)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8431">
							<sec_title>Transdermal route</sec_title>
							<para>
								<list id="lidelem4x8435">
									<item>
										<label>•</label>
										<para>Do not cut; apply to upper arm or thigh of dry intact skin; do not use over scars, tattoos, cuts, scratches, burns, abrasions</para>
									</item>
									<item>
										<label>•</label>
										<para>Apply another patch if headache is not relieved ≥2 hr after 1st patch; push activation button within 15 min of applying or patch will not work; do not bathe, shower, swim; may be taped with medical tape if needed</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use with MRI</para>
									</item>
									<item>
										<label>•</label>
										<para>Remove slowly; cleanse with soap and water; may cause redness</para>
									</item>
									<item>
										<label>•</label>
										<para>Dispose of after folding in half</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8461">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8464">
					<section type="none" id="sidelem4x8465">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tingling, hot sensation, burning, feeling of pressure, tightness, numbness, dizziness, sedation,</emphasis> headache, anxiety, fatigue, cold sensation</para>
					</section>
					<section type="none" id="sidelem4x8473">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Flushing,</emphasis><emphasis style="bold">MI,</emphasis> hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x8483">
						<sec_title>EENT:</sec_title>
						<para> Throat, mouth, nasal discomfort; vision changes</para>
					</section>
					<section type="none" id="sidelem4x8488">
						<sec_title>GI:</sec_title>
						<para> Abdominal discomfort</para>
					</section>
					<section type="none" id="sidelem4x8493">
						<sec_title>INTEG:</sec_title>
						<para> Inj-site reaction, sweating</para>
					</section>
					<section type="none" id="sidelem4x8498">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Weakness, neck stiffness,</emphasis> myalgia</para>
					</section>
					<section type="none" id="sidelem4x8506">
						<sec_title>RESP:</sec_title>
						<para> Chest tightness, pressure</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8511">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset of pain relief 10 min-2 hr, peak 10-20 min; 10%-20% plasma protein binding; metabolized in liver (metabolite); excreted in urine, feces; nasal spray half-life 2 hr</para>
			</section>
			<section type="interactions" id="sidelem4x8517">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> vasospastic effects: ergot, ergot derivatives</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—SSRIs, SNRIs, serotonin-receptor agonists, sibutramine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> SUMAtriptan effect—MAOIs</para>
				<section type="none" id="sidelem4x8531">
					<section type="none" id="sidelem4x8532">
						<sec_title>Drug/Herb</sec_title>
						<section type="none" id="sidelem4x8540">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> SAM-e, St. John’s wort</route></sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8543">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8546">
					<section type="none" id="sidelem4x8547">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x8555">
							<label>•</label>
							<sec_title>Migraine</sec_title>
							<para>
								<list id="lidelem4x8555">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Migraine:</emphasis> type of pain, aura; alleviating, aggravating factors; sensitivity to light, noise</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8560">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin syndrome: delirium, coma, agitation, diaphoresis, hypertension, fever, tremors; may resemble neuroleptic malignant syndrome in patients taking SSRIs, SNRIs</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8565">
								<item>
									<label>•</label>
									<para>B/P; signs, symptoms of coronary vasospasms, ECG</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8570">
								<item>
									<label>•</label>
									<para>Tingling, hot sensation, burning, feeling of pressure, numbness, flushing, inj-site reaction</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8575">
								<item>
									<label>•</label>
									<para>Stress level, activity, recreation, coping mechanisms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8580">
								<item>
									<label>•</label>
									<para>Neurologic status: LOC, blurring vision, nausea, vomiting, tingling in extremities preceding headache</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8585">
								<item>
									<label>•</label>
									<para>Ingestion of tyramine foods (pickled products, beer, wine, aged cheese), food additives, preservatives, colorings, artificial sweeteners, chocolate, caffeine, which may precipitate these types of headaches</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8590">
								<item>
									<label>•</label>
									<para>Renal function, urinary output</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8595">
								<item>
									<label>•</label>
									<para>Quiet, calm environment with decreased stimuli: noise, bright light, excessive talking</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8600">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8604">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in frequency, severity of migraine</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8610">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x8618">
							<label>•</label>
							<sec_title>
								<route>To report chest pain, tightness; sudden, severe abdominal pain; swelling of eyelids, face, lips; skin rash to prescriber immediately</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8621">
								<item>
									<label>•</label>
									<para>Not to use for more than 3-4 headaches per month</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8626">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected; to use contraception while taking product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8634">
							<label>•</label>
							<sec_title>Nasal spray</sec_title>
							<para>
								<list id="lidelem4x8634">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Nasal spray:</emphasis> to use 1 spray in 1 nostril; may repeat if headache returns; not to repeat if pain continues after 1st dose</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8638">
								<item>
									<label>•</label>
									<para>To have a dark, quiet environment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8643">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness, drowsiness occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8648">
								<item>
									<label>•</label>
									<para>To avoid alcohol; may increase headache</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8653">
								<item>
									<label>•</label>
									<para>To use SUBCUT inj technique, nasal route if prescribed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8658">
								<item>
									<label>•</label>
									<para>That product does not reduce number of migraines; to be used for acute migraine; to use as symptoms occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="32" status="active" ha="yes">
			<mono_name> SUNItinib (Rx)</mono_name>
			<info>
				<pronunciation>(soo-nit′-in-ib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x86700">Sutent</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Protein-tyrosine kinase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x8680">
				<sec_title>Action:</sec_title>
				<para>Inhibits multiple receptor tyrosine kinases (RTKs); some are responsible for tumor growth</para>
			</section>
			<section type="uses" id="sidelem4x8685">
				<sec_title>Uses:</sec_title>
				<para>Gastrointestinal stromal tumors (GIST) after disease progression or intolerance to imatinib; advanced renal carcinoma, pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced/metastatic disease</para>
			</section>
			<section type="contra" id="sidelem4x8690">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x8695">
					<section type="none" id="sidelem4x8696">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, active infections, QT prolongation, torsades de pointes, stroke, heart failure</para>
						<para>
							<bbw>Hepatic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8712">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8715">
					<section type="none" id="sidelem4x8716">
						<sec_title>Gastrointestinal stromal tumors (GIST)/renal cell cancer</sec_title>
						<section type="none" id="sidelem4x8724">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8724">
									<item>
										<label>•</label>
										<para> 50 mg/day × 4 wk, then 2 wk off; may increase or decrease dose by 12.5 mg; if administered with CYP3A4 inducers, give 87.5 mg/day; if given with CYP3A4 inhibitors, give 37.5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8728">
						<sec_title>Pancreatic neuroendocrine (pNET)</sec_title>
						<section type="none" id="sidelem4x8736">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8736">
									<item>
										<label>•</label>
										<para> 37.5 mg daily continuously, increase or decrease by 12.5 mg based on tolerance, avoid potent CYP3A4 inhibitors/inducers; if used with CYP3A4 inhibitors, decrease SUNItinib dose to minimum of 25 mg/day; if used with CYP3A4 inducers, increase SUNItinib to max 62.5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8740">
						<sec_title>Available forms:</sec_title>
						<para> Caps 12.5, 25, 50 mg</para>
					</section>
					<section type="none" id="sidelem4x8745">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8749">
								<item>
									<label>•</label>
									<para>With meal and large glass of water to decrease GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at 25° C (77° F)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8760">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8763">
					<section type="none" id="sidelem4x8764">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">CNS hemorrhage,</emphasis> headache, dizziness, insomnia, <emphasis style="bold">seizures,</emphasis> fatigue</para>
					</section>
					<section type="none" id="sidelem4x8775">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">left ventricular dysfunction, QT prolongation, cardiotoxicity, torsades de pointes, thrombotic microangiopathy, cardiac arrest, thromboembolism</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8782">
						<sec_title>ENDO:</sec_title>
						<para> Hypo/hyperthyroidism</para>
					</section>
					<section type="none" id="sidelem4x8787">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis><emphasis style="bold">hepatotoxicity, vomiting, dyspepsia,</emphasis><emphasis style="italic">anorexia, abdominal pain,</emphasis> altered taste, <emphasis style="italic">constipation,</emphasis> stomatitis, mucositis, <emphasis style="bold">pancreatitis,</emphasis> diarrhea, <emphasis style="bold">GI bleeding/perforation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8807">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotic syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8814">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia, hemolytic anemia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8821">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, yellow skin discoloration,</emphasis> depigmentation of hair or skin, alopecia, <emphasis style="bold">necrotizing fasciitis, pyoderma gangrenosum</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8831">
						<sec_title>MS:</sec_title>
						<para> Pain, arthralgia, myalgia, <emphasis style="bold">myopathy, rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8838">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea, <emphasis style="bold">pulmonary embolism</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8845">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Bleeding,</emphasis> electrolyte abnormalities, hand-foot syndrome, <emphasis style="bold">serious infection</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8855">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 95%; metabolized by CYP3A4; excreted in feces, small amount in urine; peak plasma levels 6-12 hr; terminal half-life 40-60 hr (SUNItinib); active metabolite 80-110 hr</para>
			</section>
			<section type="interactions" id="sidelem4x8860">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: microangiopathic hemolytic anemia—bevacizumab; avoid concurrent use</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl; CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone)</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: hepatotoxicity—acetaminophen</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentrations of simvastatin, calcium channel blockers; warfarin; avoid use with warfarin, use low-molecular-weight anticoagulants instead</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> SUNItinib concentrations—dexamethasone, phenytoin, carBAMazepine, rifampin, PHENobarbital</para>
				<section type="none" id="sidelem4x8884">
					<section type="none" id="sidelem4x8885">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> SUNItinib concentration—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x8892">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> plasma concentrations—grapefruit juice</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8900">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8903">
					<section type="none" id="sidelem4x8904">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8910">
								<item>
									<para>
										<emphasis alert="nurse">ANC and platelets; if ANC &lt;1 × 10<emphasis style="sup">9</emphasis>/L and/or platelets &lt;50 × 10<emphasis style="sup">9</emphasis>/L, stop until ANC &gt;1.5 × 10<emphasis style="sup">9</emphasis>/L and platelets &gt;75 × 10<emphasis style="sup">9</emphasis>/L; if ANC &lt;0.5 × 10<emphasis style="sup">9</emphasis>/L and/or platelets &lt;10 × 10<emphasis style="sup">9</emphasis>/L, reduce dosage by 200 mg; if cytopenia continues, reduce dosage by another 100 mg; if cytopenia continues for 4 wk, stop product until ANC ≥1 × 10<emphasis style="sup">9</emphasis>/L</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8937">
								<item>
									<para>
										<emphasis alert="nurse">CV status: hypertension, QT prolongation can occur; monitor left ventricular ejection fraction (LVEF), (MUGA) at baseline, periodically; ECG</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8943">
								<item>
									<para>
										<emphasis alert="nurse">Renal toxicity: if bilirubin &gt;3 × IULN, withhold SUNItinib until bilirubin levels return to &lt;1.5 × IULN; electrolytes</emphasis>
<bbw>Hepatotoxicity: monitor LFTs before treatment, monthly; if liver transaminases &gt;5 × IULN, withhold SUNItinib until transaminase levels return to &lt;2.5 × IULN</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8960">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x8960">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> adrenal insufficiency in those experiencing trauma</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8964">
								<item>
									<label>•</label>
									<para>Bleeding: epistaxis; rectal, gingival, upper GI, genital, wound bleeding; tumor-related hemorrhage may occur rapidly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8969">
								<item>
									<label>•</label>
									<para>Nutritious diet with iron, vitamin supplement, low fiber, few dairy products</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8974">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8978">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in size of tumor</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8984">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x8992">
							<label>•</label>
							<sec_title>To report adverse reactions immediately<route> SOB, bleeding</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8995">
								<item>
									<label>•</label>
									<para>About reason for treatment, expected result</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9000">
								<item>
									<label>•</label>
									<para>That many adverse reactions may occur: high B/P, bleeding, mouth swelling, taste change, skin discoloration, depigmentation of hair/skin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9005">
								<item>
									<label>•</label>
									<para>To avoid persons with known upper respiratory infections; that immunosuppression is common</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9010">
								<item>
									<label>•</label>
									<para>To avoid grapefruit juice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9016">
								<item>
									<para>
										<emphasis alert="nurse">To report if pregnancy is planned or suspected, pregnancy (D)</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="33" status="active" ha="yes">
			<mono_name> suvorexant</mono_name>
			<info>
				<pronunciation>(soo′voe-rex′ant)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x90280">Belsomra</tradename>
				</tradenames>
				<class type="func"> Psychotropic—sedative/hypnotic, anxiolytic</class>
				<class type="chem"> Orexin receptor antagonist</class>
			</info>
			<section type="actions" id="sidelem4x9038">
				<sec_title>Action:</sec_title>
				<para> Suvorexant alters the signaling of neurotransmitters called orexins, which are responsible for regulating the sleep–wake cycle</para>
			</section>
			<section type="uses" id="sidelem4x9043">
				<sec_title>Uses:</sec_title>
				<para> The treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance</para>
			</section>
			<section type="contra" id="sidelem4x9048">
				<sec_title>Contraindications:</sec_title>
				<para> Narcolepsy, hypersensitivity</para>
				<section type="none" id="sidelem4x9053">
					<section type="none" id="sidelem4x9054">
						<sec_title>Precautions:</sec_title>
						<para> Preexisting respiratory disease, COPD, breastfeeding, pregnancy (C), labor, geriatrics, hepatic disease, sleep apnea, substance abuse, alcohol use, suicidal ideation, mental changes, depression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9059">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9067">
					<label>•</label>
					<sec_title>Adults<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9067">
							<item>
								<label>•</label>
								<para> 10 mg every night within 30 min of going to bed, and with ≥7 hr remaining before the planned time of awakening, may increase to maximum 20 mg every night</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9071">
					<section type="none" id="sidelem4x9072">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 15, 20 mg</para>
					</section>
					<section type="none" id="sidelem4x9077">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9081">
								<item>
									<label>•</label>
									<para>Give 30 min before bedtime</para>
								</item>
								<item>
									<label>•</label>
									<para>Effect may be delayed if taken with food, take on empty stomach for faster effect</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9092">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9095">
					<section type="none" id="sidelem4x9096">
						<sec_title>CNS:</sec_title>
						<para> Amnesia, <emphasis style="bold">suicidal ideation,</emphasis> anxiety, dizziness, drowsiness, hallucinations, headache, memory impairment</para>
					</section>
					<section type="none" id="sidelem4x9104">
						<sec_title>GI:</sec_title>
						<para> Diarrhea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9109">
				<sec_title>Pharmacokinetics</sec_title>
				<para>High-protein binding, peak 2 hr, terminal half-life 12 hr, excreted by feces (66%), urine (23%)</para>
			</section>
			<section type="interactions" id="sidelem4x9114">
				<sec_title>Interactions</sec_title>
				<para>Avoid use with CYP3A inhibitors</para>
				<section type="none" id="sidelem4x9119">
					<section type="none" id="sidelem4x9120">
						<sec_title>Increase:</sec_title>
						<para> effects of both products—CNS depressants</para>
					</section>
					<section type="none" id="sidelem4x9125">
						<sec_title>Decrease:</sec_title>
						<para> suvorexant effect—CYP3A inducers</para>
					</section>
					<section type="none" id="sidelem4x9130">
						<sec_title>Drug/Herb:</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x9134">
						<sec_title>Increase:</sec_title>
						<para> suvorexant effect—kava kava, valerian, melatonin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9140">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9143">
					<section type="none" id="sidelem4x9144">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9152">
							<label>•</label>
							<sec_title>Sleeping patterns</sec_title>
							<para>
								<list id="lidelem4x9152">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Sleeping patterns:</emphasis> Waking in the night, inability to fall asleep, stay asleep, amnesia</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9156">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9160">
								<item>
									<label>•</label>
									<para>Therapeutic response: Normalized sleeping patterns</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9166">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9171">
								<item>
									<label>•</label>
									<para>To use on an empty stomach for faster effect</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9179">
							<label>•</label>
							<sec_title>
								<route>To report immediately suicidal thoughts/behaviors</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9182">
								<item>
									<label>•</label>
									<para>To avoid use with other products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>